data_5ob4_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 5ob4 _Structure_validation_residue.Date_analyzed 2017-11-17 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.861 0.362 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 9.7 t -51.0 -51.14 22.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.138 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 88.7 t -48.7 -59.61 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.146 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -49.88 -54.49 17.95 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.51 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 62.5 mt -58.48 -54.84 27.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.854 0.359 . . . . 0.0 111.114 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.42 -59.44 3.72 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.903 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.443 ' HA ' HG23 ' B' ' 126' ' ' VAL . 9.0 mt -43.44 -55.52 4.12 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.918 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 87.2 t -52.4 -51.26 34.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.144 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.8 t -61.75 -40.5 87.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.141 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.447 HG23 ' HA ' ' B' ' 123' ' ' LEU . 44.2 t -51.22 -59.28 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.149 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 47.6 mt -67.45 -46.41 73.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.894 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.62 -48.13 50.4 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.491 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.4 t -75.97 -54.19 14.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.883 0.373 . . . . 0.0 111.142 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 20.3 t -49.72 -42.78 18.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.11 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -77.52 -34.84 53.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.892 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -57.39 -48.69 78.77 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.494 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 16.0 mt -76.91 -47.56 27.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.869 0.366 . . . . 0.0 111.141 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 28.2 mt -55.41 -53.13 60.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.937 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 79.3 mt -63.46 -49.49 82.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.123 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 27.8 ttpt . . . . . 0 C--N 1.328 -0.358 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.891 179.841 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.812 0.339 . . . . 0.0 111.098 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 10.1 t -50.85 -51.45 20.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.111 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 87.8 t -48.49 -59.68 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.127 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.79 -54.74 16.61 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.481 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 63.7 mt -58.32 -54.93 26.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.843 0.354 . . . . 0.0 111.119 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 122' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.35 -59.8 3.39 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.911 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 123' ' ' LEU . . . . . 0.447 ' HA ' HG23 ' A' ' 26' ' ' VAL . 9.1 mt -43.18 -55.56 3.88 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.9 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 87.0 t -52.38 -51.61 31.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.11 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 72.5 t -61.4 -40.49 86.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.114 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 126' ' ' VAL . . . . . 0.443 HG23 ' HA ' ' A' ' 23' ' ' LEU . 43.8 t -51.27 -59.27 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.129 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 127' ' ' LEU . . . . . . . . . . . . . 47.3 mt -67.52 -46.37 73.03 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.904 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.61 -47.81 51.17 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.537 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.6 t -76.25 -54.17 13.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.911 0.386 . . . . 0.0 111.141 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 130' ' ' VAL . . . . . . . . . . . . . 19.9 t -49.81 -42.54 18.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.112 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -77.66 -35.19 52.67 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.879 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -57.32 -48.38 80.85 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.496 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 17.2 mt -77.05 -47.81 26.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.855 0.36 . . . . 0.0 111.121 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 28.2 mt -55.29 -53.05 60.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.904 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 77.9 mt -63.39 -49.84 81.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.17 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 27.9 ttpt . . . . . 0 C--N 1.328 -0.342 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.888 179.853 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.071 0 CA-C-O 120.801 0.334 . . . . 0.0 111.076 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 9.6 t -51.38 -51.07 25.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.123 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 95.0 t -48.55 -59.49 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.081 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -50.07 -54.46 18.88 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.527 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 66.9 mt -58.5 -54.77 28.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.919 0.39 . . . . 0.0 111.131 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.4 -59.7 3.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.922 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.445 ' HA ' HG23 ' B' ' 126' ' ' VAL . 9.1 mt -43.24 -55.53 3.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.905 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 87.2 t -52.4 -51.47 32.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.152 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.7 t -61.52 -40.59 87.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.118 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.435 HG23 ' HA ' ' B' ' 123' ' ' LEU . 43.3 t -51.29 -59.12 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.108 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 46.4 mt -67.79 -46.36 72.19 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.899 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.6 -47.8 51.13 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.472 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -76.26 -54.32 13.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.862 0.363 . . . . 0.0 111.11 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 20.1 t -49.7 -42.5 17.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.137 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 4.7 m-85 -77.85 -37.34 48.56 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.85 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -56.29 -47.78 79.76 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.499 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 19.5 mt -76.69 -49.4 24.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.833 0.349 . . . . 0.0 111.149 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 28.6 mt -53.81 -52.86 58.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.955 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 49.2 mt -63.59 -47.48 91.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.135 179.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 32.3 ttpt . . . . . 0 C--N 1.328 -0.352 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.844 179.904 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.811 0.339 . . . . 0.0 111.089 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.8 t -51.35 -51.0 25.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.155 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 93.6 t -48.63 -59.43 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.147 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -50.13 -54.49 18.96 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.472 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 67.0 mt -58.48 -54.85 27.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.917 0.389 . . . . 0.0 111.16 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 122' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.31 -59.94 3.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.897 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 123' ' ' LEU . . . . . 0.435 ' HA ' HG23 ' A' ' 26' ' ' VAL . 9.2 mt -43.12 -55.41 3.9 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.933 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 87.4 t -52.55 -51.62 32.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.104 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 72.5 t -61.38 -40.61 86.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.1 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 126' ' ' VAL . . . . . 0.445 HG23 ' HA ' ' A' ' 23' ' ' LEU . 43.1 t -51.19 -59.19 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.121 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 127' ' ' LEU . . . . . . . . . . . . . 45.4 mt -67.8 -46.15 72.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.972 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.69 -47.9 51.4 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.461 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.0 t -76.24 -54.19 13.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.895 0.379 . . . . 0.0 111.093 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 130' ' ' VAL . . . . . . . . . . . . . 20.2 t -49.7 -42.59 17.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.141 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -77.72 -37.03 50.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.879 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -56.04 -47.86 77.52 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.517 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 18.2 mt -77.07 -49.25 23.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.826 0.346 . . . . 0.0 111.127 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 27.8 mt -53.57 -52.02 61.07 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.919 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 49.3 mt -64.85 -46.67 91.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.096 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 32.1 ttpt . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.899 179.904 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.798 0.332 . . . . 0.0 111.069 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 12.0 t -52.24 -51.09 34.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.148 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 94.9 t -48.79 -59.15 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.137 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -50.26 -54.72 18.59 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.492 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 92.5 mt -58.37 -54.83 27.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.861 0.362 . . . . 0.0 111.089 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.28 -59.81 3.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.933 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.413 ' HA ' HG23 ' B' ' 126' ' ' VAL . 9.4 mt -43.21 -55.36 4.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.873 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 90.5 t -52.61 -51.6 33.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.112 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 70.9 t -61.37 -40.56 86.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.108 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.433 HG23 ' HA ' ' B' ' 123' ' ' LEU . 43.0 t -51.25 -59.3 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.133 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 44.5 mt -68.01 -46.26 71.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.906 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.51 -47.52 51.33 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.49 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.5 t -76.74 -54.21 13.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.855 0.359 . . . . 0.0 111.12 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 20.1 t -49.73 -42.02 17.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.118 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 5.3 m-85 -78.28 -34.29 48.99 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.885 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -57.51 -46.89 91.5 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.509 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 17.6 mt -79.38 -45.48 23.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.848 0.356 . . . . 0.0 111.116 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 27.4 mt -57.84 -43.79 86.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.868 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 72.4 mt -71.28 -58.95 4.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.161 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 8.3 pttp . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.937 179.781 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.795 0.331 . . . . 0.0 111.082 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 12.0 t -52.35 -51.09 35.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.127 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 95.5 t -48.89 -59.17 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.141 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -50.2 -54.63 18.7 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.525 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 92.9 mt -58.4 -54.84 27.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.867 0.365 . . . . 0.0 111.158 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 122' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.26 -59.87 3.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.945 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 123' ' ' LEU . . . . . 0.433 ' HA ' HG23 ' A' ' 26' ' ' VAL . 9.3 mt -43.08 -55.49 3.83 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.916 179.841 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 90.0 t -52.61 -51.51 34.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.13 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 69.9 t -61.48 -40.31 85.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.111 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 126' ' ' VAL . . . . . 0.413 HG23 ' HA ' ' A' ' 23' ' ' LEU . 43.1 t -51.4 -59.14 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.146 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 127' ' ' LEU . . . . . . . . . . . . . 45.6 mt -68.02 -46.41 71.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.875 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.6 -47.29 52.42 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.467 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.6 t -76.83 -54.18 13.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.853 0.358 . . . . 0.0 111.159 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 130' ' ' VAL . . . . . . . . . . . . . 19.7 t -49.8 -41.92 17.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.118 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -78.4 -36.37 45.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.859 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -56.06 -46.38 85.03 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.506 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 18.4 mt -79.18 -49.9 19.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 120.889 0.376 . . . . 0.0 111.151 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 27.8 mt -53.1 -48.1 68.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.933 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 69.9 mt -68.92 -49.93 58.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.125 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 11.5 tttp . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.899 179.802 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.085 0 CA-C-O 120.818 0.342 . . . . 0.0 111.092 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.3 t -51.59 -51.21 27.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.122 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 84.0 t -48.62 -59.96 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.161 179.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -49.54 -54.71 15.74 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.475 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 96.2 mt -58.35 -54.81 27.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.884 0.373 . . . . 0.0 111.183 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.45 -59.56 3.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.871 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.44 ' HA ' HG22 ' B' ' 126' ' ' VAL . 8.8 mt -43.19 -55.55 3.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.925 179.869 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 89.7 t -52.48 -51.74 31.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.144 179.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 73.4 t -61.44 -39.87 84.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.158 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.439 HG22 ' HA ' ' B' ' 123' ' ' LEU . 46.0 t -51.64 -58.69 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.131 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 56.6 mt -67.25 -47.6 70.25 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.962 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.3 -47.46 50.31 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.476 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.9 t -75.99 -54.4 13.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.904 0.383 . . . . 0.0 111.166 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 19.4 t -49.46 -43.29 17.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.13 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 7.5 m-85 -77.2 -41.53 41.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.879 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -53.35 -48.16 60.48 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.477 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 38.4 mt -74.89 -50.91 23.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.859 0.361 . . . . 0.0 111.115 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 23.2 mt -51.25 -57.64 8.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.937 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 14.4 mt -59.81 -48.48 87.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.126 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 14.8 tttm . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.914 179.824 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.847 0.356 . . . . 0.0 111.066 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 11.6 t -51.7 -51.34 27.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.181 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 89.1 t -48.6 -59.47 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.13 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -50.05 -54.88 17.09 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.484 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 96.3 mt -58.28 -54.87 26.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.908 0.385 . . . . 0.0 111.128 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 122' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.3 -59.69 3.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.907 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 123' ' ' LEU . . . . . 0.439 ' HA ' HG22 ' A' ' 26' ' ' VAL . 9.3 mt -43.22 -55.71 3.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.914 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 90.4 t -52.33 -51.83 29.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.087 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 74.0 t -61.19 -40.74 86.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.104 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 126' ' ' VAL . . . . . 0.44 HG22 ' HA ' ' A' ' 23' ' ' LEU . 45.4 t -50.89 -59.49 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.132 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 127' ' ' LEU . . . . . . . . . . . . . 49.0 mt -67.43 -46.67 72.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.924 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -50.89 -47.4 47.85 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.486 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 58.4 t -77.77 -54.66 12.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.895 0.379 . . . . 0.0 111.156 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 130' ' ' VAL . . . . . . . . . . . . . 20.4 t -49.31 -39.15 12.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.125 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 3.5 m-30 -76.32 -42.76 43.97 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.874 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -51.74 -50.21 44.26 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.509 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 40.6 mt -73.23 -52.06 23.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.907 0.384 . . . . 0.0 111.131 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 24.5 mt -50.52 -61.35 2.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.932 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 13.6 mt -56.59 -46.46 82.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.152 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 14.6 tttm . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.907 179.838 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.809 0.338 . . . . 0.0 111.077 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.3 t -51.86 -50.69 32.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.101 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 86.6 t -48.85 -60.23 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.161 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -49.49 -54.28 17.19 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.465 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 39.0 mt -58.52 -54.72 29.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.862 0.363 . . . . 0.0 111.156 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.71 -59.49 3.76 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.892 179.898 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.435 ' HA ' HG23 ' B' ' 126' ' ' VAL . 8.5 mt -43.23 -55.35 4.03 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.919 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 91.8 t -52.46 -51.74 31.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.127 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 74.8 t -61.62 -39.84 84.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.171 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.441 HG23 ' HA ' ' B' ' 123' ' ' LEU . 46.5 t -51.62 -59.51 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.13 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 57.0 mt -66.39 -47.81 72.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.876 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.18 -47.58 49.31 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.452 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.4 t -76.32 -54.59 13.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.825 0.345 . . . . 0.0 111.141 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 19.8 t -49.34 -42.33 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.141 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -77.05 -44.39 30.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -52.35 -48.61 53.81 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.458 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 42.2 mt -73.03 -52.06 23.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.88 0.371 . . . . 0.0 111.118 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 22.8 mt -51.21 -60.78 2.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.876 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 11.9 mt -55.56 -49.07 76.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.16 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 8.0 tmtt? . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 179.833 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.861 0.363 . . . . 0.0 111.09 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 11.3 t -51.86 -50.7 32.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.155 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 87.7 t -48.82 -60.26 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.134 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.44 -54.25 17.13 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.488 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 38.8 mt -58.56 -54.85 27.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.857 0.361 . . . . 0.0 111.135 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 122' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.57 -59.43 3.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.945 179.884 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 123' ' ' LEU . . . . . 0.441 ' HA ' HG23 ' A' ' 26' ' ' VAL . 8.5 mt -43.28 -55.35 4.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.942 179.883 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 92.1 t -52.39 -51.81 30.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.135 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 74.8 t -61.61 -39.83 84.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.12 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 126' ' ' VAL . . . . . 0.435 HG23 ' HA ' ' A' ' 23' ' ' LEU . 46.2 t -51.67 -59.58 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.141 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 127' ' ' LEU . . . . . . . . . . . . . 55.9 mt -66.31 -47.81 72.34 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.937 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.21 -47.52 49.61 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.47 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 55.9 t -76.34 -54.63 13.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.848 0.356 . . . . 0.0 111.142 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 130' ' ' VAL . . . . . . . . . . . . . 20.2 t -49.28 -42.37 15.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.132 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -76.95 -44.57 30.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.933 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -52.28 -48.55 53.51 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.489 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 42.2 mt -73.02 -52.1 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.846 0.355 . . . . 0.0 111.18 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 23.0 mt -51.17 -60.87 2.64 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.919 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 11.8 mt -55.42 -49.52 72.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.129 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 8.0 tmtt? . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.89 179.866 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.814 0.34 . . . . 0.0 111.096 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.4 t -50.81 -50.87 22.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.133 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 96.0 t -48.4 -59.46 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.087 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -50.44 -54.52 20.13 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.538 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 99.0 mt -58.41 -54.82 27.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.826 0.346 . . . . 0.0 111.124 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.54 -59.44 3.76 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.902 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.46 ' HA ' HG22 ' B' ' 126' ' ' VAL . 9.8 mt -43.31 -55.33 4.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.884 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 89.5 t -52.6 -52.03 30.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.114 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.9 t -61.05 -40.21 84.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.126 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.463 HG22 ' HA ' ' B' ' 123' ' ' LEU . 44.5 t -51.64 -59.29 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.101 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 48.6 mt -67.58 -46.66 71.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.893 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.6 -47.57 51.73 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.451 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -76.41 -54.16 13.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.896 0.379 . . . . 0.0 111.148 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 19.8 t -49.79 -42.65 18.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.145 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 4.7 m-85 -77.44 -40.58 42.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.902 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -53.48 -48.4 60.5 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.49 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 28.8 mt -75.56 -50.47 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.849 0.357 . . . . 0.0 111.11 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 22.4 mt -51.28 -56.71 11.55 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.947 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 18.2 mt -60.96 -49.34 85.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.116 179.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 30.7 ttpt . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.854 179.922 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.807 0.336 . . . . 0.0 111.08 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 11.0 t -51.64 -51.05 28.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.112 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 91.1 t -48.37 -59.35 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.141 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -50.51 -54.68 19.77 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.522 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 98.9 mt -58.23 -54.88 26.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.844 0.355 . . . . 0.0 111.103 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 122' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.37 -59.55 3.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.937 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 123' ' ' LEU . . . . . 0.463 ' HA ' HG22 ' A' ' 26' ' ' VAL . 9.6 mt -43.28 -55.32 4.09 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.925 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 90.4 t -52.74 -51.96 31.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.119 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 72.7 t -60.94 -40.25 84.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.129 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 126' ' ' VAL . . . . . 0.46 HG22 ' HA ' ' A' ' 23' ' ' LEU . 44.9 t -51.47 -59.3 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.141 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 127' ' ' LEU . . . . . . . . . . . . . 49.7 mt -67.59 -46.88 71.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.907 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.52 -47.53 51.33 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.453 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.0 t -76.24 -54.37 13.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.892 0.377 . . . . 0.0 111.153 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 130' ' ' VAL . . . . . . . . . . . . . 19.7 t -49.69 -42.71 17.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.114 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -77.41 -41.04 41.41 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.864 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -53.27 -48.43 59.45 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.486 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 30.1 mt -75.25 -50.37 24.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.827 0.346 . . . . 0.0 111.117 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 21.9 mt -51.53 -57.42 9.11 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.894 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 17.2 mt -59.94 -50.01 81.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.115 179.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 31.0 ttpt . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.897 179.865 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.828 0.347 . . . . 0.0 111.076 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 9.5 t -51.36 -51.62 23.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.159 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 99.4 t -48.48 -59.04 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.105 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -50.23 -54.81 18.12 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.486 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 55.1 mt -58.43 -54.89 26.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.856 0.36 . . . . 0.0 111.124 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.1 -59.83 3.31 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.948 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.446 ' HA ' HG23 ' B' ' 126' ' ' VAL . 9.6 mt -43.29 -55.65 3.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.935 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 88.4 t -52.47 -51.14 35.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.142 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 69.8 t -61.6 -40.65 87.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.082 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.438 HG23 ' HA ' ' B' ' 123' ' ' LEU . 41.8 t -51.37 -58.89 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.136 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 45.9 mt -68.47 -46.16 70.51 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.912 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.79 -47.62 52.65 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.477 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.7 t -76.11 -54.32 13.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.918 0.389 . . . . 0.0 111.169 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 20.0 t -49.8 -43.01 18.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.114 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -77.61 -41.5 38.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.902 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -53.28 -47.36 61.95 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.489 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 22.3 mt -76.04 -51.37 20.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.833 0.349 . . . . 0.0 111.141 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 23.7 mt -51.0 -55.92 15.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.903 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 18.3 mt -61.71 -48.48 88.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.116 179.83 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 3.9 tmtt? . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.886 179.882 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.82 0.343 . . . . 0.0 111.101 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.3 t -51.54 -51.51 25.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.17 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 98.9 t -48.51 -59.04 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.129 179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -50.29 -54.8 18.39 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.493 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 55.5 mt -58.46 -54.88 27.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.865 0.364 . . . . 0.0 111.119 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 122' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.1 -59.85 3.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.897 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 123' ' ' LEU . . . . . 0.438 ' HA ' HG23 ' A' ' 26' ' ' VAL . 9.7 mt -43.26 -55.77 3.84 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 89.3 t -52.43 -51.21 34.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.173 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 69.2 t -61.48 -40.56 86.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.161 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 126' ' ' VAL . . . . . 0.446 HG23 ' HA ' ' A' ' 23' ' ' LEU . 42.3 t -51.5 -59.18 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.092 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 127' ' ' LEU . . . . . . . . . . . . . 45.2 mt -68.14 -46.26 71.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.916 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.56 -47.65 51.29 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.507 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 56.0 t -76.37 -54.25 13.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.845 0.355 . . . . 0.0 111.077 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 130' ' ' VAL . . . . . . . . . . . . . 20.2 t -49.8 -42.72 18.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.114 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -77.77 -41.96 35.7 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.859 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -52.93 -47.16 60.08 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.491 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 22.6 mt -76.16 -51.55 19.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.884 0.373 . . . . 0.0 111.141 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 23.2 mt -50.8 -55.79 15.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.861 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 17.4 mt -61.87 -48.85 86.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.17 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 3.8 tmtt? . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.91 179.806 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.799 0.333 . . . . 0.0 111.115 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.7 t -51.78 -51.07 29.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.16 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 91.3 t -48.65 -59.48 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.121 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -50.05 -54.55 18.41 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.508 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 90.4 mt -58.47 -54.71 29.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.832 0.349 . . . . 0.0 111.111 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.46 -59.7 3.51 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.937 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.443 ' HA ' HG23 ' B' ' 126' ' ' VAL . 9.0 mt -43.26 -55.37 4.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.937 179.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 86.9 t -52.52 -51.61 32.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.17 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 73.6 t -61.47 -40.28 85.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.169 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.423 HG23 ' HA ' ' B' ' 123' ' ' LEU . 44.4 t -51.5 -59.0 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.124 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 48.8 mt -67.7 -46.76 71.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.941 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.54 -47.22 52.28 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.52 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 56.3 t -76.6 -54.3 13.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.913 0.387 . . . . 0.0 111.122 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 19.9 t -49.78 -42.45 18.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.116 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -77.57 -43.19 32.58 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.845 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -52.59 -47.68 57.17 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.476 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 30.3 mt -74.84 -51.86 20.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.842 0.353 . . . . 0.0 111.137 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 22.9 mt -50.97 -57.92 7.34 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.931 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 14.4 mt -59.3 -48.3 87.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.118 179.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 9.4 ttmm . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.922 179.826 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.83 0.348 . . . . 0.0 111.083 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.4 t -51.55 -51.03 27.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.115 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 90.2 t -48.7 -59.5 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.11 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -50.04 -54.55 18.39 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.46 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 90.1 mt -58.47 -54.75 28.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.83 0.347 . . . . 0.0 111.095 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 122' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.43 -59.83 3.38 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.9 179.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 123' ' ' LEU . . . . . 0.423 ' HA ' HG23 ' A' ' 26' ' ' VAL . 9.1 mt -43.13 -55.4 3.91 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.857 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 87.0 t -52.63 -51.66 33.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.116 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 73.1 t -61.41 -40.19 85.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.096 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 126' ' ' VAL . . . . . 0.443 HG23 ' HA ' ' A' ' 23' ' ' LEU . 44.1 t -51.52 -59.13 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.101 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 127' ' ' LEU . . . . . . . . . . . . . 48.5 mt -67.64 -46.83 71.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.929 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.57 -47.18 52.47 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.486 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 56.1 t -76.65 -54.25 13.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.83 0.348 . . . . 0.0 111.121 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 130' ' ' VAL . . . . . . . . . . . . . 20.0 t -49.8 -42.47 18.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.119 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 4.7 m-85 -77.46 -43.23 33.06 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.871 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -52.23 -47.9 54.61 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.501 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 30.5 mt -74.88 -51.68 21.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.841 0.353 . . . . 0.0 111.113 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 21.9 mt -50.91 -57.98 7.15 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.904 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 14.2 mt -59.28 -48.99 85.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.107 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 9.7 ttmm . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.909 179.871 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.825 0.345 . . . . 0.0 111.1 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 5.9 t -51.05 -48.92 29.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.088 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.492 ' O ' ' HG ' ' A' ' 23' ' ' LEU . 98.3 t -49.6 -63.35 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.129 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -48.57 -55.69 10.65 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.497 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 20.4 mt -55.52 -41.02 61.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.863 0.363 . . . . 0.0 111.111 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -57.15 -50.68 72.05 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.877 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.492 ' HG ' ' O ' ' A' ' 19' ' ' VAL . 1.1 mt -54.47 -51.67 64.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.901 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 98.1 t -55.44 -45.97 78.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.118 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 70.6 t -64.83 -43.18 96.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.101 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.44 HG22 ' CD2' ' B' ' 123' ' ' LEU . 73.3 t -51.27 -54.31 11.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.113 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 56.4 mt -70.13 -47.28 62.39 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.885 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.82 -45.88 55.14 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.538 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 57.4 t -76.81 -54.67 12.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.84 0.352 . . . . 0.0 111.136 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 17.6 t -49.9 -43.05 19.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.158 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -77.22 -44.95 28.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.825 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -52.29 -48.0 54.72 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.47 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 45.4 mt -73.22 -52.55 21.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.848 0.356 . . . . 0.0 111.126 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 23.7 mt -51.03 -60.75 2.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.89 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 11.8 mt -55.7 -48.68 77.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.117 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 63.6 tttt . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.877 179.897 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.827 0.346 . . . . 0.0 111.111 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 6.1 t -51.27 -48.78 32.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.103 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . 0.486 ' O ' ' HG ' ' B' ' 123' ' ' LEU . 98.4 t -49.66 -63.28 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.123 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.73 -55.48 11.2 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.499 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 20.0 mt -55.64 -40.8 61.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.884 0.373 . . . . 0.0 111.163 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 122' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -57.44 -50.25 73.61 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.945 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 123' ' ' LEU . . . . . 0.486 ' HG ' ' O ' ' B' ' 119' ' ' VAL . 1.1 mt -54.73 -51.35 65.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.956 179.875 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 99.6 t -55.93 -46.0 80.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.113 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 71.0 t -64.64 -43.12 96.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.136 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 126' ' ' VAL . . . . . 0.449 HG22 ' CD2' ' A' ' 23' ' ' LEU . 71.7 t -51.42 -54.36 12.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.105 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 127' ' ' LEU . . . . . . . . . . . . . 57.1 mt -70.15 -47.39 61.89 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.927 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.81 -45.81 55.12 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.458 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 58.1 t -76.77 -54.82 12.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.931 0.396 . . . . 0.0 111.191 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 130' ' ' VAL . . . . . . . . . . . . . 17.6 t -49.89 -43.06 19.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.137 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -77.16 -44.83 28.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.898 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -52.3 -48.11 54.57 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.479 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 46.1 mt -73.21 -52.43 21.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.874 0.369 . . . . 0.0 111.149 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 23.9 mt -51.14 -60.77 2.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.914 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 12.0 mt -55.73 -48.62 77.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.094 179.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 63.5 tttt . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.892 179.885 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.828 0.347 . . . . 0.0 111.041 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 5.9 t -51.58 -48.72 35.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.134 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.488 ' O ' ' HG ' ' A' ' 23' ' ' LEU . 92.1 t -50.04 -63.44 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.132 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -48.41 -55.48 10.69 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.527 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 22.1 mt -55.84 -40.86 64.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.816 0.341 . . . . 0.0 111.085 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -57.46 -49.62 75.69 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.927 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.488 ' HG ' ' O ' ' A' ' 19' ' ' VAL . 2.0 mt -55.18 -51.44 66.52 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.942 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 98.9 t -55.92 -46.17 80.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.122 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 76.0 t -63.75 -43.59 98.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.147 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.437 HG22 ' CD2' ' B' ' 123' ' ' LEU . 76.2 t -51.67 -53.72 15.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.107 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 54.0 mt -71.72 -45.73 60.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.923 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.77 -46.39 59.94 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.469 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -76.08 -54.21 14.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.851 0.358 . . . . 0.0 111.134 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 18.4 t -50.64 -44.6 25.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.14 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 5.3 m-85 -76.79 -39.07 52.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.9 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -54.71 -49.37 61.79 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 23.3 mt -74.78 -50.25 26.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.888 0.375 . . . . 0.0 111.165 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 25.4 mt -51.86 -56.28 14.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.934 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 21.6 mt -61.32 -44.09 97.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.179 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 16.8 mttt . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.877 179.852 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.836 0.351 . . . . 0.0 111.033 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 5.7 t -51.54 -48.77 35.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.128 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 119' ' ' VAL . . . . . 0.489 ' O ' ' HG ' ' B' ' 123' ' ' LEU . 92.9 t -49.97 -63.41 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.101 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.46 -55.46 10.79 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.459 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 22.2 mt -55.89 -40.73 63.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.877 0.37 . . . . 0.0 111.118 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 122' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -57.57 -49.49 76.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.946 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 123' ' ' LEU . . . . . 0.489 ' HG ' ' O ' ' B' ' 119' ' ' VAL . 2.0 mt -55.38 -51.48 66.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.902 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 98.0 t -55.81 -46.0 79.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.156 179.831 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 78.0 t -63.99 -43.45 97.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.148 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 126' ' ' VAL . . . . . 0.436 HG22 ' CD2' ' A' ' 23' ' ' LEU . 76.0 t -51.68 -53.68 15.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.143 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 127' ' ' LEU . . . . . . . . . . . . . 52.7 mt -71.78 -45.84 60.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.921 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -52.63 -46.12 59.4 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.506 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.4 t -76.41 -54.2 13.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.876 0.369 . . . . 0.0 111.097 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 130' ' ' VAL . . . . . . . . . . . . . 18.6 t -50.7 -44.31 25.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.179 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 5.2 m-85 -77.0 -39.29 50.94 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.863 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -54.56 -49.09 62.33 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.478 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 22.2 mt -75.04 -50.6 24.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.809 0.338 . . . . 0.0 111.129 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 25.0 mt -51.54 -55.74 17.38 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.898 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 21.9 mt -61.9 -44.34 98.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.146 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 19.8 mttt . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.898 179.838 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 N-CA-C 112.543 -0.223 . . . . 0.0 112.543 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 6.6 p -134.14 70.33 73.84 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.656 0.741 . . . . 0.0 110.883 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 173.46 10.94 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.686 2.258 . . . . 0.0 112.363 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . 55.73 45.92 23.53 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.127 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -99.74 43.01 1.08 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.927 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 23.9 mt-30 -105.51 136.0 45.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.908 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 4.0 ppt_? -115.67 34.62 4.83 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.863 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -67.11 166.94 12.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.116 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -49.34 164.9 0.29 Allowed Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.647 0.737 . . . . 0.0 110.878 -179.825 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 -11.87 31.68 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.655 2.237 . . . . 0.0 112.345 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -79.12 -36.58 40.36 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.9 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.4 t -48.88 -32.87 9.61 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.132 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -65.33 -48.37 73.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.816 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 52.3 mt -59.7 -45.24 94.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.137 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.9 mt -55.14 -51.69 52.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.127 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -58.11 -36.29 72.68 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.83 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -62.79 -58.86 5.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.118 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 9.7 t -51.0 -51.14 22.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.138 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 88.7 t -48.7 -59.61 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.146 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -49.88 -54.49 17.95 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.51 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 62.5 mt -58.48 -54.84 27.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.854 0.359 . . . . 0.0 111.114 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.42 -59.44 3.72 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.903 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.443 ' HA ' HG23 ' B' ' 126' ' ' VAL . 9.0 mt -43.44 -55.52 4.12 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.918 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 87.2 t -52.4 -51.26 34.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.144 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.8 t -61.75 -40.5 87.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.141 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.447 HG23 ' HA ' ' B' ' 123' ' ' LEU . 44.2 t -51.22 -59.28 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.149 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 47.6 mt -67.45 -46.41 73.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.894 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.62 -48.13 50.4 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.491 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.4 t -75.97 -54.19 14.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.883 0.373 . . . . 0.0 111.142 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 20.3 t -49.72 -42.78 18.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.11 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -77.52 -34.84 53.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.892 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -57.39 -48.69 78.77 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.494 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 16.0 mt -76.91 -47.56 27.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.869 0.366 . . . . 0.0 111.141 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 28.2 mt -55.41 -53.13 60.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.937 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 79.3 mt -63.46 -49.49 82.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.123 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 27.8 ttpt -62.3 -16.87 56.68 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.891 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 46.0 mtp85 -84.02 -37.91 21.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.861 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.07 -49.16 8.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.891 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.7 mt-30 49.59 52.29 14.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.875 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 11.7 mm100 -115.68 48.49 1.2 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.886 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 3.8 tppt? -152.93 136.33 15.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.906 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 1.9 mt 45.91 83.57 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.143 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 15.6 ttm180 -85.82 130.7 34.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.883 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 22.5 ttmm . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 179.95 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 7.0 p -135.15 68.84 69.86 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.62 0.724 . . . . 0.0 110.9 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 171.32 14.67 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.731 2.287 . . . . 0.0 112.37 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . 54.54 49.45 18.22 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.065 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -99.52 31.31 3.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.89 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 20.8 mt-30 -117.83 136.43 53.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.887 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 3.3 ppt_? -115.17 9.79 15.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.869 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 108' ' ' ALA . . . . . . . . . . . . . . . -100.6 166.75 10.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.091 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 109' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -50.97 164.1 0.46 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.693 0.758 . . . . 0.0 110.879 -179.76 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 -11.77 31.55 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.678 2.252 . . . . 0.0 112.359 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 111' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -81.96 -34.67 29.63 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.911 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 112' ' ' THR . . . . . . . . . . . . . 6.1 t -48.79 -31.76 7.56 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.188 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -65.4 -50.16 66.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.844 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 114' ' ' ILE . . . . . . . . . . . . . 50.1 mt -59.14 -45.91 92.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.105 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 6.8 mt -53.91 -52.23 37.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.14 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -57.85 -36.62 72.58 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.863 -179.896 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -62.7 -58.75 6.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.098 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 10.1 t -50.85 -51.45 20.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.111 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 87.8 t -48.49 -59.68 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.127 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.79 -54.74 16.61 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.481 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 63.7 mt -58.32 -54.93 26.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.843 0.354 . . . . 0.0 111.119 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 122' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.35 -59.8 3.39 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.911 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 123' ' ' LEU . . . . . 0.447 ' HA ' HG23 ' A' ' 26' ' ' VAL . 9.1 mt -43.18 -55.56 3.88 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.9 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 87.0 t -52.38 -51.61 31.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.11 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 72.5 t -61.4 -40.49 86.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.114 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 126' ' ' VAL . . . . . 0.443 HG23 ' HA ' ' A' ' 23' ' ' LEU . 43.8 t -51.27 -59.27 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.129 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 127' ' ' LEU . . . . . . . . . . . . . 47.3 mt -67.52 -46.37 73.03 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.904 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.61 -47.81 51.17 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.537 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.6 t -76.25 -54.17 13.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.911 0.386 . . . . 0.0 111.141 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 130' ' ' VAL . . . . . . . . . . . . . 19.9 t -49.81 -42.54 18.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.112 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -77.66 -35.19 52.67 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.879 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -57.32 -48.38 80.85 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.496 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 17.2 mt -77.05 -47.81 26.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.855 0.36 . . . . 0.0 111.121 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 28.2 mt -55.29 -53.05 60.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.904 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 77.9 mt -63.39 -49.84 81.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.17 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 27.9 ttpt -61.96 -17.06 55.67 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.888 179.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 46.1 mtp85 -83.74 -38.15 21.74 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.835 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.75 -49.16 8.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.865 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 2.6 mt-30 49.08 51.74 15.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.886 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 13.1 mm100 -114.68 46.36 1.41 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.965 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 4.9 tppt? -156.94 141.48 16.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.929 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 142' ' ' ILE . . . . . . . . . . . . . 5.4 pt -44.09 105.79 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.105 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 16.3 ttm180 -70.93 130.66 42.18 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.861 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 22.1 ttmm . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.867 179.979 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.504 -0.238 . . . . 0.0 112.504 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 4.6 p -140.91 156.57 68.54 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.558 0.694 . . . . 0.0 110.896 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -172.89 0.62 Allowed 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.685 2.257 . . . . 0.0 112.312 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.88 161.4 4.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.11 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 17.2 tp10 -56.65 111.84 1.12 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.889 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 1.6 tp60 -115.9 141.1 48.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.856 -179.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.37 176.94 9.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.863 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -142.38 168.78 18.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.101 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -49.62 164.51 0.33 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.663 0.744 . . . . 0.0 110.877 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.7 -11.62 31.3 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.674 2.249 . . . . 0.0 112.355 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 2.5 tm? -80.77 -35.91 32.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.902 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.4 t -48.88 -32.03 8.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.119 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.39 -50.87 65.95 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.913 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 3.3 mp -59.1 -43.16 88.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.088 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 13.1 mt -55.26 -53.17 37.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.097 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.3 t -57.87 -36.3 72.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.873 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -62.46 -58.64 6.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.076 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 9.6 t -51.38 -51.07 25.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.123 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 95.0 t -48.55 -59.49 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.081 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -50.07 -54.46 18.88 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.527 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 66.9 mt -58.5 -54.77 28.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.919 0.39 . . . . 0.0 111.131 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.4 -59.7 3.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.922 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.445 ' HA ' HG23 ' B' ' 126' ' ' VAL . 9.1 mt -43.24 -55.53 3.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.905 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 87.2 t -52.4 -51.47 32.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.152 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.7 t -61.52 -40.59 87.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.118 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.435 HG23 ' HA ' ' B' ' 123' ' ' LEU . 43.3 t -51.29 -59.12 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.108 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 46.4 mt -67.79 -46.36 72.19 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.899 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.6 -47.8 51.13 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.472 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -76.26 -54.32 13.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.862 0.363 . . . . 0.0 111.11 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 20.1 t -49.7 -42.5 17.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.137 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 4.7 m-85 -77.85 -37.34 48.56 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.85 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -56.29 -47.78 79.76 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.499 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 19.5 mt -76.69 -49.4 24.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.833 0.349 . . . . 0.0 111.149 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 28.6 mt -53.81 -52.86 58.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.955 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 49.2 mt -63.59 -47.48 91.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.135 179.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 32.3 ttpt -62.84 -17.97 62.16 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.844 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -82.53 -39.38 22.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.863 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 11.0 mtp180 -83.71 -48.99 9.57 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.866 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 3.7 mt-30 49.55 41.81 21.89 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.864 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 9.1 mm100 -125.13 116.29 21.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.915 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 25.4 pttt -171.6 167.44 6.57 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.928 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 4.6 pt -63.57 143.11 15.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.11 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? -103.3 62.55 0.79 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.884 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.911 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.46 -0.256 . . . . 0.0 112.46 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 4.5 p -141.64 156.6 66.28 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.656 0.741 . . . . 0.0 110.875 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -171.99 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.699 2.266 . . . . 0.0 112.361 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . -58.47 161.45 4.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.112 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 16.8 tp10 -56.91 110.82 0.88 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.872 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -117.65 141.09 48.78 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.89 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.41 177.44 8.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.875 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 108' ' ' ALA . . . . . . . . . . . . . . . -138.74 169.09 18.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.076 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 109' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -49.9 164.53 0.35 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.678 0.751 . . . . 0.0 110.834 -179.798 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -11.57 31.17 Favored 'Trans proline' 0 C--O 1.232 0.223 0 C-N-CA 122.693 2.262 . . . . 0.0 112.368 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 111' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -80.75 -36.05 32.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.937 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 112' ' ' THR . . . . . . . . . . . . . 6.4 t -49.13 -31.8 8.86 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.15 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.83 -50.88 64.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.803 -179.847 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 114' ' ' ILE . . . . . . . . . . . . . 3.3 mp -58.9 -43.51 88.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.095 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 13.1 mt -55.11 -53.77 31.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.117 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 11.7 t -57.47 -35.59 70.36 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.902 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -63.1 -58.65 6.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.089 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.8 t -51.35 -51.0 25.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.155 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 93.6 t -48.63 -59.43 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.147 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -50.13 -54.49 18.96 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.472 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 67.0 mt -58.48 -54.85 27.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.917 0.389 . . . . 0.0 111.16 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 122' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.31 -59.94 3.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.897 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 123' ' ' LEU . . . . . 0.435 ' HA ' HG23 ' A' ' 26' ' ' VAL . 9.2 mt -43.12 -55.41 3.9 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.933 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 87.4 t -52.55 -51.62 32.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.104 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 72.5 t -61.38 -40.61 86.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.1 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 126' ' ' VAL . . . . . 0.445 HG23 ' HA ' ' A' ' 23' ' ' LEU . 43.1 t -51.19 -59.19 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.121 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 127' ' ' LEU . . . . . . . . . . . . . 45.4 mt -67.8 -46.15 72.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.972 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.69 -47.9 51.4 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.461 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.0 t -76.24 -54.19 13.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.895 0.379 . . . . 0.0 111.093 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 130' ' ' VAL . . . . . . . . . . . . . 20.2 t -49.7 -42.59 17.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.141 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -77.72 -37.03 50.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.879 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -56.04 -47.86 77.52 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.517 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 18.2 mt -77.07 -49.25 23.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.826 0.346 . . . . 0.0 111.127 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 27.8 mt -53.57 -52.02 61.07 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.919 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 49.3 mt -64.85 -46.67 91.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.096 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 32.1 ttpt -63.36 -17.28 62.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.899 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -83.8 -38.83 20.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.908 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 11.1 mtp180 -84.38 -48.82 9.29 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.874 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 50.66 41.27 25.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.905 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 9.0 mm100 -126.68 115.7 19.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.935 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 25.1 pttt -169.32 176.8 5.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.865 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 142' ' ' ILE . . . . . . . . . . . . . 4.7 pt -55.57 148.87 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.142 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 2.2 mtt180 -97.1 77.13 2.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.827 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.934 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.454 -0.258 . . . . 0.0 112.454 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 26.5 t -173.8 72.46 0.36 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.604 0.716 . . . . 0.0 110.899 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 84.04 0.68 Allowed 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.666 2.244 . . . . 0.0 112.353 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -171.18 179.4 3.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.094 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -63.08 -177.18 0.16 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.857 -179.908 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -70.56 83.96 0.61 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.874 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 21.5 ttm-85 -105.68 130.36 53.71 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.924 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -137.0 157.95 45.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.09 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -51.13 163.48 0.52 Allowed Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.705 0.764 . . . . 0.0 110.852 -179.763 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -11.96 31.91 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.648 2.232 . . . . 0.0 112.368 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -79.02 -26.26 43.24 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.916 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 13.6 t -50.71 -36.08 34.42 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.166 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -56.86 -52.52 64.79 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.866 -179.838 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 4.1 mp -60.16 -40.4 83.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.097 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 44.7 mt -54.37 -55.84 12.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.184 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.8 t -58.64 -36.71 74.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.884 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -62.34 -57.16 12.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.069 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 12.0 t -52.24 -51.09 34.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.148 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 94.9 t -48.79 -59.15 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.137 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -50.26 -54.72 18.59 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.492 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 92.5 mt -58.37 -54.83 27.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.861 0.362 . . . . 0.0 111.089 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.28 -59.81 3.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.933 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.413 ' HA ' HG23 ' B' ' 126' ' ' VAL . 9.4 mt -43.21 -55.36 4.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.873 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 90.5 t -52.61 -51.6 33.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.112 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 70.9 t -61.37 -40.56 86.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.108 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.433 HG23 ' HA ' ' B' ' 123' ' ' LEU . 43.0 t -51.25 -59.3 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.133 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 44.5 mt -68.01 -46.26 71.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.906 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.51 -47.52 51.33 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.49 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.5 t -76.74 -54.21 13.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.855 0.359 . . . . 0.0 111.12 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 20.1 t -49.73 -42.02 17.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.118 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 5.3 m-85 -78.28 -34.29 48.99 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.885 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -57.51 -46.89 91.5 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.509 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 17.6 mt -79.38 -45.48 23.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.848 0.356 . . . . 0.0 111.116 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 27.4 mt -57.84 -43.79 86.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.868 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 72.4 mt -71.28 -58.95 4.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.161 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 8.3 pttp -51.56 -28.06 12.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.937 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 49.5 mtp85 -77.75 -37.14 49.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.9 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 29.3 mtt180 -63.26 -28.35 69.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.878 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -174.36 138.23 0.54 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.947 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 18.3 pt20 -171.54 164.3 6.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.919 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 14.4 pttp -98.37 31.91 2.66 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.846 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.5 pp -148.59 178.24 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.118 179.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 6.3 ptm180 -121.93 141.28 51.46 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.921 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 6.5 tmtt? . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.908 179.904 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.286 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 24.1 t -174.11 72.87 0.34 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.605 0.716 . . . . 0.0 110.912 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.76 83.14 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.623 2.215 . . . . 0.0 112.341 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . -171.2 178.24 3.37 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.135 179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -64.17 -176.62 0.22 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.873 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -71.15 83.19 0.72 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.908 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 21.6 ttm-85 -105.69 128.81 53.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.846 -179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 108' ' ' ALA . . . . . . . . . . . . . . . -139.78 158.37 44.21 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.131 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 109' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -51.06 163.36 0.52 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.632 0.729 . . . . 0.0 110.872 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -11.98 31.93 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.718 2.279 . . . . 0.0 112.314 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 111' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -79.33 -26.35 42.18 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.95 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 112' ' ' THR . . . . . . . . . . . . . 13.1 t -50.77 -35.96 34.45 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.152 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -56.91 -52.52 64.86 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.867 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 114' ' ' ILE . . . . . . . . . . . . . 4.1 mp -60.18 -40.41 83.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.118 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 42.7 mt -54.28 -55.96 12.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.122 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 7.7 t -58.78 -36.49 74.51 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.85 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -62.64 -57.0 12.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.082 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 12.0 t -52.35 -51.09 35.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.127 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 95.5 t -48.89 -59.17 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.141 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -50.2 -54.63 18.7 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.525 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 92.9 mt -58.4 -54.84 27.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.867 0.365 . . . . 0.0 111.158 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 122' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.26 -59.87 3.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.945 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 123' ' ' LEU . . . . . 0.433 ' HA ' HG23 ' A' ' 26' ' ' VAL . 9.3 mt -43.08 -55.49 3.83 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.916 179.841 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 90.0 t -52.61 -51.51 34.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.13 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 69.9 t -61.48 -40.31 85.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.111 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 126' ' ' VAL . . . . . 0.413 HG23 ' HA ' ' A' ' 23' ' ' LEU . 43.1 t -51.4 -59.14 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.146 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 127' ' ' LEU . . . . . . . . . . . . . 45.6 mt -68.02 -46.41 71.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.875 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.6 -47.29 52.42 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.467 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.6 t -76.83 -54.18 13.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.853 0.358 . . . . 0.0 111.159 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 130' ' ' VAL . . . . . . . . . . . . . 19.7 t -49.8 -41.92 17.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.118 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -78.4 -36.37 45.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.859 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -56.06 -46.38 85.03 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.506 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 18.4 mt -79.18 -49.9 19.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 120.889 0.376 . . . . 0.0 111.151 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 27.8 mt -53.1 -48.1 68.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.933 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 69.9 mt -68.92 -49.93 58.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.125 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 11.5 tttp -52.68 -30.53 32.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.899 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 54.2 mtp85 -80.2 -35.07 36.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.86 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 29.5 mtt180 -61.49 -25.58 67.34 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 12.4 pt20 -172.82 138.07 0.79 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.893 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 18.0 pt20 -172.29 165.32 5.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.862 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 14.4 pttp -96.52 32.92 1.91 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.915 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 142' ' ' ILE . . . . . . . . . . . . . 2.5 pp -147.85 177.77 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.119 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 19.6 ttm-85 -122.77 141.38 51.88 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.82 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 6.5 tmtt? . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.966 179.923 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.381 0 N-CA-C 112.531 -0.228 . . . . 0.0 112.531 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 79.3 m -142.5 71.14 21.17 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-O 121.645 0.736 . . . . 0.0 110.89 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.77 154.87 67.18 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.692 2.261 . . . . 0.0 112.333 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -167.5 163.8 14.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.092 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -70.2 120.2 15.53 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.881 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 41.6 tt0 -154.91 150.03 26.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.916 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -78.07 132.22 37.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.915 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -137.75 169.89 17.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.031 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -50.71 163.92 0.45 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.668 0.747 . . . . 0.0 110.866 -179.801 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 -11.94 31.9 Favored 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.63 2.22 . . . . 0.0 112.346 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -79.9 -30.38 40.1 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.931 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 8.3 t -51.14 -34.78 32.6 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.156 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -59.46 -49.99 75.65 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.906 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 60.3 mt -61.14 -41.21 88.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.108 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 26.6 mm -55.14 -54.9 19.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.094 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -58.15 -37.36 74.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.888 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -61.74 -57.82 10.41 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.092 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.3 t -51.59 -51.21 27.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.122 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 84.0 t -48.62 -59.96 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.161 179.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -49.54 -54.71 15.74 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.475 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 96.2 mt -58.35 -54.81 27.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.884 0.373 . . . . 0.0 111.183 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.45 -59.56 3.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.871 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.44 ' HA ' HG22 ' B' ' 126' ' ' VAL . 8.8 mt -43.19 -55.55 3.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.925 179.869 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 89.7 t -52.48 -51.74 31.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.144 179.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 73.4 t -61.44 -39.87 84.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.158 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.439 HG22 ' HA ' ' B' ' 123' ' ' LEU . 46.0 t -51.64 -58.69 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.131 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 56.6 mt -67.25 -47.6 70.25 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.962 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.3 -47.46 50.31 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.476 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.9 t -75.99 -54.4 13.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.904 0.383 . . . . 0.0 111.166 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 19.4 t -49.46 -43.29 17.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.13 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 7.5 m-85 -77.2 -41.53 41.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.879 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -53.35 -48.16 60.48 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.477 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 38.4 mt -74.89 -50.91 23.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.859 0.361 . . . . 0.0 111.115 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 23.2 mt -51.25 -57.64 8.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.937 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 14.4 mt -59.81 -48.48 87.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.126 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 14.8 tttm -50.48 -52.88 34.2 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.914 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 46.3 mtp85 -59.12 -38.68 80.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.91 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 48.8 mtp180 -65.16 -47.71 76.07 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.866 -179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 67.4 mt-30 -55.31 174.74 0.08 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.892 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -90.7 107.95 19.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.949 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 31.4 mttt -140.03 168.51 19.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.875 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 70.4 mt -136.39 126.31 39.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.115 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 13.1 mmt-85 -70.11 168.83 14.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.918 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 1.6 mtpp . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.894 179.97 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.372 0 N-CA-C 112.514 -0.234 . . . . 0.0 112.514 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 79.1 m -142.48 71.31 21.19 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.623 0.725 . . . . 0.0 110.864 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 154.6 67.39 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.69 2.26 . . . . 0.0 112.309 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . -167.58 164.53 14.69 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.076 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -69.38 121.46 16.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.908 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 41.5 tt0 -152.29 149.43 28.67 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.914 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -79.51 132.65 36.39 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.839 -179.858 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 108' ' ' ALA . . . . . . . . . . . . . . . -136.46 169.25 17.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.089 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 109' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -50.67 163.66 0.46 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.701 0.762 . . . . 0.0 110.841 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -11.66 31.29 Favored 'Trans proline' 0 C--O 1.233 0.231 0 C-N-CA 122.645 2.23 . . . . 0.0 112.35 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 111' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -81.58 -30.71 32.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.882 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 112' ' ' THR . . . . . . . . . . . . . 6.8 t -51.29 -34.55 33.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.185 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -59.43 -49.61 77.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.892 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 114' ' ' ILE . . . . . . . . . . . . . 60.2 mt -61.74 -41.63 91.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.164 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 26.5 mm -54.48 -55.58 14.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.134 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -58.38 -36.93 74.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.854 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -62.15 -57.66 10.7 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.066 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 11.6 t -51.7 -51.34 27.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.181 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 89.1 t -48.6 -59.47 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.13 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -50.05 -54.88 17.09 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.484 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 96.3 mt -58.28 -54.87 26.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.908 0.385 . . . . 0.0 111.128 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 122' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.3 -59.69 3.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.907 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 123' ' ' LEU . . . . . 0.439 ' HA ' HG22 ' A' ' 26' ' ' VAL . 9.3 mt -43.22 -55.71 3.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.914 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 90.4 t -52.33 -51.83 29.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.087 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 74.0 t -61.19 -40.74 86.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.104 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 126' ' ' VAL . . . . . 0.44 HG22 ' HA ' ' A' ' 23' ' ' LEU . 45.4 t -50.89 -59.49 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.132 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 127' ' ' LEU . . . . . . . . . . . . . 49.0 mt -67.43 -46.67 72.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.924 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -50.89 -47.4 47.85 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.486 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 58.4 t -77.77 -54.66 12.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.895 0.379 . . . . 0.0 111.156 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 130' ' ' VAL . . . . . . . . . . . . . 20.4 t -49.31 -39.15 12.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.125 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 3.5 m-30 -76.32 -42.76 43.97 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.874 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -51.74 -50.21 44.26 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.509 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 40.6 mt -73.23 -52.06 23.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.907 0.384 . . . . 0.0 111.131 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 24.5 mt -50.52 -61.35 2.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.932 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 13.6 mt -56.59 -46.46 82.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.152 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 14.6 tttm -51.08 -55.97 14.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.907 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 46.6 mtp85 -53.63 -39.8 65.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.846 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 47.8 mtp180 -64.21 -45.95 86.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.873 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 67.6 mt-30 -55.85 176.42 0.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.9 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -89.42 106.95 18.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.883 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 31.0 mttt -139.73 166.96 23.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.892 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 142' ' ' ILE . . . . . . . . . . . . . 70.0 mt -138.43 125.02 26.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.075 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 13.5 mmt-85 -71.65 170.23 13.9 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.925 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 1.4 mppp? . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.901 179.985 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 112.522 -0.231 . . . . 0.0 112.522 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 1.2 m -53.53 160.75 1.77 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.598 0.713 . . . . 0.0 110.864 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 165.45 30.99 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.664 2.242 . . . . 0.0 112.309 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -46.15 105.51 0.06 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.128 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -91.89 160.26 15.37 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.852 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 14.6 tt0 -56.96 157.81 5.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.912 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.79 -29.25 29.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.899 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -156.89 165.17 36.96 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.062 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -51.77 162.54 0.74 Allowed Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.69 0.757 . . . . 0.0 110.862 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 -14.81 36.37 Favored 'Trans proline' 0 C--O 1.232 0.203 0 C-N-CA 122.676 2.251 . . . . 0.0 112.349 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -74.19 -18.15 60.8 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.937 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 8.9 t -48.6 -39.95 25.67 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.121 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -51.62 -53.9 33.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.861 -179.849 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 58.9 mt -60.31 -41.25 86.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.139 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 26.2 mt -52.72 -57.75 3.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.121 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 33.5 t -57.46 -37.55 73.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.885 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -61.01 -57.79 11.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.077 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.3 t -51.86 -50.69 32.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.101 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 86.6 t -48.85 -60.23 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.161 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -49.49 -54.28 17.19 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.465 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 39.0 mt -58.52 -54.72 29.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.862 0.363 . . . . 0.0 111.156 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.71 -59.49 3.76 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.892 179.898 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.435 ' HA ' HG23 ' B' ' 126' ' ' VAL . 8.5 mt -43.23 -55.35 4.03 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.919 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 91.8 t -52.46 -51.74 31.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.127 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 74.8 t -61.62 -39.84 84.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.171 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.441 HG23 ' HA ' ' B' ' 123' ' ' LEU . 46.5 t -51.62 -59.51 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.13 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 57.0 mt -66.39 -47.81 72.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.876 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.18 -47.58 49.31 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.452 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.4 t -76.32 -54.59 13.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.825 0.345 . . . . 0.0 111.141 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 19.8 t -49.34 -42.33 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.141 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -77.05 -44.39 30.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -52.35 -48.61 53.81 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.458 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 42.2 mt -73.03 -52.06 23.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.88 0.371 . . . . 0.0 111.118 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 22.8 mt -51.21 -60.78 2.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.876 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 11.9 mt -55.56 -49.07 76.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.16 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 8.0 tmtt? -58.13 -25.99 62.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 32.4 mtp180 -81.65 -31.57 32.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.04 -47.97 82.35 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.879 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -59.79 123.48 17.12 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.914 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -175.37 172.37 2.7 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.861 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 21.2 mttm -85.81 139.88 30.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.852 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -154.25 144.83 13.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.111 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 44.4 mtp180 -107.19 112.54 25.47 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.854 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 4.4 tppp? . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.862 179.942 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.455 -0.258 . . . . 0.0 112.455 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 1.2 m -54.58 160.71 2.53 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.582 0.706 . . . . 0.0 110.877 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 160.43 49.72 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.687 2.258 . . . . 0.0 112.322 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . 45.98 84.87 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -100.12 159.13 15.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.903 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 14.1 tt0 -57.64 161.17 3.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.88 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.87 -26.61 40.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.873 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 108' ' ' ALA . . . . . . . . . . . . . . . -155.32 167.64 29.69 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.078 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 109' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -51.52 162.58 0.68 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.685 0.755 . . . . 0.0 110.836 -179.811 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 -15.09 37.1 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.701 2.267 . . . . 0.0 112.348 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 111' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -74.46 -18.45 60.63 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.947 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 112' ' ' THR . . . . . . . . . . . . . 10.1 t -48.58 -39.81 25.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.169 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -51.75 -53.59 37.91 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.869 -179.841 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 114' ' ' ILE . . . . . . . . . . . . . 59.2 mt -60.49 -41.29 87.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.085 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 25.4 mt -53.12 -57.73 4.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.12 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 33.6 t -57.26 -37.41 72.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.846 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -60.99 -58.02 10.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.09 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 11.3 t -51.86 -50.7 32.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.155 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 87.7 t -48.82 -60.26 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.134 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.44 -54.25 17.13 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.488 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 38.8 mt -58.56 -54.85 27.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.857 0.361 . . . . 0.0 111.135 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 122' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.57 -59.43 3.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.945 179.884 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 123' ' ' LEU . . . . . 0.441 ' HA ' HG23 ' A' ' 26' ' ' VAL . 8.5 mt -43.28 -55.35 4.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.942 179.883 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 92.1 t -52.39 -51.81 30.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.135 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 74.8 t -61.61 -39.83 84.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.12 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 126' ' ' VAL . . . . . 0.435 HG23 ' HA ' ' A' ' 23' ' ' LEU . 46.2 t -51.67 -59.58 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.141 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 127' ' ' LEU . . . . . . . . . . . . . 55.9 mt -66.31 -47.81 72.34 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.937 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.21 -47.52 49.61 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.47 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 55.9 t -76.34 -54.63 13.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.848 0.356 . . . . 0.0 111.142 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 130' ' ' VAL . . . . . . . . . . . . . 20.2 t -49.28 -42.37 15.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.132 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -76.95 -44.57 30.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.933 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -52.28 -48.55 53.51 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.489 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 42.2 mt -73.02 -52.1 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.846 0.355 . . . . 0.0 111.18 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 23.0 mt -51.17 -60.87 2.64 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.919 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 11.8 mt -55.42 -49.52 72.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.129 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 8.0 tmtt? -57.7 -26.18 61.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.89 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 32.1 mtp180 -81.41 -31.69 33.08 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.892 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.6 -47.9 83.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.889 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -60.49 123.65 17.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -175.4 174.18 2.38 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.934 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 21.2 mttm -84.14 141.15 31.29 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.875 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 142' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -153.5 145.39 14.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.121 179.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 23.5 mtm180 -106.92 113.45 26.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.882 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 4.4 tppp? . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.91 179.956 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 N-CA-C 112.511 -0.236 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 36.5 m -132.43 72.66 77.98 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.624 0.726 . . . . 0.0 110.886 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.71 -177.5 1.89 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.663 2.242 . . . . 0.0 112.403 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -78.56 -167.13 0.99 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.089 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -81.91 109.1 15.96 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.88 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 6.9 tp60 -71.23 142.74 50.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.896 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 20.8 ptt180 -69.21 146.94 51.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -126.29 166.82 16.43 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.141 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -49.39 165.13 0.29 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.646 0.736 . . . . 0.0 110.895 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.72 -11.54 31.09 Favored 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.702 2.268 . . . . 0.0 112.355 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -77.24 -36.45 54.54 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.878 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.7 t -48.7 -33.2 9.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.125 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 1.5 t -64.98 -49.4 70.42 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.933 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 56.2 mt -58.77 -46.0 90.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.088 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 17.0 mt -54.55 -51.44 50.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.098 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 1.9 t -57.14 -37.86 72.66 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.887 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -62.02 -59.57 4.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.096 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.4 t -50.81 -50.87 22.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.133 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 96.0 t -48.4 -59.46 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.087 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -50.44 -54.52 20.13 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.538 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 99.0 mt -58.41 -54.82 27.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.826 0.346 . . . . 0.0 111.124 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.54 -59.44 3.76 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.902 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.46 ' HA ' HG22 ' B' ' 126' ' ' VAL . 9.8 mt -43.31 -55.33 4.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.884 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 89.5 t -52.6 -52.03 30.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.114 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.9 t -61.05 -40.21 84.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.126 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.463 HG22 ' HA ' ' B' ' 123' ' ' LEU . 44.5 t -51.64 -59.29 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.101 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 48.6 mt -67.58 -46.66 71.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.893 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.6 -47.57 51.73 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.451 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -76.41 -54.16 13.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.896 0.379 . . . . 0.0 111.148 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 19.8 t -49.79 -42.65 18.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.145 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 4.7 m-85 -77.44 -40.58 42.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.902 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -53.48 -48.4 60.5 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.49 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 28.8 mt -75.56 -50.47 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.849 0.357 . . . . 0.0 111.11 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 22.4 mt -51.28 -56.71 11.55 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.947 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 18.2 mt -60.96 -49.34 85.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.116 179.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 30.7 ttpt -54.98 -29.44 57.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.854 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 56.8 mtp180 -78.04 -37.0 47.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.879 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -67.96 -42.07 81.47 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.841 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -76.26 75.68 3.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.932 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 7.4 mm-40 -118.41 176.31 5.3 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.932 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 16.2 mmtp -108.19 140.1 41.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.929 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.2 tt -129.02 148.75 33.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.141 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 65.5 mtt180 -95.25 176.44 6.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.887 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 10.6 ptpp? . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.914 179.971 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 36.2 m -131.56 72.87 80.1 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.641 0.734 . . . . 0.0 110.88 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 -174.41 0.91 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.695 2.263 . . . . 0.0 112.342 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . -75.09 -82.38 0.07 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.09 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -78.32 112.13 15.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.865 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 6.9 tp60 -67.8 144.92 55.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.918 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 20.9 ptt180 -66.65 149.5 50.41 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 108' ' ' ALA . . . . . . . . . . . . . . . -123.18 159.69 28.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.05 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 109' ' ' SER . . . . . 0.404 ' CB ' ' HD2' ' B' ' 110' ' ' PRO . 0.3 OUTLIER -48.51 165.71 0.24 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.668 0.747 . . . . 0.0 110.836 -179.791 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 110' ' ' PRO . . . . . 0.404 ' HD2' ' CB ' ' B' ' 109' ' ' SER . 53.9 Cg_endo -69.75 -17.23 37.75 Favored 'Trans proline' 0 C--O 1.232 0.201 0 C-N-CA 122.69 2.26 . . . . 0.0 112.326 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 111' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -88.52 -45.34 9.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.903 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 112' ' ' THR . . . . . . . . . . . . . 1.4 t -69.54 -30.58 68.42 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.167 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 1.8 t -65.97 -50.16 65.3 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.886 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 114' ' ' ILE . . . . . . . . . . . . . 71.5 mt -62.34 -49.0 85.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.13 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 39.6 mt -51.79 -50.39 32.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.143 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 1.9 t -59.93 -37.5 79.68 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.872 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -61.25 -58.29 8.88 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.08 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 11.0 t -51.64 -51.05 28.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.112 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 91.1 t -48.37 -59.35 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.141 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -50.51 -54.68 19.77 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.522 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 98.9 mt -58.23 -54.88 26.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.844 0.355 . . . . 0.0 111.103 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 122' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.37 -59.55 3.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.937 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 123' ' ' LEU . . . . . 0.463 ' HA ' HG22 ' A' ' 26' ' ' VAL . 9.6 mt -43.28 -55.32 4.09 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.925 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 90.4 t -52.74 -51.96 31.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.119 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 72.7 t -60.94 -40.25 84.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.129 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 126' ' ' VAL . . . . . 0.46 HG22 ' HA ' ' A' ' 23' ' ' LEU . 44.9 t -51.47 -59.3 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.141 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 127' ' ' LEU . . . . . . . . . . . . . 49.7 mt -67.59 -46.88 71.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.907 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.52 -47.53 51.33 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.453 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.0 t -76.24 -54.37 13.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.892 0.377 . . . . 0.0 111.153 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 130' ' ' VAL . . . . . . . . . . . . . 19.7 t -49.69 -42.71 17.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.114 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -77.41 -41.04 41.41 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.864 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -53.27 -48.43 59.45 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.486 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 30.1 mt -75.25 -50.37 24.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.827 0.346 . . . . 0.0 111.117 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 21.9 mt -51.53 -57.42 9.11 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.894 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 17.2 mt -59.94 -50.01 81.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.115 179.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 31.0 ttpt -55.82 -28.02 54.2 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.897 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 55.3 mtp180 -79.68 -33.55 41.06 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.883 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 1.2 mtt-85 -57.56 -46.13 84.3 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.879 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -91.83 43.46 1.14 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.944 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 9.9 mm-40 -152.32 -179.63 7.72 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.887 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 15.2 mmtp -107.09 129.86 54.76 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.9 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 142' ' ' ILE . . . . . . . . . . . . . 21.5 tt -135.96 149.34 27.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.133 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 66.5 mtt180 -96.5 179.34 5.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.897 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 10.6 ptpp? . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.909 179.957 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 N-CA-C 112.453 -0.259 . . . . 0.0 112.453 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 4.8 t -154.99 68.27 5.43 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.629 0.728 . . . . 0.0 110.901 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 -174.06 0.83 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.688 2.258 . . . . 0.0 112.31 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -104.15 150.69 24.12 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.097 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 13.0 tt0 -59.41 146.46 39.96 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.867 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 34.6 mm-40 -100.53 39.24 1.39 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.912 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 3.6 tpp85 -102.94 149.92 24.05 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.886 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -150.71 170.97 17.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.104 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -50.32 164.57 0.38 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.691 0.758 . . . . 0.0 110.873 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -11.74 31.51 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 122.707 2.272 . . . . 0.0 112.347 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -80.7 -36.46 32.23 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.916 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.3 t -48.45 -32.22 7.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.169 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -64.69 -48.09 75.96 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.884 -179.877 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 53.6 mt -61.35 -45.6 98.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.144 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 10.9 mt -53.45 -53.86 21.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.144 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 43.6 t -57.62 -37.44 73.28 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.853 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -62.79 -57.96 9.1 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.076 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 9.5 t -51.36 -51.62 23.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.159 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 99.4 t -48.48 -59.04 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.105 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -50.23 -54.81 18.12 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.486 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 55.1 mt -58.43 -54.89 26.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.856 0.36 . . . . 0.0 111.124 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.1 -59.83 3.31 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.948 179.884 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.446 ' HA ' HG23 ' B' ' 126' ' ' VAL . 9.6 mt -43.29 -55.65 3.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.935 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 88.4 t -52.47 -51.14 35.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.142 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 69.8 t -61.6 -40.65 87.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.082 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.438 HG23 ' HA ' ' B' ' 123' ' ' LEU . 41.8 t -51.37 -58.89 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.136 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 45.9 mt -68.47 -46.16 70.51 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.912 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.79 -47.62 52.65 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.477 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.7 t -76.11 -54.32 13.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.918 0.389 . . . . 0.0 111.169 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 20.0 t -49.8 -43.01 18.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.114 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -77.61 -41.5 38.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.902 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -53.28 -47.36 61.95 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.489 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 22.3 mt -76.04 -51.37 20.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.833 0.349 . . . . 0.0 111.141 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 23.7 mt -51.0 -55.92 15.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.903 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 18.3 mt -61.71 -48.48 88.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.116 179.83 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 3.9 tmtt? -51.13 -45.3 61.58 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.886 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 43.1 mtp85 -63.9 -38.75 92.24 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.903 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 65.0 mtp85 -68.54 -43.77 75.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.856 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 13.8 mm100 -57.52 -179.51 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.9 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -70.3 176.31 4.04 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.896 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 4.6 mmmm -115.84 65.45 0.7 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.93 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 32.3 mm -91.88 122.49 43.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.175 179.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 71.0 mtm180 -108.01 69.04 0.72 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.975 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.484 -0.246 . . . . 0.0 112.484 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 4.8 t -155.02 69.13 5.59 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.633 0.73 . . . . 0.0 110.848 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -175.81 1.27 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.652 2.235 . . . . 0.0 112.357 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . -106.29 150.67 25.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.113 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -60.91 150.36 33.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.894 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 37.2 mm-40 -95.79 37.69 1.2 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.943 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 2.9 tpp85 -105.23 -78.67 0.57 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.852 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 108' ' ' ALA . . . . . . . . . . . . . . . -141.07 173.18 11.73 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.128 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 109' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -49.51 164.34 0.33 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.654 0.74 . . . . 0.0 110.849 -179.756 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -11.61 31.18 Favored 'Trans proline' 0 C--O 1.232 0.216 0 C-N-CA 122.685 2.256 . . . . 0.0 112.329 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 111' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -81.84 -36.61 28.09 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.929 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 112' ' ' THR . . . . . . . . . . . . . 6.0 t -48.62 -31.86 7.31 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.134 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -65.12 -47.71 76.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.83 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 114' ' ' ILE . . . . . . . . . . . . . 52.6 mt -61.68 -45.66 98.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.099 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 10.9 mt -53.53 -54.04 21.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.147 179.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 43.5 t -57.52 -37.5 73.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.852 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -62.81 -57.88 9.37 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.101 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.3 t -51.54 -51.51 25.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.17 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 98.9 t -48.51 -59.04 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.129 179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -50.29 -54.8 18.39 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.493 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 55.5 mt -58.46 -54.88 27.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.865 0.364 . . . . 0.0 111.119 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 122' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.1 -59.85 3.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.897 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 123' ' ' LEU . . . . . 0.438 ' HA ' HG23 ' A' ' 26' ' ' VAL . 9.7 mt -43.26 -55.77 3.84 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 89.3 t -52.43 -51.21 34.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.173 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 69.2 t -61.48 -40.56 86.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.161 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 126' ' ' VAL . . . . . 0.446 HG23 ' HA ' ' A' ' 23' ' ' LEU . 42.3 t -51.5 -59.18 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.092 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 127' ' ' LEU . . . . . . . . . . . . . 45.2 mt -68.14 -46.26 71.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.916 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.56 -47.65 51.29 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.507 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 56.0 t -76.37 -54.25 13.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.845 0.355 . . . . 0.0 111.077 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 130' ' ' VAL . . . . . . . . . . . . . 20.2 t -49.8 -42.72 18.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.114 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -77.77 -41.96 35.7 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.859 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -52.93 -47.16 60.08 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.491 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 22.6 mt -76.16 -51.55 19.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.884 0.373 . . . . 0.0 111.141 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 23.2 mt -50.8 -55.79 15.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.861 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 17.4 mt -61.87 -48.85 86.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.17 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 3.8 tmtt? -51.2 -44.51 61.59 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.91 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 45.4 mtp85 -64.89 -38.37 90.74 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.907 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 65.0 mtp85 -67.57 -48.03 68.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.863 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 14.1 mm100 -62.02 176.03 0.62 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.938 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -75.32 177.38 6.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.864 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 3.6 mmmm -111.07 47.79 0.97 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.917 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 142' ' ' ILE . . . . . . . . . . . . . 30.5 mm -111.11 123.17 66.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.088 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -107.48 70.46 0.78 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.877 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.871 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.476 -0.249 . . . . 0.0 112.476 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 1.8 m -87.25 160.53 48.45 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.576 0.703 . . . . 0.0 110.896 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 78.59 1.01 Allowed 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.691 2.261 . . . . 0.0 112.324 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.53 93.89 3.12 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.142 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -57.97 118.63 5.59 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.881 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -98.19 -167.1 1.46 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.872 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -61.67 -166.0 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.831 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -127.85 164.86 21.3 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.13 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -50.52 164.21 0.42 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.689 0.757 . . . . 0.0 110.832 -179.758 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -11.93 31.81 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.681 2.254 . . . . 0.0 112.366 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -81.08 -33.63 33.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.934 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.6 t -49.06 -31.65 8.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.093 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 1.3 t -62.64 -53.26 57.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.844 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 3.7 mp -59.05 -43.16 88.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.123 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 4.0 mt -53.77 -53.1 28.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.125 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 3.5 t -58.74 -37.43 76.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.872 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -61.8 -57.84 10.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.115 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.7 t -51.78 -51.07 29.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.16 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 91.3 t -48.65 -59.48 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.121 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -50.05 -54.55 18.41 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.508 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 90.4 mt -58.47 -54.71 29.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.832 0.349 . . . . 0.0 111.111 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.46 -59.7 3.51 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.937 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.443 ' HA ' HG23 ' B' ' 126' ' ' VAL . 9.0 mt -43.26 -55.37 4.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.937 179.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 86.9 t -52.52 -51.61 32.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.17 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 73.6 t -61.47 -40.28 85.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.169 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.423 HG23 ' HA ' ' B' ' 123' ' ' LEU . 44.4 t -51.5 -59.0 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.124 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 48.8 mt -67.7 -46.76 71.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.941 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.54 -47.22 52.28 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.52 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 56.3 t -76.6 -54.3 13.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.913 0.387 . . . . 0.0 111.122 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 19.9 t -49.78 -42.45 18.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.116 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -77.57 -43.19 32.58 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.845 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -52.59 -47.68 57.17 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.476 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 30.3 mt -74.84 -51.86 20.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.842 0.353 . . . . 0.0 111.137 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 22.9 mt -50.97 -57.92 7.34 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.931 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 14.4 mt -59.3 -48.3 87.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.118 179.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 9.4 ttmm -50.81 -38.01 46.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.922 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 66.4 mtp180 -75.33 -34.5 61.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.908 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 70.8 mtp85 -64.66 -33.22 75.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.848 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 50.5 mt-30 -51.63 148.96 4.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.922 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 32.6 mt-30 -97.96 88.47 4.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.895 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 5.9 ttmm -115.11 42.0 2.3 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.868 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.4 tt -125.62 135.44 63.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.099 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 63.0 mtp180 -80.82 67.11 6.59 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.879 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 6.7 tptt . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.922 179.956 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.536 -0.226 . . . . 0.0 112.536 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 1.8 m -87.75 160.31 47.39 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.582 0.706 . . . . 0.0 110.898 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 81.86 0.79 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.656 2.238 . . . . 0.0 112.353 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . -133.16 95.22 3.49 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.087 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -56.95 119.58 6.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.872 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 1.4 mt-30 -99.84 -86.25 0.39 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.908 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 14.6 ttt180 -52.22 -76.81 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.884 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 108' ' ' ALA . . . . . . . . . . . . . . . -119.09 166.0 13.46 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.07 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 109' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -49.56 164.36 0.34 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.692 0.758 . . . . 0.0 110.808 -179.758 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 -11.89 31.72 Favored 'Trans proline' 0 C--O 1.232 0.201 0 C-N-CA 122.678 2.252 . . . . 0.0 112.345 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 111' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -81.06 -34.94 32.37 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.902 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 112' ' ' THR . . . . . . . . . . . . . 6.3 t -49.05 -31.38 7.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.113 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 1.3 t -63.73 -53.03 57.48 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.883 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 114' ' ' ILE . . . . . . . . . . . . . 3.7 mp -58.55 -43.3 86.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.13 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 4.4 mt -54.0 -52.85 32.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.094 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 3.5 t -58.74 -36.9 75.09 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.865 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -62.18 -58.22 8.58 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.083 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.4 t -51.55 -51.03 27.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.115 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . . . . . . . . . 90.2 t -48.7 -59.5 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.11 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -50.04 -54.55 18.39 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.46 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 90.1 mt -58.47 -54.75 28.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.83 0.347 . . . . 0.0 111.095 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 122' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -49.43 -59.83 3.38 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.9 179.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 123' ' ' LEU . . . . . 0.423 ' HA ' HG23 ' A' ' 26' ' ' VAL . 9.1 mt -43.13 -55.4 3.91 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.857 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 87.0 t -52.63 -51.66 33.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.116 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 73.1 t -61.41 -40.19 85.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.096 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 126' ' ' VAL . . . . . 0.443 HG23 ' HA ' ' A' ' 23' ' ' LEU . 44.1 t -51.52 -59.13 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.101 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 127' ' ' LEU . . . . . . . . . . . . . 48.5 mt -67.64 -46.83 71.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.929 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.57 -47.18 52.47 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.486 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 56.1 t -76.65 -54.25 13.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.83 0.348 . . . . 0.0 111.121 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 130' ' ' VAL . . . . . . . . . . . . . 20.0 t -49.8 -42.47 18.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.119 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 4.7 m-85 -77.46 -43.23 33.06 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.871 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -52.23 -47.9 54.61 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.501 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 30.5 mt -74.88 -51.68 21.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.841 0.353 . . . . 0.0 111.113 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 21.9 mt -50.91 -57.98 7.15 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.904 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 14.2 mt -59.28 -48.99 85.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.107 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 9.7 ttmm -51.44 -36.85 45.8 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.909 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 67.7 mtp180 -75.36 -34.72 61.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.888 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 70.2 mtp85 -62.5 -47.96 81.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.881 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 50.0 mt-30 -63.88 153.55 36.48 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.912 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 31.8 mt-30 -91.73 62.55 4.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.925 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 3.6 ttmm -134.61 71.84 1.45 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.89 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 142' ' ' ILE . . . . . . . . . . . . . 20.2 tt -101.2 140.29 20.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.132 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 69.9 mtp180 -75.23 86.55 2.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.855 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 3.4 tptt . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.907 179.95 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 38.6 t -159.03 70.12 3.47 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.652 0.739 . . . . 0.0 110.913 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 159.61 52.79 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.688 2.259 . . . . 0.0 112.339 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -106.65 105.22 15.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.093 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -121.16 154.37 36.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.882 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 86.0 mt-30 -91.69 106.91 18.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.881 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.67 -165.83 0.07 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.872 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.78 175.99 5.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.129 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -50.84 163.83 0.46 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.683 0.754 . . . . 0.0 110.844 -179.807 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 -16.41 37.57 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.696 2.264 . . . . 0.0 112.348 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 2.5 tm? -86.93 -37.82 17.27 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.93 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 25.9 p -50.55 -43.58 56.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.135 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -51.62 -51.34 56.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.861 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 3.1 mp -58.7 -45.54 90.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.112 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 25.6 mt -54.08 -51.11 49.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.132 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -58.82 -36.11 73.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.83 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -61.77 -60.12 4.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.1 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 5.9 t -51.05 -48.92 29.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.088 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.492 ' O ' ' HG ' ' A' ' 23' ' ' LEU . 98.3 t -49.6 -63.35 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.129 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -48.57 -55.69 10.65 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.497 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 20.4 mt -55.52 -41.02 61.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.863 0.363 . . . . 0.0 111.111 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -57.15 -50.68 72.05 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.877 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.492 ' HG ' ' O ' ' A' ' 19' ' ' VAL . 1.1 mt -54.47 -51.67 64.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.901 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 98.1 t -55.44 -45.97 78.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.118 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 70.6 t -64.83 -43.18 96.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.101 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.44 HG22 ' CD2' ' B' ' 123' ' ' LEU . 73.3 t -51.27 -54.31 11.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.113 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 56.4 mt -70.13 -47.28 62.39 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.885 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.82 -45.88 55.14 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.538 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 57.4 t -76.81 -54.67 12.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.84 0.352 . . . . 0.0 111.136 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 17.6 t -49.9 -43.05 19.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.158 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -77.22 -44.95 28.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.825 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -52.29 -48.0 54.72 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.47 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 45.4 mt -73.22 -52.55 21.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.848 0.356 . . . . 0.0 111.126 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 23.7 mt -51.03 -60.75 2.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.89 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 11.8 mt -55.7 -48.68 77.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.117 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 63.6 tttt -52.45 -51.58 58.51 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.877 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 68.0 mtp180 -52.23 -43.69 64.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.845 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 51.0 mtp85 -66.19 -48.25 71.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.875 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 6.0 mm100 -67.01 179.56 1.11 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.957 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 17.2 mm100 -72.71 174.43 7.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.887 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 12.5 ttmt -136.4 156.16 49.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.913 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 14.1 pt -133.49 -179.96 3.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.106 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 26.8 ptt85 -123.6 177.09 5.84 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.868 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 16.1 mmtt . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.933 179.94 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.372 0 N-CA-C 112.467 -0.253 . . . . 0.0 112.467 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 38.7 t -159.01 72.94 3.55 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.599 0.714 . . . . 0.0 110.849 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 160.72 48.65 Favored 'Trans proline' 0 N--CA 1.465 -0.169 0 C-N-CA 122.694 2.262 . . . . 0.0 112.353 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . -105.83 96.78 6.73 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.128 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -128.63 152.34 48.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.936 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 87.3 mt-30 -92.87 79.93 4.66 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.88 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.49 -76.49 0.51 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.913 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 108' ' ' ALA . . . . . . . . . . . . . . . -107.57 -179.64 3.97 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.094 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 109' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -50.28 164.34 0.39 Allowed Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.657 0.741 . . . . 0.0 110.87 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -16.24 37.4 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.673 2.249 . . . . 0.0 112.336 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 111' ' ' LEU . . . . . . . . . . . . . 2.5 tm? -87.93 -37.96 15.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.901 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 112' ' ' THR . . . . . . . . . . . . . 26.6 p -51.23 -43.62 61.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.122 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -51.4 -51.93 50.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.842 -179.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 114' ' ' ILE . . . . . . . . . . . . . 2.9 mp -58.39 -45.39 89.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.147 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 23.5 mt -54.0 -51.42 46.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.143 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -58.75 -35.97 73.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.854 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -61.63 -59.97 4.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.111 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 6.1 t -51.27 -48.78 32.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.103 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . 0.486 ' O ' ' HG ' ' B' ' 123' ' ' LEU . 98.4 t -49.66 -63.28 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.123 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.73 -55.48 11.2 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.499 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 20.0 mt -55.64 -40.8 61.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.884 0.373 . . . . 0.0 111.163 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 122' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -57.44 -50.25 73.61 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.945 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 123' ' ' LEU . . . . . 0.486 ' HG ' ' O ' ' B' ' 119' ' ' VAL . 1.1 mt -54.73 -51.35 65.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.956 179.875 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 99.6 t -55.93 -46.0 80.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.113 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 71.0 t -64.64 -43.12 96.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.136 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 126' ' ' VAL . . . . . 0.449 HG22 ' CD2' ' A' ' 23' ' ' LEU . 71.7 t -51.42 -54.36 12.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.105 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 127' ' ' LEU . . . . . . . . . . . . . 57.1 mt -70.15 -47.39 61.89 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.927 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.81 -45.81 55.12 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.458 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 58.1 t -76.77 -54.82 12.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.931 0.396 . . . . 0.0 111.191 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 130' ' ' VAL . . . . . . . . . . . . . 17.6 t -49.89 -43.06 19.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.137 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 -77.16 -44.83 28.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.898 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -52.3 -48.11 54.57 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.479 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 46.1 mt -73.21 -52.43 21.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.874 0.369 . . . . 0.0 111.149 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 23.9 mt -51.14 -60.77 2.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.914 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 12.0 mt -55.73 -48.62 77.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.094 179.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 63.5 tttt -52.44 -51.66 58.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.892 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 68.5 mtp180 -52.38 -43.59 64.8 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.876 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 51.4 mtp85 -63.61 -47.96 79.28 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.88 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 6.2 mm100 -63.87 179.35 0.52 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.895 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 17.1 mm100 -73.6 174.54 8.17 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.918 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 12.4 ttmt -136.57 156.95 47.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.92 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 142' ' ' ILE . . . . . . . . . . . . . 14.2 pt -132.94 179.65 4.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.119 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 27.2 ptt85 -123.7 177.69 5.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.854 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 16.2 mmtt . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.898 179.965 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.275 0 N-CA-C 112.473 -0.251 . . . . 0.0 112.473 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 1.7 m -101.06 160.48 26.55 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-O 121.599 0.714 . . . . 0.0 110.918 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -7.62 21.51 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.658 2.239 . . . . 0.0 112.361 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.17 -18.07 23.21 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.104 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -67.84 117.33 9.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.914 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 9.0 tt0 -91.65 100.91 13.55 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.898 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.76 151.17 39.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.911 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -129.96 177.65 7.12 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.12 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -49.48 164.57 0.32 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.671 0.748 . . . . 0.0 110.892 -179.809 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -11.87 31.72 Favored 'Trans proline' 0 C--O 1.232 0.221 0 C-N-CA 122.675 2.25 . . . . 0.0 112.332 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 2.5 tm? -82.4 -36.48 26.68 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.881 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 5.5 t -49.56 -31.38 10.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.156 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -68.25 -44.61 75.24 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.89 -179.857 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 51.0 mt -62.09 -45.81 97.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.143 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 25.0 mt -57.11 -51.46 68.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.128 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 10.8 t -59.3 -32.9 70.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.851 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -64.5 -60.29 3.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.041 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 5.9 t -51.58 -48.72 35.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.134 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.488 ' O ' ' HG ' ' A' ' 23' ' ' LEU . 92.1 t -50.04 -63.44 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.132 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -48.41 -55.48 10.69 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.527 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 22.1 mt -55.84 -40.86 64.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.816 0.341 . . . . 0.0 111.085 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -57.46 -49.62 75.69 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.927 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.488 ' HG ' ' O ' ' A' ' 19' ' ' VAL . 2.0 mt -55.18 -51.44 66.52 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.942 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 98.9 t -55.92 -46.17 80.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.122 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 76.0 t -63.75 -43.59 98.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.147 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.437 HG22 ' CD2' ' B' ' 123' ' ' LEU . 76.2 t -51.67 -53.72 15.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.107 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 54.0 mt -71.72 -45.73 60.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.923 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.77 -46.39 59.94 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.469 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -76.08 -54.21 14.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.851 0.358 . . . . 0.0 111.134 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 18.4 t -50.64 -44.6 25.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.14 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 5.3 m-85 -76.79 -39.07 52.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.9 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -54.71 -49.37 61.79 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 23.3 mt -74.78 -50.25 26.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.888 0.375 . . . . 0.0 111.165 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 25.4 mt -51.86 -56.28 14.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.934 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 21.6 mt -61.32 -44.09 97.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.179 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 16.8 mttt -50.52 -42.89 55.63 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.877 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 33.8 mtp180 -74.24 -32.98 63.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.917 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 79.6 mtp180 -69.97 -31.7 69.54 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.861 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -174.23 177.85 2.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.939 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 2.2 tp60 -122.77 168.32 12.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.906 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 7.5 mmtp -123.31 179.38 4.74 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.866 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.89 173.38 14.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.152 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 4.8 ptp180 -144.64 178.06 8.25 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.927 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.333 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.881 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.466 -0.253 . . . . 0.0 112.466 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 1.7 m -100.86 160.38 26.92 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.61 0.719 . . . . 0.0 110.885 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 -7.56 21.37 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.727 2.284 . . . . 0.0 112.365 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . 48.12 30.21 2.06 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.092 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -67.07 112.84 4.61 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.892 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 8.8 tt0 -95.43 104.45 16.35 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.919 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.41 147.31 41.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.841 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 108' ' ' ALA . . . . . . . . . . . . . . . -132.67 176.79 8.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.115 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 109' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -49.53 164.85 0.31 Allowed Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.639 0.733 . . . . 0.0 110.897 -179.797 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -11.81 31.63 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.687 2.258 . . . . 0.0 112.382 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 111' ' ' LEU . . . . . . . . . . . . . 2.5 tm? -81.96 -36.55 27.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.877 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 112' ' ' THR . . . . . . . . . . . . . 5.7 t -49.38 -31.51 9.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.145 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -67.85 -45.0 75.86 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.846 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 114' ' ' ILE . . . . . . . . . . . . . 51.4 mt -61.89 -45.53 98.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.15 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 25.7 mt -57.04 -51.0 74.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.099 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 10.6 t -59.59 -33.19 71.14 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.844 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -64.25 -60.2 3.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.033 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 5.7 t -51.54 -48.77 35.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.128 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 119' ' ' VAL . . . . . 0.489 ' O ' ' HG ' ' B' ' 123' ' ' LEU . 92.9 t -49.97 -63.41 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.101 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.46 -55.46 10.79 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.459 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 22.2 mt -55.89 -40.73 63.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.877 0.37 . . . . 0.0 111.118 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 122' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -57.57 -49.49 76.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.946 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 123' ' ' LEU . . . . . 0.489 ' HG ' ' O ' ' B' ' 119' ' ' VAL . 2.0 mt -55.38 -51.48 66.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.902 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 98.0 t -55.81 -46.0 79.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.156 179.831 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 78.0 t -63.99 -43.45 97.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.148 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 126' ' ' VAL . . . . . 0.436 HG22 ' CD2' ' A' ' 23' ' ' LEU . 76.0 t -51.68 -53.68 15.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.143 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 127' ' ' LEU . . . . . . . . . . . . . 52.7 mt -71.78 -45.84 60.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.921 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -52.63 -46.12 59.4 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.506 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.4 t -76.41 -54.2 13.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.876 0.369 . . . . 0.0 111.097 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 130' ' ' VAL . . . . . . . . . . . . . 18.6 t -50.7 -44.31 25.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.179 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 5.2 m-85 -77.0 -39.29 50.94 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.863 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -54.56 -49.09 62.33 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.478 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 22.2 mt -75.04 -50.6 24.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.809 0.338 . . . . 0.0 111.129 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 25.0 mt -51.54 -55.74 17.38 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.898 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 21.9 mt -61.9 -44.34 98.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.146 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 19.8 mttt -50.52 -42.44 55.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.898 179.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 33.6 mtp180 -74.56 -33.24 62.65 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.839 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 79.8 mtp180 -68.98 -35.38 76.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.847 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -174.84 -179.48 1.44 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.929 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 3.7 tp60 -121.96 171.28 9.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.959 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 7.3 mmtp -119.51 174.96 6.08 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.888 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 142' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -140.55 176.23 5.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.124 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 4.5 ptp180 -142.8 176.75 8.82 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.872 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.918 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.861 0.362 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.424 HG23 ' H ' ' A' ' 18' ' ' VAL . 9.7 t -51.0 -51.14 22.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.138 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.699 HG12 HD11 ' A' ' 23' ' ' LEU . 88.7 t -48.7 -59.61 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.146 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.481 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -49.88 -54.49 17.95 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.51 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 62.5 mt -58.48 -54.84 27.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.854 0.359 . . . . 0.0 111.114 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.871 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.42 -59.44 3.72 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.903 179.955 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.977 HD23 HG22 ' B' ' 126' ' ' VAL . 9.0 mt -43.44 -55.52 4.12 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.918 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 20' ' ' GLY . 87.2 t -52.4 -51.26 34.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.144 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.8 t -61.75 -40.5 87.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.141 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.987 HG22 HD23 ' B' ' 123' ' ' LEU . 44.2 t -51.22 -59.28 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.149 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.726 HD23 HD23 ' B' ' 127' ' ' LEU . 47.6 mt -67.45 -46.41 73.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.894 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.62 -48.13 50.4 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.491 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.4 t -75.97 -54.19 14.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.883 0.373 . . . . 0.0 111.142 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.728 HG21 HD11 ' B' ' 127' ' ' LEU . 20.3 t -49.72 -42.78 18.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.11 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -77.52 -34.84 53.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.892 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -57.39 -48.69 78.77 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.494 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 16.0 mt -76.91 -47.56 27.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.869 0.366 . . . . 0.0 111.141 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 28.2 mt -55.41 -53.13 60.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.937 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 79.3 mt -63.46 -49.49 82.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.123 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 27.8 ttpt . . . . . 0 C--N 1.328 -0.358 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.891 179.841 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.812 0.339 . . . . 0.0 111.098 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 10.1 t -50.85 -51.45 20.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.111 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.717 HG12 HD11 ' B' ' 123' ' ' LEU . 87.8 t -48.49 -59.68 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.127 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 120' ' ' GLY . . . . . 0.48 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -49.79 -54.74 16.61 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.481 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 63.7 mt -58.32 -54.93 26.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.843 0.354 . . . . 0.0 111.119 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 122' ' ' LEU . . . . . 0.859 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.35 -59.8 3.39 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.911 179.913 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 123' ' ' LEU . . . . . 0.987 HD23 HG22 ' A' ' 26' ' ' VAL . 9.1 mt -43.18 -55.56 3.88 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.9 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 124' ' ' VAL . . . . . 0.48 HG23 ' O ' ' B' ' 120' ' ' GLY . 87.0 t -52.38 -51.61 31.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.11 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 72.5 t -61.4 -40.49 86.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.114 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 126' ' ' VAL . . . . . 0.977 HG22 HD23 ' A' ' 23' ' ' LEU . 43.8 t -51.27 -59.27 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.129 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 127' ' ' LEU . . . . . 0.728 HD11 HG21 ' A' ' 30' ' ' VAL . 47.3 mt -67.52 -46.37 73.03 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.904 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.61 -47.81 51.17 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.537 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.6 t -76.25 -54.17 13.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.911 0.386 . . . . 0.0 111.141 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 130' ' ' VAL . . . . . 0.705 HG21 HD11 ' A' ' 27' ' ' LEU . 19.9 t -49.81 -42.54 18.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.112 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -77.66 -35.19 52.67 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.879 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -57.32 -48.38 80.85 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.496 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 17.2 mt -77.05 -47.81 26.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.855 0.36 . . . . 0.0 111.121 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 28.2 mt -55.29 -53.05 60.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.904 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 77.9 mt -63.39 -49.84 81.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.17 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 27.9 ttpt . . . . . 0 C--N 1.328 -0.342 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.888 179.853 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.071 0 CA-C-O 120.801 0.334 . . . . 0.0 111.076 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.403 HG23 ' H ' ' A' ' 18' ' ' VAL . 9.6 t -51.38 -51.07 25.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.123 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.685 HG12 HD11 ' A' ' 23' ' ' LEU . 95.0 t -48.55 -59.49 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.081 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.484 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -50.07 -54.46 18.88 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.527 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 66.9 mt -58.5 -54.77 28.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.919 0.39 . . . . 0.0 111.131 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.869 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.4 -59.7 3.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.922 179.922 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.987 HD23 HG22 ' B' ' 126' ' ' VAL . 9.1 mt -43.24 -55.53 3.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.905 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 20' ' ' GLY . 87.2 t -52.4 -51.47 32.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.152 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.7 t -61.52 -40.59 87.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.118 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.976 HG22 HD23 ' B' ' 123' ' ' LEU . 43.3 t -51.29 -59.12 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.108 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.722 HD23 HD23 ' B' ' 127' ' ' LEU . 46.4 mt -67.79 -46.36 72.19 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.899 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.6 -47.8 51.13 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.472 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -76.26 -54.32 13.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.862 0.363 . . . . 0.0 111.11 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.722 HG21 HD11 ' B' ' 127' ' ' LEU . 20.1 t -49.7 -42.5 17.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.137 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.422 ' HB3' HD12 ' A' ' 35' ' ' ILE . 4.7 m-85 -77.85 -37.34 48.56 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.85 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -56.29 -47.78 79.76 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.499 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 19.5 mt -76.69 -49.4 24.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.833 0.349 . . . . 0.0 111.149 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 28.6 mt -53.81 -52.86 58.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.955 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.422 HD12 ' HB3' ' A' ' 31' ' ' PHE . 49.2 mt -63.59 -47.48 91.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.135 179.787 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 32.3 ttpt . . . . . 0 C--N 1.328 -0.352 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.844 179.904 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.811 0.339 . . . . 0.0 111.089 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.8 t -51.35 -51.0 25.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.155 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.706 HG12 HD11 ' B' ' 123' ' ' LEU . 93.6 t -48.63 -59.43 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.147 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 120' ' ' GLY . . . . . 0.48 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -50.13 -54.49 18.96 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.472 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 67.0 mt -58.48 -54.85 27.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.917 0.389 . . . . 0.0 111.16 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 122' ' ' LEU . . . . . 0.867 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.31 -59.94 3.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.897 179.894 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 123' ' ' LEU . . . . . 0.976 HD23 HG22 ' A' ' 26' ' ' VAL . 9.2 mt -43.12 -55.41 3.9 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.933 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 124' ' ' VAL . . . . . 0.48 HG23 ' O ' ' B' ' 120' ' ' GLY . 87.4 t -52.55 -51.62 32.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.104 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 72.5 t -61.38 -40.61 86.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.1 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 126' ' ' VAL . . . . . 0.987 HG22 HD23 ' A' ' 23' ' ' LEU . 43.1 t -51.19 -59.19 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.121 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 127' ' ' LEU . . . . . 0.722 HD11 HG21 ' A' ' 30' ' ' VAL . 45.4 mt -67.8 -46.15 72.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.972 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.69 -47.9 51.4 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.461 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.0 t -76.24 -54.19 13.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.895 0.379 . . . . 0.0 111.093 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 130' ' ' VAL . . . . . 0.721 HG21 HD11 ' A' ' 27' ' ' LEU . 20.2 t -49.7 -42.59 17.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.141 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 131' ' ' PHE . . . . . 0.439 ' HB3' HD12 ' B' ' 135' ' ' ILE . 4.6 m-85 -77.72 -37.03 50.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.879 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -56.04 -47.86 77.52 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.517 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 18.2 mt -77.07 -49.25 23.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.826 0.346 . . . . 0.0 111.127 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 27.8 mt -53.57 -52.02 61.07 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.919 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.439 HD12 ' HB3' ' B' ' 131' ' ' PHE . 49.3 mt -64.85 -46.67 91.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.096 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 32.1 ttpt . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.899 179.904 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.798 0.332 . . . . 0.0 111.069 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.408 HG23 ' H ' ' A' ' 18' ' ' VAL . 12.0 t -52.24 -51.09 34.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.148 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.68 HG12 HD11 ' A' ' 23' ' ' LEU . 94.9 t -48.79 -59.15 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.137 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.483 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -50.26 -54.72 18.59 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.492 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 92.5 mt -58.37 -54.83 27.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.861 0.362 . . . . 0.0 111.089 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.885 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.28 -59.81 3.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.933 179.922 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 1.038 HD23 HG22 ' B' ' 126' ' ' VAL . 9.4 mt -43.21 -55.36 4.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.873 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.483 HG23 ' O ' ' A' ' 20' ' ' GLY . 90.5 t -52.61 -51.6 33.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.112 179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 70.9 t -61.37 -40.56 86.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.108 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 1.027 HG22 HD23 ' B' ' 123' ' ' LEU . 43.0 t -51.25 -59.3 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.133 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.707 HD11 HG21 ' B' ' 130' ' ' VAL . 44.5 mt -68.01 -46.26 71.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.906 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.51 -47.52 51.33 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.49 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.5 t -76.74 -54.21 13.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.855 0.359 . . . . 0.0 111.12 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.686 HG21 HD11 ' B' ' 127' ' ' LEU . 20.1 t -49.73 -42.02 17.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.118 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 5.3 m-85 -78.28 -34.29 48.99 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.885 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -57.51 -46.89 91.5 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.509 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 17.6 mt -79.38 -45.48 23.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.848 0.356 . . . . 0.0 111.116 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 27.4 mt -57.84 -43.79 86.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.868 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 72.4 mt -71.28 -58.95 4.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.161 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 8.3 pttp . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.937 179.781 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.795 0.331 . . . . 0.0 111.082 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 12.0 t -52.35 -51.09 35.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.127 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.689 HG12 HD11 ' B' ' 123' ' ' LEU . 95.5 t -48.89 -59.17 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.141 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 120' ' ' GLY . . . . . 0.48 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -50.2 -54.63 18.7 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.525 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 92.9 mt -58.4 -54.84 27.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.867 0.365 . . . . 0.0 111.158 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 122' ' ' LEU . . . . . 0.871 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.26 -59.87 3.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.945 179.877 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 123' ' ' LEU . . . . . 1.027 HD23 HG22 ' A' ' 26' ' ' VAL . 9.3 mt -43.08 -55.49 3.83 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.916 179.841 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 124' ' ' VAL . . . . . 0.48 HG23 ' O ' ' B' ' 120' ' ' GLY . 90.0 t -52.61 -51.51 34.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.13 179.87 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 69.9 t -61.48 -40.31 85.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.111 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 126' ' ' VAL . . . . . 1.038 HG22 HD23 ' A' ' 23' ' ' LEU . 43.1 t -51.4 -59.14 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.146 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 127' ' ' LEU . . . . . 0.701 HD23 HD23 ' A' ' 27' ' ' LEU . 45.6 mt -68.02 -46.41 71.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.875 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.6 -47.29 52.42 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.467 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.6 t -76.83 -54.18 13.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.853 0.358 . . . . 0.0 111.159 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 130' ' ' VAL . . . . . 0.707 HG21 HD11 ' A' ' 27' ' ' LEU . 19.7 t -49.8 -41.92 17.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.118 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -78.4 -36.37 45.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.859 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -56.06 -46.38 85.03 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.506 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 18.4 mt -79.18 -49.9 19.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 120.889 0.376 . . . . 0.0 111.151 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 27.8 mt -53.1 -48.1 68.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.933 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 69.9 mt -68.92 -49.93 58.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.125 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 11.5 tttp . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.899 179.802 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.085 0 CA-C-O 120.818 0.342 . . . . 0.0 111.092 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.427 HG23 ' H ' ' A' ' 18' ' ' VAL . 11.3 t -51.59 -51.21 27.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.122 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.723 HG12 HD11 ' A' ' 23' ' ' LEU . 84.0 t -48.62 -59.96 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.161 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.477 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -49.54 -54.71 15.74 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.475 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 96.2 mt -58.35 -54.81 27.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.884 0.373 . . . . 0.0 111.183 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.87 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.45 -59.56 3.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.871 179.907 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.992 HD23 HG22 ' B' ' 126' ' ' VAL . 8.8 mt -43.19 -55.55 3.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.925 179.869 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.477 HG23 ' O ' ' A' ' 20' ' ' GLY . 89.7 t -52.48 -51.74 31.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.144 179.849 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 73.4 t -61.44 -39.87 84.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.158 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 1.001 HG22 HD23 ' B' ' 123' ' ' LEU . 46.0 t -51.64 -58.69 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.131 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.726 HD23 HD23 ' B' ' 127' ' ' LEU . 56.6 mt -67.25 -47.6 70.25 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.962 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.3 -47.46 50.31 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.476 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.9 t -75.99 -54.4 13.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.904 0.383 . . . . 0.0 111.166 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.795 HG21 HD11 ' B' ' 127' ' ' LEU . 19.4 t -49.46 -43.29 17.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.13 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.404 ' HB3' HD12 ' A' ' 35' ' ' ILE . 7.5 m-85 -77.2 -41.53 41.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.879 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -53.35 -48.16 60.48 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.477 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 38.4 mt -74.89 -50.91 23.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.859 0.361 . . . . 0.0 111.115 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 23.2 mt -51.25 -57.64 8.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.937 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.404 HD12 ' HB3' ' A' ' 31' ' ' PHE . 14.4 mt -59.81 -48.48 87.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.126 179.838 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 14.8 tttm . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.914 179.824 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.847 0.356 . . . . 0.0 111.066 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 118' ' ' VAL . . . . . 0.418 ' H ' HG23 ' B' ' 118' ' ' VAL . 11.6 t -51.7 -51.34 27.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.181 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.712 HG12 HD11 ' B' ' 123' ' ' LEU . 89.1 t -48.6 -59.47 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.13 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 120' ' ' GLY . . . . . 0.473 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -50.05 -54.88 17.09 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.484 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 96.3 mt -58.28 -54.87 26.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.908 0.385 . . . . 0.0 111.128 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 122' ' ' LEU . . . . . 0.87 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.3 -59.69 3.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.907 179.93 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 123' ' ' LEU . . . . . 1.001 HD23 HG22 ' A' ' 26' ' ' VAL . 9.3 mt -43.22 -55.71 3.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.914 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 124' ' ' VAL . . . . . 0.473 HG23 ' O ' ' B' ' 120' ' ' GLY . 90.4 t -52.33 -51.83 29.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.087 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 74.0 t -61.19 -40.74 86.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.104 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 126' ' ' VAL . . . . . 0.992 HG22 HD23 ' A' ' 23' ' ' LEU . 45.4 t -50.89 -59.49 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.132 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 127' ' ' LEU . . . . . 0.795 HD11 HG21 ' A' ' 30' ' ' VAL . 49.0 mt -67.43 -46.67 72.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.924 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -50.89 -47.4 47.85 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.486 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 58.4 t -77.77 -54.66 12.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.895 0.379 . . . . 0.0 111.156 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 130' ' ' VAL . . . . . 0.659 HG21 HD11 ' A' ' 27' ' ' LEU . 20.4 t -49.31 -39.15 12.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.125 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 131' ' ' PHE . . . . . 0.5 ' HB3' HD12 ' B' ' 135' ' ' ILE . 3.5 m-30 -76.32 -42.76 43.97 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.874 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -51.74 -50.21 44.26 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.509 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 40.6 mt -73.23 -52.06 23.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.907 0.384 . . . . 0.0 111.131 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 24.5 mt -50.52 -61.35 2.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.932 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.5 HD12 ' HB3' ' B' ' 131' ' ' PHE . 13.6 mt -56.59 -46.46 82.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.152 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 14.6 tttm . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.907 179.838 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.809 0.338 . . . . 0.0 111.077 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.412 HG23 ' H ' ' A' ' 18' ' ' VAL . 11.3 t -51.86 -50.69 32.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.101 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.75 HG12 HD11 ' A' ' 23' ' ' LEU . 86.6 t -48.85 -60.23 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.161 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.489 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -49.49 -54.28 17.19 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.465 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 39.0 mt -58.52 -54.72 29.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.862 0.363 . . . . 0.0 111.156 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.872 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.71 -59.49 3.76 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.892 179.898 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.985 HD23 HG22 ' B' ' 126' ' ' VAL . 8.5 mt -43.23 -55.35 4.03 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.919 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.489 HG23 ' O ' ' A' ' 20' ' ' GLY . 91.8 t -52.46 -51.74 31.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.127 179.852 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 74.8 t -61.62 -39.84 84.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.171 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.989 HG22 HD23 ' B' ' 123' ' ' LEU . 46.5 t -51.62 -59.51 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.13 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.72 HD11 HG21 ' B' ' 130' ' ' VAL . 57.0 mt -66.39 -47.81 72.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.876 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.18 -47.58 49.31 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.452 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.4 t -76.32 -54.59 13.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.825 0.345 . . . . 0.0 111.141 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.731 HG21 HD11 ' B' ' 127' ' ' LEU . 19.8 t -49.34 -42.33 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.141 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.402 ' HB3' HD12 ' A' ' 35' ' ' ILE . 4.9 m-85 -77.05 -44.39 30.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -52.35 -48.61 53.81 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.458 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 42.2 mt -73.03 -52.06 23.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.88 0.371 . . . . 0.0 111.118 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 22.8 mt -51.21 -60.78 2.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.876 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.402 HD12 ' HB3' ' A' ' 31' ' ' PHE . 11.9 mt -55.56 -49.07 76.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.16 179.828 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 8.0 tmtt? . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 179.833 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.861 0.363 . . . . 0.0 111.09 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 118' ' ' VAL . . . . . 0.414 ' H ' HG23 ' B' ' 118' ' ' VAL . 11.3 t -51.86 -50.7 32.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.155 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.74 HG12 HD11 ' B' ' 123' ' ' LEU . 87.7 t -48.82 -60.26 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.134 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 120' ' ' GLY . . . . . 0.49 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -49.44 -54.25 17.13 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.488 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 38.8 mt -58.56 -54.85 27.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.857 0.361 . . . . 0.0 111.135 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 122' ' ' LEU . . . . . 0.874 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.57 -59.43 3.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.945 179.884 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 123' ' ' LEU . . . . . 0.989 HD23 HG22 ' A' ' 26' ' ' VAL . 8.5 mt -43.28 -55.35 4.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.942 179.883 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 124' ' ' VAL . . . . . 0.49 HG23 ' O ' ' B' ' 120' ' ' GLY . 92.1 t -52.39 -51.81 30.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.135 179.823 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 74.8 t -61.61 -39.83 84.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.12 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 126' ' ' VAL . . . . . 0.985 HG22 HD23 ' A' ' 23' ' ' LEU . 46.2 t -51.67 -59.58 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.141 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 127' ' ' LEU . . . . . 0.731 HD11 HG21 ' A' ' 30' ' ' VAL . 55.9 mt -66.31 -47.81 72.34 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.937 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.21 -47.52 49.61 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.47 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 55.9 t -76.34 -54.63 13.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.848 0.356 . . . . 0.0 111.142 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 130' ' ' VAL . . . . . 0.72 HG21 HD11 ' A' ' 27' ' ' LEU . 20.2 t -49.28 -42.37 15.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.132 179.883 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 131' ' ' PHE . . . . . 0.414 ' HB3' HD12 ' B' ' 135' ' ' ILE . 4.8 m-85 -76.95 -44.57 30.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.933 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -52.28 -48.55 53.51 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.489 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 42.2 mt -73.02 -52.1 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.846 0.355 . . . . 0.0 111.18 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 23.0 mt -51.17 -60.87 2.64 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.919 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.414 HD12 ' HB3' ' B' ' 131' ' ' PHE . 11.8 mt -55.42 -49.52 72.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.129 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 8.0 tmtt? . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.89 179.866 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.814 0.34 . . . . 0.0 111.096 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.4 t -50.81 -50.87 22.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.133 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.69 HG12 HD11 ' A' ' 23' ' ' LEU . 96.0 t -48.4 -59.46 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.087 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.48 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -50.44 -54.52 20.13 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.538 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 99.0 mt -58.41 -54.82 27.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.826 0.346 . . . . 0.0 111.124 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.891 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.54 -59.44 3.76 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.902 179.921 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 1.017 HD23 HG22 ' B' ' 126' ' ' VAL . 9.8 mt -43.31 -55.33 4.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.884 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 20' ' ' GLY . 89.5 t -52.6 -52.03 30.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.114 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.9 t -61.05 -40.21 84.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.126 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 1.012 HG22 HD23 ' B' ' 123' ' ' LEU . 44.5 t -51.64 -59.29 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.101 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.745 HD11 HG21 ' B' ' 130' ' ' VAL . 48.6 mt -67.58 -46.66 71.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.893 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.6 -47.57 51.73 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.451 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -76.41 -54.16 13.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.896 0.379 . . . . 0.0 111.148 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.739 HG21 HD11 ' B' ' 127' ' ' LEU . 19.8 t -49.79 -42.65 18.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.145 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.411 ' HB3' HD12 ' A' ' 35' ' ' ILE . 4.7 m-85 -77.44 -40.58 42.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.902 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -53.48 -48.4 60.5 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.49 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 28.8 mt -75.56 -50.47 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.849 0.357 . . . . 0.0 111.11 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 22.4 mt -51.28 -56.71 11.55 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.947 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.411 HD12 ' HB3' ' A' ' 31' ' ' PHE . 18.2 mt -60.96 -49.34 85.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.116 179.822 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 30.7 ttpt . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.854 179.922 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.807 0.336 . . . . 0.0 111.08 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 118' ' ' VAL . . . . . 0.416 HG23 ' H ' ' B' ' 118' ' ' VAL . 11.0 t -51.64 -51.05 28.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.112 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.685 HG12 HD11 ' B' ' 123' ' ' LEU . 91.1 t -48.37 -59.35 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.141 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 120' ' ' GLY . . . . . 0.468 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -50.51 -54.68 19.77 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.522 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 98.9 mt -58.23 -54.88 26.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.844 0.355 . . . . 0.0 111.103 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 122' ' ' LEU . . . . . 0.89 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.37 -59.55 3.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.937 179.877 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 123' ' ' LEU . . . . . 1.012 HD23 HG22 ' A' ' 26' ' ' VAL . 9.6 mt -43.28 -55.32 4.09 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.925 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 124' ' ' VAL . . . . . 0.468 HG23 ' O ' ' B' ' 120' ' ' GLY . 90.4 t -52.74 -51.96 31.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.119 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 72.7 t -60.94 -40.25 84.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.129 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 126' ' ' VAL . . . . . 1.017 HG22 HD23 ' A' ' 23' ' ' LEU . 44.9 t -51.47 -59.3 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.141 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 127' ' ' LEU . . . . . 0.742 HD23 HD23 ' A' ' 27' ' ' LEU . 49.7 mt -67.59 -46.88 71.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.907 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.52 -47.53 51.33 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.453 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.0 t -76.24 -54.37 13.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.892 0.377 . . . . 0.0 111.153 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 130' ' ' VAL . . . . . 0.745 HG21 HD11 ' A' ' 27' ' ' LEU . 19.7 t -49.69 -42.71 17.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.114 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 131' ' ' PHE . . . . . 0.423 ' HB3' HD12 ' B' ' 135' ' ' ILE . 4.8 m-85 -77.41 -41.04 41.41 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.864 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -53.27 -48.43 59.45 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.486 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 30.1 mt -75.25 -50.37 24.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.827 0.346 . . . . 0.0 111.117 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 21.9 mt -51.53 -57.42 9.11 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.894 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.423 HD12 ' HB3' ' B' ' 131' ' ' PHE . 17.2 mt -59.94 -50.01 81.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.115 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 31.0 ttpt . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.897 179.865 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.828 0.347 . . . . 0.0 111.076 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 9.5 t -51.36 -51.62 23.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.159 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.673 HG12 HD11 ' A' ' 23' ' ' LEU . 99.4 t -48.48 -59.04 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.105 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.475 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -50.23 -54.81 18.12 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.486 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 55.1 mt -58.43 -54.89 26.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.856 0.36 . . . . 0.0 111.124 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.863 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.1 -59.83 3.31 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.948 179.884 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 1.001 HD23 HG22 ' B' ' 126' ' ' VAL . 9.6 mt -43.29 -55.65 3.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.935 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.475 HG23 ' O ' ' A' ' 20' ' ' GLY . 88.4 t -52.47 -51.14 35.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.142 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 69.8 t -61.6 -40.65 87.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.082 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 1.012 HG22 HD23 ' B' ' 123' ' ' LEU . 41.8 t -51.37 -58.89 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.136 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.74 HD23 HD23 ' B' ' 127' ' ' LEU . 45.9 mt -68.47 -46.16 70.51 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.912 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.79 -47.62 52.65 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.477 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.7 t -76.11 -54.32 13.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.918 0.389 . . . . 0.0 111.169 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.704 HG21 HD11 ' B' ' 127' ' ' LEU . 20.0 t -49.8 -43.01 18.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.114 179.883 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.423 ' HB3' HD12 ' A' ' 35' ' ' ILE . 4.8 m-85 -77.61 -41.5 38.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.902 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -53.28 -47.36 61.95 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.489 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 22.3 mt -76.04 -51.37 20.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.833 0.349 . . . . 0.0 111.141 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 23.7 mt -51.0 -55.92 15.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.903 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.423 HD12 ' HB3' ' A' ' 31' ' ' PHE . 18.3 mt -61.71 -48.48 88.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.116 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 3.9 tmtt? . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.886 179.882 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.82 0.343 . . . . 0.0 111.101 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.3 t -51.54 -51.51 25.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.17 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.68 HG12 HD11 ' B' ' 123' ' ' LEU . 98.9 t -48.51 -59.04 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.129 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 120' ' ' GLY . . . . . 0.477 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -50.29 -54.8 18.39 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.493 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 55.5 mt -58.46 -54.88 27.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.865 0.364 . . . . 0.0 111.119 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 122' ' ' LEU . . . . . 0.877 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.1 -59.85 3.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.897 179.903 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 123' ' ' LEU . . . . . 1.012 HD23 HG22 ' A' ' 26' ' ' VAL . 9.7 mt -43.26 -55.77 3.84 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 124' ' ' VAL . . . . . 0.477 HG23 ' O ' ' B' ' 120' ' ' GLY . 89.3 t -52.43 -51.21 34.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.173 179.82 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 69.2 t -61.48 -40.56 86.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.161 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 126' ' ' VAL . . . . . 1.001 HG22 HD23 ' A' ' 23' ' ' LEU . 42.3 t -51.5 -59.18 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.092 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 127' ' ' LEU . . . . . 0.74 HD23 HD23 ' A' ' 27' ' ' LEU . 45.2 mt -68.14 -46.26 71.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.916 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.56 -47.65 51.29 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.507 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 56.0 t -76.37 -54.25 13.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.845 0.355 . . . . 0.0 111.077 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 130' ' ' VAL . . . . . 0.705 HG21 HD11 ' A' ' 27' ' ' LEU . 20.2 t -49.8 -42.72 18.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.114 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 131' ' ' PHE . . . . . 0.404 ' HB3' HD12 ' B' ' 135' ' ' ILE . 4.8 m-85 -77.77 -41.96 35.7 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.859 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -52.93 -47.16 60.08 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.491 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 22.6 mt -76.16 -51.55 19.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.884 0.373 . . . . 0.0 111.141 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 134' ' ' LEU . . . . . 0.409 HD23 ' HA ' ' B' ' 134' ' ' LEU . 23.2 mt -50.8 -55.79 15.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.861 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.404 HD12 ' HB3' ' B' ' 131' ' ' PHE . 17.4 mt -61.87 -48.85 86.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.17 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 3.8 tmtt? . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.91 179.806 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.799 0.333 . . . . 0.0 111.115 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.7 t -51.78 -51.07 29.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.16 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.697 HG12 HD11 ' A' ' 23' ' ' LEU . 91.3 t -48.65 -59.48 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.121 179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.47 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -50.05 -54.55 18.41 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.508 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 90.4 mt -58.47 -54.71 29.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.832 0.349 . . . . 0.0 111.111 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.876 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.46 -59.7 3.51 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.937 179.908 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 1.025 HD23 HG22 ' B' ' 126' ' ' VAL . 9.0 mt -43.26 -55.37 4.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.937 179.877 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.47 HG23 ' O ' ' A' ' 20' ' ' GLY . 86.9 t -52.52 -51.61 32.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.17 179.809 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 73.6 t -61.47 -40.28 85.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.169 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 1.026 HG22 HD23 ' B' ' 123' ' ' LEU . 44.4 t -51.5 -59.0 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.124 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.73 HD11 HG21 ' B' ' 130' ' ' VAL . 48.8 mt -67.7 -46.76 71.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.941 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.54 -47.22 52.28 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.52 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 56.3 t -76.6 -54.3 13.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.913 0.387 . . . . 0.0 111.122 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.727 HG21 HD11 ' B' ' 127' ' ' LEU . 19.9 t -49.78 -42.45 18.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.116 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.41 ' HB3' HD12 ' A' ' 35' ' ' ILE . 4.8 m-85 -77.57 -43.19 32.58 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.845 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -52.59 -47.68 57.17 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.476 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 30.3 mt -74.84 -51.86 20.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.842 0.353 . . . . 0.0 111.137 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 22.9 mt -50.97 -57.92 7.34 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.931 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.41 HD12 ' HB3' ' A' ' 31' ' ' PHE . 14.4 mt -59.3 -48.3 87.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.118 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 9.4 ttmm . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.922 179.826 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.83 0.348 . . . . 0.0 111.083 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.4 t -51.55 -51.03 27.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.115 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.708 HG12 HD11 ' B' ' 123' ' ' LEU . 90.2 t -48.7 -59.5 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.11 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 120' ' ' GLY . . . . . 0.473 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -50.04 -54.55 18.39 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.46 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 90.1 mt -58.47 -54.75 28.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.83 0.347 . . . . 0.0 111.095 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 122' ' ' LEU . . . . . 0.875 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.43 -59.83 3.38 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.9 179.886 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 123' ' ' LEU . . . . . 1.026 HD23 HG22 ' A' ' 26' ' ' VAL . 9.1 mt -43.13 -55.4 3.91 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.857 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 124' ' ' VAL . . . . . 0.473 HG23 ' O ' ' B' ' 120' ' ' GLY . 87.0 t -52.63 -51.66 33.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.116 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 73.1 t -61.41 -40.19 85.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.096 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 126' ' ' VAL . . . . . 1.025 HG22 HD23 ' A' ' 23' ' ' LEU . 44.1 t -51.52 -59.13 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.101 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 127' ' ' LEU . . . . . 0.727 HD11 HG21 ' A' ' 30' ' ' VAL . 48.5 mt -67.64 -46.83 71.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.929 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.57 -47.18 52.47 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.486 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 56.1 t -76.65 -54.25 13.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.83 0.348 . . . . 0.0 111.121 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 130' ' ' VAL . . . . . 0.73 HG21 HD11 ' A' ' 27' ' ' LEU . 20.0 t -49.8 -42.47 18.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.119 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 131' ' ' PHE . . . . . 0.42 ' HB3' HD12 ' B' ' 135' ' ' ILE . 4.7 m-85 -77.46 -43.23 33.06 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.871 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -52.23 -47.9 54.61 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.501 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 30.5 mt -74.88 -51.68 21.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.841 0.353 . . . . 0.0 111.113 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 134' ' ' LEU . . . . . 0.402 HD23 ' HA ' ' B' ' 134' ' ' LEU . 21.9 mt -50.91 -57.98 7.15 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.904 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.42 HD12 ' HB3' ' B' ' 131' ' ' PHE . 14.2 mt -59.28 -48.99 85.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.107 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 9.7 ttmm . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.909 179.871 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.825 0.345 . . . . 0.0 111.1 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 5.9 t -51.05 -48.92 29.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.088 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.494 ' O ' ' HG ' ' A' ' 23' ' ' LEU . 98.3 t -49.6 -63.35 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.129 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -48.57 -55.69 10.65 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.497 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.402 ' O ' HG23 ' A' ' 25' ' ' VAL . 20.4 mt -55.52 -41.02 61.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.863 0.363 . . . . 0.0 111.111 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.77 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.8 OUTLIER -57.15 -50.68 72.05 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.877 179.926 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.808 HD22 HG22 ' B' ' 126' ' ' VAL . 1.1 mt -54.47 -51.67 64.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.901 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 98.1 t -55.44 -45.97 78.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.118 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.402 HG23 ' O ' ' A' ' 21' ' ' ILE . 70.6 t -64.83 -43.18 96.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.101 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.806 HG22 HD22 ' B' ' 123' ' ' LEU . 73.3 t -51.27 -54.31 11.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.113 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.814 HD23 HD23 ' B' ' 127' ' ' LEU . 56.4 mt -70.13 -47.28 62.39 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.885 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.82 -45.88 55.14 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.538 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 57.4 t -76.81 -54.67 12.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.84 0.352 . . . . 0.0 111.136 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.732 HG21 HD11 ' B' ' 127' ' ' LEU . 17.6 t -49.9 -43.05 19.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.158 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.404 ' HB3' HD12 ' A' ' 35' ' ' ILE . 5.1 m-85 -77.22 -44.95 28.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.825 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -52.29 -48.0 54.72 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.47 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 45.4 mt -73.22 -52.55 21.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.848 0.356 . . . . 0.0 111.126 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 23.7 mt -51.03 -60.75 2.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.89 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.404 HD12 ' HB3' ' A' ' 31' ' ' PHE . 11.8 mt -55.7 -48.68 77.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.117 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 63.6 tttt . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.877 179.897 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.827 0.346 . . . . 0.0 111.111 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 6.1 t -51.27 -48.78 32.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.103 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.491 ' O ' ' HG ' ' B' ' 123' ' ' LEU . 98.4 t -49.66 -63.28 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.123 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.73 -55.48 11.2 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.499 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 20.0 mt -55.64 -40.8 61.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.884 0.373 . . . . 0.0 111.163 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 122' ' ' LEU . . . . . 0.773 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.8 OUTLIER -57.44 -50.25 73.61 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.945 179.868 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 123' ' ' LEU . . . . . 0.806 HD22 HG22 ' A' ' 26' ' ' VAL . 1.1 mt -54.73 -51.35 65.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.956 179.875 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 99.6 t -55.93 -46.0 80.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.113 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 71.0 t -64.64 -43.12 96.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.136 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 126' ' ' VAL . . . . . 0.808 HG22 HD22 ' A' ' 23' ' ' LEU . 71.7 t -51.42 -54.36 12.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.105 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 127' ' ' LEU . . . . . 0.814 HD23 HD23 ' A' ' 27' ' ' LEU . 57.1 mt -70.15 -47.39 61.89 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.927 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.81 -45.81 55.12 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.458 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 58.1 t -76.77 -54.82 12.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.931 0.396 . . . . 0.0 111.191 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 130' ' ' VAL . . . . . 0.726 HG21 HD11 ' A' ' 27' ' ' LEU . 17.6 t -49.89 -43.06 19.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.137 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 131' ' ' PHE . . . . . 0.415 ' HB3' HD12 ' B' ' 135' ' ' ILE . 5.1 m-85 -77.16 -44.83 28.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.898 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -52.3 -48.11 54.57 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.479 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 46.1 mt -73.21 -52.43 21.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.874 0.369 . . . . 0.0 111.149 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 134' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' B' ' 134' ' ' LEU . 23.9 mt -51.14 -60.77 2.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.914 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.415 HD12 ' HB3' ' B' ' 131' ' ' PHE . 12.0 mt -55.73 -48.62 77.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.094 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 63.5 tttt . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.892 179.885 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.828 0.347 . . . . 0.0 111.041 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.408 HG23 ' H ' ' A' ' 18' ' ' VAL . 5.9 t -51.58 -48.72 35.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.134 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.493 ' O ' ' HG ' ' A' ' 23' ' ' LEU . 92.1 t -50.04 -63.44 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.132 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -48.41 -55.48 10.69 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.527 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 22.1 mt -55.84 -40.86 64.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.816 0.341 . . . . 0.0 111.085 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.777 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.9 OUTLIER -57.46 -49.62 75.69 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.927 179.897 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.811 HD22 HG22 ' B' ' 126' ' ' VAL . 2.0 mt -55.18 -51.44 66.52 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.942 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 98.9 t -55.92 -46.17 80.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.122 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 76.0 t -63.75 -43.59 98.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.147 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.83 HG22 HD22 ' B' ' 123' ' ' LEU . 76.2 t -51.67 -53.72 15.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.107 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.793 HD23 HD23 ' B' ' 127' ' ' LEU . 54.0 mt -71.72 -45.73 60.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.923 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.77 -46.39 59.94 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.469 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -76.08 -54.21 14.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.851 0.358 . . . . 0.0 111.134 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.667 HG21 HD11 ' B' ' 127' ' ' LEU . 18.4 t -50.64 -44.6 25.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.14 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.442 ' HB3' HD12 ' A' ' 35' ' ' ILE . 5.3 m-85 -76.79 -39.07 52.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.9 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -54.71 -49.37 61.79 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 23.3 mt -74.78 -50.25 26.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.888 0.375 . . . . 0.0 111.165 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 25.4 mt -51.86 -56.28 14.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.934 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.442 HD12 ' HB3' ' A' ' 31' ' ' PHE . 21.6 mt -61.32 -44.09 97.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.179 179.799 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 16.8 mttt . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.877 179.852 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.836 0.351 . . . . 0.0 111.033 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 5.7 t -51.54 -48.77 35.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.128 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 119' ' ' VAL . . . . . 0.491 ' O ' ' HG ' ' B' ' 123' ' ' LEU . 92.9 t -49.97 -63.41 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.101 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.46 -55.46 10.79 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.459 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 22.2 mt -55.89 -40.73 63.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.877 0.37 . . . . 0.0 111.118 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 122' ' ' LEU . . . . . 0.778 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.9 OUTLIER -57.57 -49.49 76.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.946 179.867 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 123' ' ' LEU . . . . . 0.83 HD22 HG22 ' A' ' 26' ' ' VAL . 2.0 mt -55.38 -51.48 66.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.902 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 98.0 t -55.81 -46.0 79.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.156 179.831 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 78.0 t -63.99 -43.45 97.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.148 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 126' ' ' VAL . . . . . 0.811 HG22 HD22 ' A' ' 23' ' ' LEU . 76.0 t -51.68 -53.68 15.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.143 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 127' ' ' LEU . . . . . 0.793 HD23 HD23 ' A' ' 27' ' ' LEU . 52.7 mt -71.78 -45.84 60.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.921 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -52.63 -46.12 59.4 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.506 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.4 t -76.41 -54.2 13.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.876 0.369 . . . . 0.0 111.097 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 130' ' ' VAL . . . . . 0.691 HG21 HD11 ' A' ' 27' ' ' LEU . 18.6 t -50.7 -44.31 25.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.179 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 131' ' ' PHE . . . . . 0.436 ' HB3' HD12 ' B' ' 135' ' ' ILE . 5.2 m-85 -77.0 -39.29 50.94 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.863 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -54.56 -49.09 62.33 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.478 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 22.2 mt -75.04 -50.6 24.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.809 0.338 . . . . 0.0 111.129 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 25.0 mt -51.54 -55.74 17.38 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.898 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.436 HD12 ' HB3' ' B' ' 131' ' ' PHE . 21.9 mt -61.9 -44.34 98.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.146 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 19.8 mttt . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.898 179.838 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 N-CA-C 112.543 -0.223 . . . . 0.0 112.543 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 6.6 p -134.14 70.33 73.84 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.656 0.741 . . . . 0.0 110.883 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 173.46 10.94 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.686 2.258 . . . . 0.0 112.363 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . 55.73 45.92 23.53 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.127 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -99.74 43.01 1.08 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.927 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 23.9 mt-30 -105.51 136.0 45.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.908 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 4.0 ppt_? -115.67 34.62 4.83 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.863 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.612 ' HB3' HG21 ' A' ' 12' ' ' THR . . . -67.11 166.94 12.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.116 179.886 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.705 ' O ' HG22 ' A' ' 12' ' ' THR . 0.3 OUTLIER -49.34 164.9 0.29 Allowed Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.647 0.737 . . . . 0.0 110.878 -179.825 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 -11.87 31.68 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.655 2.237 . . . . 0.0 112.345 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.459 HD13 ' C ' ' A' ' 11' ' ' LEU . 3.0 tm? -79.12 -36.58 40.36 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.9 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.705 HG22 ' O ' ' A' ' 9' ' ' SER . 7.4 t -48.88 -32.87 9.61 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.132 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -65.33 -48.37 73.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.816 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.54 ' O ' HG23 ' A' ' 18' ' ' VAL . 52.3 mt -59.7 -45.24 94.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.137 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.556 ' O ' HG23 ' A' ' 19' ' ' VAL . 11.9 mt -55.14 -51.69 52.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.127 179.834 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -58.11 -36.29 72.68 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.83 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -62.79 -58.86 5.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.118 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.54 HG23 ' O ' ' A' ' 14' ' ' ILE . 9.7 t -51.0 -51.14 22.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.138 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.699 HG12 HD11 ' A' ' 23' ' ' LEU . 88.7 t -48.7 -59.61 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.146 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.481 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -49.88 -54.49 17.95 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.51 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 62.5 mt -58.48 -54.84 27.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.854 0.359 . . . . 0.0 111.114 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.871 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.42 -59.44 3.72 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.903 179.955 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.977 HD23 HG22 ' B' ' 126' ' ' VAL . 9.0 mt -43.44 -55.52 4.12 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.918 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 20' ' ' GLY . 87.2 t -52.4 -51.26 34.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.144 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.8 t -61.75 -40.5 87.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.141 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.987 HG22 HD23 ' B' ' 123' ' ' LEU . 44.2 t -51.22 -59.28 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.149 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.726 HD23 HD23 ' B' ' 127' ' ' LEU . 47.6 mt -67.45 -46.41 73.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.894 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.62 -48.13 50.4 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.491 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.4 t -75.97 -54.19 14.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.883 0.373 . . . . 0.0 111.142 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.728 HG21 HD11 ' B' ' 127' ' ' LEU . 20.3 t -49.72 -42.78 18.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.11 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -77.52 -34.84 53.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.892 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -57.39 -48.69 78.77 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.494 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 16.0 mt -76.91 -47.56 27.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.869 0.366 . . . . 0.0 111.141 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 28.2 mt -55.41 -53.13 60.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.937 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 79.3 mt -63.46 -49.49 82.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.123 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 27.8 ttpt -62.3 -16.87 56.68 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.891 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 46.0 mtp85 -84.02 -37.91 21.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.861 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.07 -49.16 8.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.891 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.7 mt-30 49.59 52.29 14.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.875 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 11.7 mm100 -115.68 48.49 1.2 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.886 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 3.8 tppt? -152.93 136.33 15.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.906 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 1.9 mt 45.91 83.57 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.143 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 15.6 ttm180 -85.82 130.7 34.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.883 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 22.5 ttmm . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 179.95 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 7.0 p -135.15 68.84 69.86 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.62 0.724 . . . . 0.0 110.9 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 171.32 14.67 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.731 2.287 . . . . 0.0 112.37 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . 54.54 49.45 18.22 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.065 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -99.52 31.31 3.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.89 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 20.8 mt-30 -117.83 136.43 53.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.887 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 3.3 ppt_? -115.17 9.79 15.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.869 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 108' ' ' ALA . . . . . 0.657 ' HB3' HG21 ' B' ' 112' ' ' THR . . . -100.6 166.75 10.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.091 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 109' ' ' SER . . . . . 0.673 ' O ' HG22 ' B' ' 112' ' ' THR . 0.3 OUTLIER -50.97 164.1 0.46 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.693 0.758 . . . . 0.0 110.879 -179.76 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 -11.77 31.55 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.678 2.252 . . . . 0.0 112.359 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 111' ' ' LEU . . . . . 0.462 HD13 ' C ' ' B' ' 111' ' ' LEU . 3.0 tm? -81.96 -34.67 29.63 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.911 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 112' ' ' THR . . . . . 0.673 HG22 ' O ' ' B' ' 109' ' ' SER . 6.1 t -48.79 -31.76 7.56 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.188 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -65.4 -50.16 66.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.844 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 114' ' ' ILE . . . . . 0.537 ' O ' HG23 ' B' ' 118' ' ' VAL . 50.1 mt -59.14 -45.91 92.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.105 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.546 ' O ' HG23 ' B' ' 119' ' ' VAL . 6.8 mt -53.91 -52.23 37.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.14 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -57.85 -36.62 72.58 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.863 -179.896 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -62.7 -58.75 6.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.098 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.537 HG23 ' O ' ' B' ' 114' ' ' ILE . 10.1 t -50.85 -51.45 20.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.111 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.717 HG12 HD11 ' B' ' 123' ' ' LEU . 87.8 t -48.49 -59.68 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.127 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 120' ' ' GLY . . . . . 0.48 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -49.79 -54.74 16.61 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.481 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 63.7 mt -58.32 -54.93 26.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.843 0.354 . . . . 0.0 111.119 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 122' ' ' LEU . . . . . 0.859 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.35 -59.8 3.39 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.911 179.913 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 123' ' ' LEU . . . . . 0.987 HD23 HG22 ' A' ' 26' ' ' VAL . 9.1 mt -43.18 -55.56 3.88 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.9 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 124' ' ' VAL . . . . . 0.48 HG23 ' O ' ' B' ' 120' ' ' GLY . 87.0 t -52.38 -51.61 31.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.11 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 72.5 t -61.4 -40.49 86.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.114 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 126' ' ' VAL . . . . . 0.977 HG22 HD23 ' A' ' 23' ' ' LEU . 43.8 t -51.27 -59.27 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.129 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 127' ' ' LEU . . . . . 0.728 HD11 HG21 ' A' ' 30' ' ' VAL . 47.3 mt -67.52 -46.37 73.03 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.904 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.61 -47.81 51.17 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.537 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.6 t -76.25 -54.17 13.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.911 0.386 . . . . 0.0 111.141 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 130' ' ' VAL . . . . . 0.705 HG21 HD11 ' A' ' 27' ' ' LEU . 19.9 t -49.81 -42.54 18.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.112 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -77.66 -35.19 52.67 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.879 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -57.32 -48.38 80.85 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.496 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 17.2 mt -77.05 -47.81 26.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.855 0.36 . . . . 0.0 111.121 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 28.2 mt -55.29 -53.05 60.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.904 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 77.9 mt -63.39 -49.84 81.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.17 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 27.9 ttpt -61.96 -17.06 55.67 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.888 179.853 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 46.1 mtp85 -83.74 -38.15 21.74 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.835 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.75 -49.16 8.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.865 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 2.6 mt-30 49.08 51.74 15.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.886 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 13.1 mm100 -114.68 46.36 1.41 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.965 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 4.9 tppt? -156.94 141.48 16.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.929 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 142' ' ' ILE . . . . . . . . . . . . . 5.4 pt -44.09 105.79 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.105 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 16.3 ttm180 -70.93 130.66 42.18 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.861 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 22.1 ttmm . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.867 179.979 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.504 -0.238 . . . . 0.0 112.504 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 4.6 p -140.91 156.57 68.54 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.558 0.694 . . . . 0.0 110.896 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -172.89 0.62 Allowed 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.685 2.257 . . . . 0.0 112.312 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.88 161.4 4.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.11 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 17.2 tp10 -56.65 111.84 1.12 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.889 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 1.6 tp60 -115.9 141.1 48.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.856 -179.882 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.37 176.94 9.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.863 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.65 ' HB3' HG21 ' A' ' 12' ' ' THR . . . -142.38 168.78 18.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.101 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.678 ' O ' HG22 ' A' ' 12' ' ' THR . 0.3 OUTLIER -49.62 164.51 0.33 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.663 0.744 . . . . 0.0 110.877 -179.799 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.7 -11.62 31.3 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.674 2.249 . . . . 0.0 112.355 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.462 HD22 ' O ' ' A' ' 11' ' ' LEU . 2.5 tm? -80.77 -35.91 32.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.902 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.678 HG22 ' O ' ' A' ' 9' ' ' SER . 6.4 t -48.88 -32.03 8.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.119 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.39 -50.87 65.95 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.913 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.596 ' O ' HG23 ' A' ' 18' ' ' VAL . 3.3 mp -59.1 -43.16 88.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.088 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.52 ' O ' HG23 ' A' ' 19' ' ' VAL . 13.1 mt -55.26 -53.17 37.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.097 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.3 t -57.87 -36.3 72.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.873 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -62.46 -58.64 6.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.076 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.596 HG23 ' O ' ' A' ' 14' ' ' ILE . 9.6 t -51.38 -51.07 25.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.123 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.685 HG12 HD11 ' A' ' 23' ' ' LEU . 95.0 t -48.55 -59.49 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.081 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.484 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -50.07 -54.46 18.88 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.527 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 66.9 mt -58.5 -54.77 28.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.919 0.39 . . . . 0.0 111.131 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.869 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.4 -59.7 3.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.922 179.922 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.987 HD23 HG22 ' B' ' 126' ' ' VAL . 9.1 mt -43.24 -55.53 3.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.905 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 20' ' ' GLY . 87.2 t -52.4 -51.47 32.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.152 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.7 t -61.52 -40.59 87.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.118 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.976 HG22 HD23 ' B' ' 123' ' ' LEU . 43.3 t -51.29 -59.12 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.108 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.722 HD23 HD23 ' B' ' 127' ' ' LEU . 46.4 mt -67.79 -46.36 72.19 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.899 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.6 -47.8 51.13 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.472 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -76.26 -54.32 13.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.862 0.363 . . . . 0.0 111.11 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.722 HG21 HD11 ' B' ' 127' ' ' LEU . 20.1 t -49.7 -42.5 17.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.137 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.422 ' HB3' HD12 ' A' ' 35' ' ' ILE . 4.7 m-85 -77.85 -37.34 48.56 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.85 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -56.29 -47.78 79.76 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.499 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.614 HG22 ' HD2' ' A' ' 37' ' ' ARG . 19.5 mt -76.69 -49.4 24.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.833 0.349 . . . . 0.0 111.149 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 28.6 mt -53.81 -52.86 58.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.955 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.422 HD12 ' HB3' ' A' ' 31' ' ' PHE . 49.2 mt -63.59 -47.48 91.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.135 179.787 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 32.3 ttpt -62.84 -17.97 62.16 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.844 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.614 ' HD2' HG22 ' A' ' 33' ' ' ILE . 0.2 OUTLIER -82.53 -39.38 22.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.863 179.973 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 11.0 mtp180 -83.71 -48.99 9.57 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.866 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 3.7 mt-30 49.55 41.81 21.89 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.864 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 9.1 mm100 -125.13 116.29 21.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.915 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 25.4 pttt -171.6 167.44 6.57 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.928 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 4.6 pt -63.57 143.11 15.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.11 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? -103.3 62.55 0.79 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.884 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.911 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.46 -0.256 . . . . 0.0 112.46 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 4.5 p -141.64 156.6 66.28 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.656 0.741 . . . . 0.0 110.875 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -171.99 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.699 2.266 . . . . 0.0 112.361 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . -58.47 161.45 4.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.112 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 16.8 tp10 -56.91 110.82 0.88 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.872 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -117.65 141.09 48.78 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.89 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.41 177.44 8.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.875 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 108' ' ' ALA . . . . . 0.653 ' HB3' HG21 ' B' ' 112' ' ' THR . . . -138.74 169.09 18.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.076 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 109' ' ' SER . . . . . 0.678 ' O ' HG22 ' B' ' 112' ' ' THR . 0.3 OUTLIER -49.9 164.53 0.35 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.678 0.751 . . . . 0.0 110.834 -179.798 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -11.57 31.17 Favored 'Trans proline' 0 C--O 1.232 0.223 0 C-N-CA 122.693 2.262 . . . . 0.0 112.368 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 111' ' ' LEU . . . . . 0.467 ' O ' HD22 ' B' ' 111' ' ' LEU . 2.6 tm? -80.75 -36.05 32.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.937 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 112' ' ' THR . . . . . 0.678 HG22 ' O ' ' B' ' 109' ' ' SER . 6.4 t -49.13 -31.8 8.86 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.15 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.83 -50.88 64.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.803 -179.847 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 114' ' ' ILE . . . . . 0.582 ' O ' HG23 ' B' ' 118' ' ' VAL . 3.3 mp -58.9 -43.51 88.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.095 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.516 ' O ' HG23 ' B' ' 119' ' ' VAL . 13.1 mt -55.11 -53.77 31.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.117 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 11.7 t -57.47 -35.59 70.36 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.902 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -63.1 -58.65 6.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.089 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.582 HG23 ' O ' ' B' ' 114' ' ' ILE . 9.8 t -51.35 -51.0 25.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.155 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.706 HG12 HD11 ' B' ' 123' ' ' LEU . 93.6 t -48.63 -59.43 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.147 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 120' ' ' GLY . . . . . 0.48 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -50.13 -54.49 18.96 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.472 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 67.0 mt -58.48 -54.85 27.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.917 0.389 . . . . 0.0 111.16 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 122' ' ' LEU . . . . . 0.867 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.31 -59.94 3.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.897 179.894 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 123' ' ' LEU . . . . . 0.976 HD23 HG22 ' A' ' 26' ' ' VAL . 9.2 mt -43.12 -55.41 3.9 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.933 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 124' ' ' VAL . . . . . 0.48 HG23 ' O ' ' B' ' 120' ' ' GLY . 87.4 t -52.55 -51.62 32.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.104 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 72.5 t -61.38 -40.61 86.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.1 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 126' ' ' VAL . . . . . 0.987 HG22 HD23 ' A' ' 23' ' ' LEU . 43.1 t -51.19 -59.19 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.121 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 127' ' ' LEU . . . . . 0.722 HD11 HG21 ' A' ' 30' ' ' VAL . 45.4 mt -67.8 -46.15 72.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.972 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.69 -47.9 51.4 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.461 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.0 t -76.24 -54.19 13.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.895 0.379 . . . . 0.0 111.093 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 130' ' ' VAL . . . . . 0.721 HG21 HD11 ' A' ' 27' ' ' LEU . 20.2 t -49.7 -42.59 17.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.141 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 131' ' ' PHE . . . . . 0.439 ' HB3' HD12 ' B' ' 135' ' ' ILE . 4.6 m-85 -77.72 -37.03 50.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.879 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -56.04 -47.86 77.52 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.517 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 133' ' ' ILE . . . . . 0.627 HG22 ' HD2' ' B' ' 137' ' ' ARG . 18.2 mt -77.07 -49.25 23.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.826 0.346 . . . . 0.0 111.127 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 27.8 mt -53.57 -52.02 61.07 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.919 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.439 HD12 ' HB3' ' B' ' 131' ' ' PHE . 49.3 mt -64.85 -46.67 91.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.096 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 32.1 ttpt -63.36 -17.28 62.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.899 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 137' ' ' ARG . . . . . 0.627 ' HD2' HG22 ' B' ' 133' ' ' ILE . 0.2 OUTLIER -83.8 -38.83 20.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.908 179.961 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 11.1 mtp180 -84.38 -48.82 9.29 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.874 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 50.66 41.27 25.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.905 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 9.0 mm100 -126.68 115.7 19.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.935 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 25.1 pttt -169.32 176.8 5.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.865 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 142' ' ' ILE . . . . . 0.536 HD12 ' HB2' ' B' ' 144' ' ' LYS . 4.7 pt -55.57 148.87 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.142 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 2.2 mtt180 -97.1 77.13 2.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.827 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 144' ' ' LYS . . . . . 0.536 ' HB2' HD12 ' B' ' 142' ' ' ILE . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.934 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.454 -0.258 . . . . 0.0 112.454 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 26.5 t -173.8 72.46 0.36 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.604 0.716 . . . . 0.0 110.899 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 84.04 0.68 Allowed 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.666 2.244 . . . . 0.0 112.353 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -171.18 179.4 3.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.094 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -63.08 -177.18 0.16 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.857 -179.908 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -70.56 83.96 0.61 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.874 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 21.5 ttm-85 -105.68 130.36 53.71 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.924 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -137.0 157.95 45.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.09 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.607 ' O ' HG22 ' A' ' 12' ' ' THR . 0.3 OUTLIER -51.13 163.48 0.52 Allowed Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.705 0.764 . . . . 0.0 110.852 -179.763 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -11.96 31.91 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.648 2.232 . . . . 0.0 112.368 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.688 HD13 HG13 ' A' ' 15' ' ' ILE . 2.3 tm? -79.02 -26.26 43.24 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.916 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.607 HG22 ' O ' ' A' ' 9' ' ' SER . 13.6 t -50.71 -36.08 34.42 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.166 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -56.86 -52.52 64.79 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.866 -179.838 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.729 ' O ' HG23 ' A' ' 18' ' ' VAL . 4.1 mp -60.16 -40.4 83.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.097 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.688 HG13 HD13 ' A' ' 11' ' ' LEU . 44.7 mt -54.37 -55.84 12.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.184 179.88 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.8 t -58.64 -36.71 74.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.884 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -62.34 -57.16 12.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.069 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.729 HG23 ' O ' ' A' ' 14' ' ' ILE . 12.0 t -52.24 -51.09 34.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.148 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.68 HG12 HD11 ' A' ' 23' ' ' LEU . 94.9 t -48.79 -59.15 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.137 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.483 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -50.26 -54.72 18.59 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.492 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 92.5 mt -58.37 -54.83 27.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.861 0.362 . . . . 0.0 111.089 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.885 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.28 -59.81 3.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.933 179.922 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 1.038 HD23 HG22 ' B' ' 126' ' ' VAL . 9.4 mt -43.21 -55.36 4.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.873 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.483 HG23 ' O ' ' A' ' 20' ' ' GLY . 90.5 t -52.61 -51.6 33.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.112 179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 70.9 t -61.37 -40.56 86.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.108 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 1.027 HG22 HD23 ' B' ' 123' ' ' LEU . 43.0 t -51.25 -59.3 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.133 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.707 HD11 HG21 ' B' ' 130' ' ' VAL . 44.5 mt -68.01 -46.26 71.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.906 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.51 -47.52 51.33 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.49 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.5 t -76.74 -54.21 13.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.855 0.359 . . . . 0.0 111.12 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.686 HG21 HD11 ' B' ' 127' ' ' LEU . 20.1 t -49.73 -42.02 17.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.118 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 5.3 m-85 -78.28 -34.29 48.99 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.885 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -57.51 -46.89 91.5 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.509 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.497 HG22 ' CD ' ' A' ' 37' ' ' ARG . 17.6 mt -79.38 -45.48 23.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.848 0.356 . . . . 0.0 111.116 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 27.4 mt -57.84 -43.79 86.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.868 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 72.4 mt -71.28 -58.95 4.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.161 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 8.3 pttp -51.56 -28.06 12.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.937 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.497 ' CD ' HG22 ' A' ' 33' ' ' ILE . 49.5 mtp85 -77.75 -37.14 49.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.9 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 29.3 mtt180 -63.26 -28.35 69.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.878 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -174.36 138.23 0.54 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.947 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 18.3 pt20 -171.54 164.3 6.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.919 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 14.4 pttp -98.37 31.91 2.66 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.846 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.5 pp -148.59 178.24 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.118 179.845 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 6.3 ptm180 -121.93 141.28 51.46 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.921 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 6.5 tmtt? . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.908 179.904 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.286 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 24.1 t -174.11 72.87 0.34 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.605 0.716 . . . . 0.0 110.912 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.76 83.14 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.623 2.215 . . . . 0.0 112.341 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . -171.2 178.24 3.37 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.135 179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -64.17 -176.62 0.22 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.873 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -71.15 83.19 0.72 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.908 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 21.6 ttm-85 -105.69 128.81 53.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.846 -179.904 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 108' ' ' ALA . . . . . . . . . . . . . . . -139.78 158.37 44.21 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.131 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 109' ' ' SER . . . . . 0.594 ' O ' HG22 ' B' ' 112' ' ' THR . 0.3 OUTLIER -51.06 163.36 0.52 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.632 0.729 . . . . 0.0 110.872 -179.74 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -11.98 31.93 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.718 2.279 . . . . 0.0 112.314 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 111' ' ' LEU . . . . . 0.717 HD13 HG13 ' B' ' 115' ' ' ILE . 2.3 tm? -79.33 -26.35 42.18 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.95 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 112' ' ' THR . . . . . 0.594 HG22 ' O ' ' B' ' 109' ' ' SER . 13.1 t -50.77 -35.96 34.45 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.152 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -56.91 -52.52 64.86 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.867 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 114' ' ' ILE . . . . . 0.732 ' O ' HG23 ' B' ' 118' ' ' VAL . 4.1 mp -60.18 -40.41 83.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.118 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.717 HG13 HD13 ' B' ' 111' ' ' LEU . 42.7 mt -54.28 -55.96 12.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.122 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 7.7 t -58.78 -36.49 74.51 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.85 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -62.64 -57.0 12.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.082 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.732 HG23 ' O ' ' B' ' 114' ' ' ILE . 12.0 t -52.35 -51.09 35.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.127 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.689 HG12 HD11 ' B' ' 123' ' ' LEU . 95.5 t -48.89 -59.17 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.141 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 120' ' ' GLY . . . . . 0.48 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -50.2 -54.63 18.7 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.525 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 92.9 mt -58.4 -54.84 27.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.867 0.365 . . . . 0.0 111.158 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 122' ' ' LEU . . . . . 0.871 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.26 -59.87 3.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.945 179.877 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 123' ' ' LEU . . . . . 1.027 HD23 HG22 ' A' ' 26' ' ' VAL . 9.3 mt -43.08 -55.49 3.83 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.916 179.841 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 124' ' ' VAL . . . . . 0.48 HG23 ' O ' ' B' ' 120' ' ' GLY . 90.0 t -52.61 -51.51 34.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.13 179.87 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 69.9 t -61.48 -40.31 85.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.111 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 126' ' ' VAL . . . . . 1.038 HG22 HD23 ' A' ' 23' ' ' LEU . 43.1 t -51.4 -59.14 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.146 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 127' ' ' LEU . . . . . 0.701 HD23 HD23 ' A' ' 27' ' ' LEU . 45.6 mt -68.02 -46.41 71.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.875 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.6 -47.29 52.42 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.467 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.6 t -76.83 -54.18 13.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.853 0.358 . . . . 0.0 111.159 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 130' ' ' VAL . . . . . 0.707 HG21 HD11 ' A' ' 27' ' ' LEU . 19.7 t -49.8 -41.92 17.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.118 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -78.4 -36.37 45.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.859 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -56.06 -46.38 85.03 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.506 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 18.4 mt -79.18 -49.9 19.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 120.889 0.376 . . . . 0.0 111.151 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 27.8 mt -53.1 -48.1 68.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.933 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 69.9 mt -68.92 -49.93 58.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.125 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 11.5 tttp -52.68 -30.53 32.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.899 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 54.2 mtp85 -80.2 -35.07 36.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.86 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 29.5 mtt180 -61.49 -25.58 67.34 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 12.4 pt20 -172.82 138.07 0.79 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.893 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 140' ' ' GLN . . . . . 0.417 ' OE1' HD11 ' B' ' 142' ' ' ILE . 18.0 pt20 -172.29 165.32 5.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.862 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 14.4 pttp -96.52 32.92 1.91 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.915 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 142' ' ' ILE . . . . . 0.417 HD11 ' OE1' ' B' ' 140' ' ' GLN . 2.5 pp -147.85 177.77 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.119 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 19.6 ttm-85 -122.77 141.38 51.88 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.82 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 6.5 tmtt? . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.966 179.923 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.381 0 N-CA-C 112.531 -0.228 . . . . 0.0 112.531 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 79.3 m -142.5 71.14 21.17 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-O 121.645 0.736 . . . . 0.0 110.89 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.77 154.87 67.18 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.692 2.261 . . . . 0.0 112.333 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -167.5 163.8 14.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.092 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -70.2 120.2 15.53 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.881 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 41.6 tt0 -154.91 150.03 26.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.916 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -78.07 132.22 37.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.915 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -137.75 169.89 17.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.031 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.662 ' O ' HG22 ' A' ' 12' ' ' THR . 0.3 OUTLIER -50.71 163.92 0.45 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.668 0.747 . . . . 0.0 110.866 -179.801 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 -11.94 31.9 Favored 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.63 2.22 . . . . 0.0 112.346 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.611 HD13 HG12 ' A' ' 15' ' ' ILE . 2.6 tm? -79.9 -30.38 40.1 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.931 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.662 HG22 ' O ' ' A' ' 9' ' ' SER . 8.3 t -51.14 -34.78 32.6 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.156 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -59.46 -49.99 75.65 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.906 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.703 ' O ' HG23 ' A' ' 18' ' ' VAL . 60.3 mt -61.14 -41.21 88.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.108 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.611 HG12 HD13 ' A' ' 11' ' ' LEU . 26.6 mm -55.14 -54.9 19.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.094 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -58.15 -37.36 74.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.888 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -61.74 -57.82 10.41 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.092 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.703 HG23 ' O ' ' A' ' 14' ' ' ILE . 11.3 t -51.59 -51.21 27.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.122 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.723 HG12 HD11 ' A' ' 23' ' ' LEU . 84.0 t -48.62 -59.96 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.161 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.477 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -49.54 -54.71 15.74 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.475 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 96.2 mt -58.35 -54.81 27.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.884 0.373 . . . . 0.0 111.183 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.87 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.45 -59.56 3.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.871 179.907 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.992 HD23 HG22 ' B' ' 126' ' ' VAL . 8.8 mt -43.19 -55.55 3.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.925 179.869 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.477 HG23 ' O ' ' A' ' 20' ' ' GLY . 89.7 t -52.48 -51.74 31.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.144 179.849 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 73.4 t -61.44 -39.87 84.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.158 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 1.001 HG22 HD23 ' B' ' 123' ' ' LEU . 46.0 t -51.64 -58.69 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.131 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.726 HD23 HD23 ' B' ' 127' ' ' LEU . 56.6 mt -67.25 -47.6 70.25 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.962 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.3 -47.46 50.31 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.476 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.9 t -75.99 -54.4 13.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.904 0.383 . . . . 0.0 111.166 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.795 HG21 HD11 ' B' ' 127' ' ' LEU . 19.4 t -49.46 -43.29 17.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.13 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.404 ' HB3' HD12 ' A' ' 35' ' ' ILE . 7.5 m-85 -77.2 -41.53 41.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.879 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -53.35 -48.16 60.48 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.477 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 38.4 mt -74.89 -50.91 23.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.859 0.361 . . . . 0.0 111.115 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 23.2 mt -51.25 -57.64 8.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.937 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.404 HD12 ' HB3' ' A' ' 31' ' ' PHE . 14.4 mt -59.81 -48.48 87.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.126 179.838 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 14.8 tttm -50.48 -52.88 34.2 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.914 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 46.3 mtp85 -59.12 -38.68 80.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.91 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 48.8 mtp180 -65.16 -47.71 76.07 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.866 -179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 67.4 mt-30 -55.31 174.74 0.08 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.892 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -90.7 107.95 19.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.949 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 31.4 mttt -140.03 168.51 19.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.875 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 70.4 mt -136.39 126.31 39.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.115 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 13.1 mmt-85 -70.11 168.83 14.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.918 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 1.6 mtpp . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.894 179.97 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.372 0 N-CA-C 112.514 -0.234 . . . . 0.0 112.514 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 79.1 m -142.48 71.31 21.19 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.623 0.725 . . . . 0.0 110.864 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 154.6 67.39 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.69 2.26 . . . . 0.0 112.309 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . -167.58 164.53 14.69 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.076 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -69.38 121.46 16.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.908 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 41.5 tt0 -152.29 149.43 28.67 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.914 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -79.51 132.65 36.39 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.839 -179.858 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 108' ' ' ALA . . . . . 0.49 ' HB3' HG21 ' B' ' 112' ' ' THR . . . -136.46 169.25 17.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.089 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 109' ' ' SER . . . . . 0.673 ' O ' HG22 ' B' ' 112' ' ' THR . 0.3 OUTLIER -50.67 163.66 0.46 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.701 0.762 . . . . 0.0 110.841 -179.8 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -11.66 31.29 Favored 'Trans proline' 0 C--O 1.233 0.231 0 C-N-CA 122.645 2.23 . . . . 0.0 112.35 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 111' ' ' LEU . . . . . 0.619 HD13 HG12 ' B' ' 115' ' ' ILE . 2.6 tm? -81.58 -30.71 32.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.882 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 112' ' ' THR . . . . . 0.673 HG22 ' O ' ' B' ' 109' ' ' SER . 6.8 t -51.29 -34.55 33.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.185 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -59.43 -49.61 77.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.892 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 114' ' ' ILE . . . . . 0.716 ' O ' HG23 ' B' ' 118' ' ' VAL . 60.2 mt -61.74 -41.63 91.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.164 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.619 HG12 HD13 ' B' ' 111' ' ' LEU . 26.5 mm -54.48 -55.58 14.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.134 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -58.38 -36.93 74.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.854 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -62.15 -57.66 10.7 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.066 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.716 HG23 ' O ' ' B' ' 114' ' ' ILE . 11.6 t -51.7 -51.34 27.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.181 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.712 HG12 HD11 ' B' ' 123' ' ' LEU . 89.1 t -48.6 -59.47 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.13 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 120' ' ' GLY . . . . . 0.473 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -50.05 -54.88 17.09 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.484 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 96.3 mt -58.28 -54.87 26.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.908 0.385 . . . . 0.0 111.128 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 122' ' ' LEU . . . . . 0.87 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.3 -59.69 3.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.907 179.93 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 123' ' ' LEU . . . . . 1.001 HD23 HG22 ' A' ' 26' ' ' VAL . 9.3 mt -43.22 -55.71 3.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.914 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 124' ' ' VAL . . . . . 0.473 HG23 ' O ' ' B' ' 120' ' ' GLY . 90.4 t -52.33 -51.83 29.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.087 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 74.0 t -61.19 -40.74 86.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.104 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 126' ' ' VAL . . . . . 0.992 HG22 HD23 ' A' ' 23' ' ' LEU . 45.4 t -50.89 -59.49 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.132 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 127' ' ' LEU . . . . . 0.795 HD11 HG21 ' A' ' 30' ' ' VAL . 49.0 mt -67.43 -46.67 72.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.924 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -50.89 -47.4 47.85 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.486 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 58.4 t -77.77 -54.66 12.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.895 0.379 . . . . 0.0 111.156 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 130' ' ' VAL . . . . . 0.659 HG21 HD11 ' A' ' 27' ' ' LEU . 20.4 t -49.31 -39.15 12.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.125 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 131' ' ' PHE . . . . . 0.5 ' HB3' HD12 ' B' ' 135' ' ' ILE . 3.5 m-30 -76.32 -42.76 43.97 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.874 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -51.74 -50.21 44.26 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.509 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 40.6 mt -73.23 -52.06 23.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.907 0.384 . . . . 0.0 111.131 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 24.5 mt -50.52 -61.35 2.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.932 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.5 HD12 ' HB3' ' B' ' 131' ' ' PHE . 13.6 mt -56.59 -46.46 82.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.152 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 14.6 tttm -51.08 -55.97 14.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.907 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 46.6 mtp85 -53.63 -39.8 65.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.846 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 47.8 mtp180 -64.21 -45.95 86.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.873 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 67.6 mt-30 -55.85 176.42 0.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.9 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -89.42 106.95 18.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.883 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 31.0 mttt -139.73 166.96 23.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.892 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 142' ' ' ILE . . . . . . . . . . . . . 70.0 mt -138.43 125.02 26.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.075 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 13.5 mmt-85 -71.65 170.23 13.9 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.925 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 1.4 mppp? . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.901 179.985 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 112.522 -0.231 . . . . 0.0 112.522 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 1.2 m -53.53 160.75 1.77 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.598 0.713 . . . . 0.0 110.864 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 165.45 30.99 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.664 2.242 . . . . 0.0 112.309 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -46.15 105.51 0.06 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.128 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -91.89 160.26 15.37 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.852 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 14.6 tt0 -56.96 157.81 5.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.912 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.79 -29.25 29.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.899 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -156.89 165.17 36.96 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.062 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.534 ' O ' HG22 ' A' ' 12' ' ' THR . 0.3 OUTLIER -51.77 162.54 0.74 Allowed Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.69 0.757 . . . . 0.0 110.862 -179.807 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 -14.81 36.37 Favored 'Trans proline' 0 C--O 1.232 0.203 0 C-N-CA 122.676 2.251 . . . . 0.0 112.349 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.69 HD13 HG13 ' A' ' 15' ' ' ILE . 2.3 tm? -74.19 -18.15 60.8 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.937 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.534 HG22 ' O ' ' A' ' 9' ' ' SER . 8.9 t -48.6 -39.95 25.67 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.121 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -51.62 -53.9 33.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.861 -179.849 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.72 ' O ' HG23 ' A' ' 18' ' ' VAL . 58.9 mt -60.31 -41.25 86.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.139 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.69 HG13 HD13 ' A' ' 11' ' ' LEU . 26.2 mt -52.72 -57.75 3.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.121 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 33.5 t -57.46 -37.55 73.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.885 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -61.01 -57.79 11.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.077 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.72 HG23 ' O ' ' A' ' 14' ' ' ILE . 11.3 t -51.86 -50.69 32.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.101 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.75 HG12 HD11 ' A' ' 23' ' ' LEU . 86.6 t -48.85 -60.23 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.161 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.489 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -49.49 -54.28 17.19 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.465 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 39.0 mt -58.52 -54.72 29.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.862 0.363 . . . . 0.0 111.156 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.872 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.71 -59.49 3.76 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.892 179.898 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.985 HD23 HG22 ' B' ' 126' ' ' VAL . 8.5 mt -43.23 -55.35 4.03 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.919 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.489 HG23 ' O ' ' A' ' 20' ' ' GLY . 91.8 t -52.46 -51.74 31.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.127 179.852 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 74.8 t -61.62 -39.84 84.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.171 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.989 HG22 HD23 ' B' ' 123' ' ' LEU . 46.5 t -51.62 -59.51 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.13 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.72 HD11 HG21 ' B' ' 130' ' ' VAL . 57.0 mt -66.39 -47.81 72.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.876 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.18 -47.58 49.31 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.452 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.4 t -76.32 -54.59 13.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.825 0.345 . . . . 0.0 111.141 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.731 HG21 HD11 ' B' ' 127' ' ' LEU . 19.8 t -49.34 -42.33 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.141 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.402 ' HB3' HD12 ' A' ' 35' ' ' ILE . 4.9 m-85 -77.05 -44.39 30.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -52.35 -48.61 53.81 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.458 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 42.2 mt -73.03 -52.06 23.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.88 0.371 . . . . 0.0 111.118 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 22.8 mt -51.21 -60.78 2.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.876 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.402 HD12 ' HB3' ' A' ' 31' ' ' PHE . 11.9 mt -55.56 -49.07 76.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.16 179.828 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 8.0 tmtt? -58.13 -25.99 62.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 32.4 mtp180 -81.65 -31.57 32.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.04 -47.97 82.35 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.879 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -59.79 123.48 17.12 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.914 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -175.37 172.37 2.7 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.861 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 21.2 mttm -85.81 139.88 30.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.852 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.441 HD13 ' N ' ' A' ' 43' ' ' ARG . 0.0 OUTLIER -154.25 144.83 13.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.111 179.82 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.441 ' N ' HD13 ' A' ' 42' ' ' ILE . 44.4 mtp180 -107.19 112.54 25.47 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.854 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 4.4 tppp? . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.862 179.942 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.455 -0.258 . . . . 0.0 112.455 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 1.2 m -54.58 160.71 2.53 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.582 0.706 . . . . 0.0 110.877 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 160.43 49.72 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.687 2.258 . . . . 0.0 112.322 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . 45.98 84.87 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -100.12 159.13 15.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.903 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 14.1 tt0 -57.64 161.17 3.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.88 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.87 -26.61 40.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.873 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 108' ' ' ALA . . . . . . . . . . . . . . . -155.32 167.64 29.69 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.078 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 109' ' ' SER . . . . . 0.525 ' O ' HG22 ' B' ' 112' ' ' THR . 0.3 OUTLIER -51.52 162.58 0.68 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.685 0.755 . . . . 0.0 110.836 -179.811 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 -15.09 37.1 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.701 2.267 . . . . 0.0 112.348 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 111' ' ' LEU . . . . . 0.701 ' CD2' HD12 ' B' ' 114' ' ' ILE . 2.3 tm? -74.46 -18.45 60.63 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.947 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 112' ' ' THR . . . . . 0.525 HG22 ' O ' ' B' ' 109' ' ' SER . 10.1 t -48.58 -39.81 25.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.169 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -51.75 -53.59 37.91 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.869 -179.841 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 114' ' ' ILE . . . . . 0.706 ' O ' HG23 ' B' ' 118' ' ' VAL . 59.2 mt -60.49 -41.29 87.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.085 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.674 HG13 HD13 ' B' ' 111' ' ' LEU . 25.4 mt -53.12 -57.73 4.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.12 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 33.6 t -57.26 -37.41 72.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.846 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -60.99 -58.02 10.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.09 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.706 HG23 ' O ' ' B' ' 114' ' ' ILE . 11.3 t -51.86 -50.7 32.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.155 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.74 HG12 HD11 ' B' ' 123' ' ' LEU . 87.7 t -48.82 -60.26 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.134 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 120' ' ' GLY . . . . . 0.49 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -49.44 -54.25 17.13 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.488 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 38.8 mt -58.56 -54.85 27.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.857 0.361 . . . . 0.0 111.135 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 122' ' ' LEU . . . . . 0.874 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.57 -59.43 3.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.945 179.884 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 123' ' ' LEU . . . . . 0.989 HD23 HG22 ' A' ' 26' ' ' VAL . 8.5 mt -43.28 -55.35 4.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.942 179.883 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 124' ' ' VAL . . . . . 0.49 HG23 ' O ' ' B' ' 120' ' ' GLY . 92.1 t -52.39 -51.81 30.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.135 179.823 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 74.8 t -61.61 -39.83 84.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.12 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 126' ' ' VAL . . . . . 0.985 HG22 HD23 ' A' ' 23' ' ' LEU . 46.2 t -51.67 -59.58 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.141 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 127' ' ' LEU . . . . . 0.731 HD11 HG21 ' A' ' 30' ' ' VAL . 55.9 mt -66.31 -47.81 72.34 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.937 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.21 -47.52 49.61 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.47 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 55.9 t -76.34 -54.63 13.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.848 0.356 . . . . 0.0 111.142 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 130' ' ' VAL . . . . . 0.72 HG21 HD11 ' A' ' 27' ' ' LEU . 20.2 t -49.28 -42.37 15.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.132 179.883 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 131' ' ' PHE . . . . . 0.414 ' HB3' HD12 ' B' ' 135' ' ' ILE . 4.8 m-85 -76.95 -44.57 30.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.933 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -52.28 -48.55 53.51 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.489 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 42.2 mt -73.02 -52.1 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.846 0.355 . . . . 0.0 111.18 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 23.0 mt -51.17 -60.87 2.64 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.919 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.414 HD12 ' HB3' ' B' ' 131' ' ' PHE . 11.8 mt -55.42 -49.52 72.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.129 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 8.0 tmtt? -57.7 -26.18 61.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.89 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 32.1 mtp180 -81.41 -31.69 33.08 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.892 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.6 -47.9 83.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.889 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -60.49 123.65 17.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -175.4 174.18 2.38 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.934 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 21.2 mttm -84.14 141.15 31.29 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.875 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 142' ' ' ILE . . . . . 0.461 HD13 ' N ' ' B' ' 143' ' ' ARG . 0.0 OUTLIER -153.5 145.39 14.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.121 179.876 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 143' ' ' ARG . . . . . 0.461 ' N ' HD13 ' B' ' 142' ' ' ILE . 23.5 mtm180 -106.92 113.45 26.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.882 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 4.4 tppp? . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.91 179.956 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 N-CA-C 112.511 -0.236 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 36.5 m -132.43 72.66 77.98 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.624 0.726 . . . . 0.0 110.886 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.71 -177.5 1.89 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.663 2.242 . . . . 0.0 112.403 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -78.56 -167.13 0.99 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.089 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -81.91 109.1 15.96 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.88 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 6.9 tp60 -71.23 142.74 50.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.896 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 20.8 ptt180 -69.21 146.94 51.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.41 ' HB3' HG21 ' A' ' 12' ' ' THR . . . -126.29 166.82 16.43 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.141 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.622 ' O ' HG22 ' A' ' 12' ' ' THR . 0.3 OUTLIER -49.39 165.13 0.29 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.646 0.736 . . . . 0.0 110.895 -179.795 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.72 -11.54 31.09 Favored 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.702 2.268 . . . . 0.0 112.355 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.424 HD13 ' C ' ' A' ' 11' ' ' LEU . 2.8 tm? -77.24 -36.45 54.54 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.878 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.622 HG22 ' O ' ' A' ' 9' ' ' SER . 6.7 t -48.7 -33.2 9.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.125 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 1.5 t -64.98 -49.4 70.42 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.933 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.49 ' O ' HG23 ' A' ' 18' ' ' VAL . 56.2 mt -58.77 -46.0 90.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.088 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.588 ' O ' HG23 ' A' ' 19' ' ' VAL . 17.0 mt -54.55 -51.44 50.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.098 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 1.9 t -57.14 -37.86 72.66 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.887 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -62.02 -59.57 4.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.096 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 14' ' ' ILE . 11.4 t -50.81 -50.87 22.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.133 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.69 HG12 HD11 ' A' ' 23' ' ' LEU . 96.0 t -48.4 -59.46 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.087 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.48 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -50.44 -54.52 20.13 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.538 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 99.0 mt -58.41 -54.82 27.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.826 0.346 . . . . 0.0 111.124 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.891 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.54 -59.44 3.76 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.902 179.921 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 1.017 HD23 HG22 ' B' ' 126' ' ' VAL . 9.8 mt -43.31 -55.33 4.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.884 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 20' ' ' GLY . 89.5 t -52.6 -52.03 30.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.114 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.9 t -61.05 -40.21 84.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.126 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 1.012 HG22 HD23 ' B' ' 123' ' ' LEU . 44.5 t -51.64 -59.29 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.101 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.745 HD11 HG21 ' B' ' 130' ' ' VAL . 48.6 mt -67.58 -46.66 71.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.893 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.6 -47.57 51.73 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.451 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -76.41 -54.16 13.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.896 0.379 . . . . 0.0 111.148 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.739 HG21 HD11 ' B' ' 127' ' ' LEU . 19.8 t -49.79 -42.65 18.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.145 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.411 ' HB3' HD12 ' A' ' 35' ' ' ILE . 4.7 m-85 -77.44 -40.58 42.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.902 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -53.48 -48.4 60.5 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.49 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 28.8 mt -75.56 -50.47 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.849 0.357 . . . . 0.0 111.11 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 22.4 mt -51.28 -56.71 11.55 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.947 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.411 HD12 ' HB3' ' A' ' 31' ' ' PHE . 18.2 mt -60.96 -49.34 85.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.116 179.822 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 30.7 ttpt -54.98 -29.44 57.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.854 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 56.8 mtp180 -78.04 -37.0 47.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.879 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -67.96 -42.07 81.47 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.841 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -76.26 75.68 3.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.932 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 7.4 mm-40 -118.41 176.31 5.3 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.932 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 16.2 mmtp -108.19 140.1 41.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.929 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.2 tt -129.02 148.75 33.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.141 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 65.5 mtt180 -95.25 176.44 6.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.887 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 10.6 ptpp? . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.914 179.971 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 36.2 m -131.56 72.87 80.1 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.641 0.734 . . . . 0.0 110.88 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 -174.41 0.91 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.695 2.263 . . . . 0.0 112.342 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . -75.09 -82.38 0.07 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.09 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -78.32 112.13 15.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.865 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 6.9 tp60 -67.8 144.92 55.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.918 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 20.9 ptt180 -66.65 149.5 50.41 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 108' ' ' ALA . . . . . 0.649 ' HB1' ' CG2' ' B' ' 112' ' ' THR . . . -123.18 159.69 28.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.05 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 109' ' ' SER . . . . . 0.412 ' CB ' ' HD2' ' B' ' 110' ' ' PRO . 0.3 OUTLIER -48.51 165.71 0.24 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.668 0.747 . . . . 0.0 110.836 -179.791 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 110' ' ' PRO . . . . . 0.412 ' HD2' ' CB ' ' B' ' 109' ' ' SER . 53.9 Cg_endo -69.75 -17.23 37.75 Favored 'Trans proline' 0 C--O 1.232 0.201 0 C-N-CA 122.69 2.26 . . . . 0.0 112.326 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 111' ' ' LEU . . . . . 0.468 HD13 ' C ' ' B' ' 111' ' ' LEU . 2.9 tm? -88.52 -45.34 9.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.903 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 112' ' ' THR . . . . . 0.649 ' CG2' ' HB1' ' B' ' 108' ' ' ALA . 1.4 t -69.54 -30.58 68.42 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.167 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 1.8 t -65.97 -50.16 65.3 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.886 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 114' ' ' ILE . . . . . 0.467 ' O ' HG23 ' B' ' 118' ' ' VAL . 71.5 mt -62.34 -49.0 85.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.13 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.604 ' O ' HG23 ' B' ' 119' ' ' VAL . 39.6 mt -51.79 -50.39 32.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.143 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 1.9 t -59.93 -37.5 79.68 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.872 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -61.25 -58.29 8.88 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.08 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.467 HG23 ' O ' ' B' ' 114' ' ' ILE . 11.0 t -51.64 -51.05 28.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.112 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.685 HG12 HD11 ' B' ' 123' ' ' LEU . 91.1 t -48.37 -59.35 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.141 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 120' ' ' GLY . . . . . 0.468 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -50.51 -54.68 19.77 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.522 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 98.9 mt -58.23 -54.88 26.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.844 0.355 . . . . 0.0 111.103 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 122' ' ' LEU . . . . . 0.89 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.37 -59.55 3.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.937 179.877 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 123' ' ' LEU . . . . . 1.012 HD23 HG22 ' A' ' 26' ' ' VAL . 9.6 mt -43.28 -55.32 4.09 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.925 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 124' ' ' VAL . . . . . 0.468 HG23 ' O ' ' B' ' 120' ' ' GLY . 90.4 t -52.74 -51.96 31.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.119 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 72.7 t -60.94 -40.25 84.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.129 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 126' ' ' VAL . . . . . 1.017 HG22 HD23 ' A' ' 23' ' ' LEU . 44.9 t -51.47 -59.3 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.141 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 127' ' ' LEU . . . . . 0.742 HD23 HD23 ' A' ' 27' ' ' LEU . 49.7 mt -67.59 -46.88 71.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.907 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.52 -47.53 51.33 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.453 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.0 t -76.24 -54.37 13.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.892 0.377 . . . . 0.0 111.153 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 130' ' ' VAL . . . . . 0.745 HG21 HD11 ' A' ' 27' ' ' LEU . 19.7 t -49.69 -42.71 17.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.114 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 131' ' ' PHE . . . . . 0.423 ' HB3' HD12 ' B' ' 135' ' ' ILE . 4.8 m-85 -77.41 -41.04 41.41 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.864 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -53.27 -48.43 59.45 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.486 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 133' ' ' ILE . . . . . 0.433 HG22 ' CD ' ' B' ' 137' ' ' ARG . 30.1 mt -75.25 -50.37 24.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.827 0.346 . . . . 0.0 111.117 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 21.9 mt -51.53 -57.42 9.11 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.894 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.423 HD12 ' HB3' ' B' ' 131' ' ' PHE . 17.2 mt -59.94 -50.01 81.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.115 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 31.0 ttpt -55.82 -28.02 54.2 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.897 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 137' ' ' ARG . . . . . 0.433 ' CD ' HG22 ' B' ' 133' ' ' ILE . 55.3 mtp180 -79.68 -33.55 41.06 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.883 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 1.2 mtt-85 -57.56 -46.13 84.3 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.879 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -91.83 43.46 1.14 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.944 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 9.9 mm-40 -152.32 -179.63 7.72 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.887 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 15.2 mmtp -107.09 129.86 54.76 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.9 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 142' ' ' ILE . . . . . . . . . . . . . 21.5 tt -135.96 149.34 27.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.133 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 66.5 mtt180 -96.5 179.34 5.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.897 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 10.6 ptpp? . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.909 179.957 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 N-CA-C 112.453 -0.259 . . . . 0.0 112.453 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 4.8 t -154.99 68.27 5.43 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.629 0.728 . . . . 0.0 110.901 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 -174.06 0.83 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.688 2.258 . . . . 0.0 112.31 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -104.15 150.69 24.12 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.097 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 13.0 tt0 -59.41 146.46 39.96 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.867 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 34.6 mm-40 -100.53 39.24 1.39 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.912 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 3.6 tpp85 -102.94 149.92 24.05 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.886 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.613 ' HB3' HG21 ' A' ' 12' ' ' THR . . . -150.71 170.97 17.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.104 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.667 ' O ' HG22 ' A' ' 12' ' ' THR . 0.3 OUTLIER -50.32 164.57 0.38 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.691 0.758 . . . . 0.0 110.873 -179.803 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -11.74 31.51 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 122.707 2.272 . . . . 0.0 112.347 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.435 HD13 ' C ' ' A' ' 11' ' ' LEU . 2.9 tm? -80.7 -36.46 32.23 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.916 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.667 HG22 ' O ' ' A' ' 9' ' ' SER . 6.3 t -48.45 -32.22 7.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.169 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -64.69 -48.09 75.96 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.884 -179.877 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.645 ' O ' HG23 ' A' ' 18' ' ' VAL . 53.6 mt -61.35 -45.6 98.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.144 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.538 ' O ' HG23 ' A' ' 19' ' ' VAL . 10.9 mt -53.45 -53.86 21.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.144 179.857 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 43.6 t -57.62 -37.44 73.28 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.853 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -62.79 -57.96 9.1 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.076 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.645 HG23 ' O ' ' A' ' 14' ' ' ILE . 9.5 t -51.36 -51.62 23.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.159 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.673 HG12 HD11 ' A' ' 23' ' ' LEU . 99.4 t -48.48 -59.04 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.105 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.475 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -50.23 -54.81 18.12 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.486 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 55.1 mt -58.43 -54.89 26.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.856 0.36 . . . . 0.0 111.124 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.863 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.1 -59.83 3.31 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.948 179.884 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 1.001 HD23 HG22 ' B' ' 126' ' ' VAL . 9.6 mt -43.29 -55.65 3.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.935 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.475 HG23 ' O ' ' A' ' 20' ' ' GLY . 88.4 t -52.47 -51.14 35.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.142 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 69.8 t -61.6 -40.65 87.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.082 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 1.012 HG22 HD23 ' B' ' 123' ' ' LEU . 41.8 t -51.37 -58.89 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.136 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.74 HD23 HD23 ' B' ' 127' ' ' LEU . 45.9 mt -68.47 -46.16 70.51 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.912 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.79 -47.62 52.65 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.477 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.7 t -76.11 -54.32 13.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.918 0.389 . . . . 0.0 111.169 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.704 HG21 HD11 ' B' ' 127' ' ' LEU . 20.0 t -49.8 -43.01 18.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.114 179.883 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.423 ' HB3' HD12 ' A' ' 35' ' ' ILE . 4.8 m-85 -77.61 -41.5 38.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.902 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -53.28 -47.36 61.95 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.489 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 22.3 mt -76.04 -51.37 20.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.833 0.349 . . . . 0.0 111.141 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 23.7 mt -51.0 -55.92 15.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.903 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.423 HD12 ' HB3' ' A' ' 31' ' ' PHE . 18.3 mt -61.71 -48.48 88.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.116 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 3.9 tmtt? -51.13 -45.3 61.58 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.886 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 43.1 mtp85 -63.9 -38.75 92.24 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.903 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 65.0 mtp85 -68.54 -43.77 75.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.856 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 13.8 mm100 -57.52 -179.51 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.9 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -70.3 176.31 4.04 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.896 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 4.6 mmmm -115.84 65.45 0.7 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.93 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 32.3 mm -91.88 122.49 43.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.175 179.839 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 71.0 mtm180 -108.01 69.04 0.72 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.975 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.484 -0.246 . . . . 0.0 112.484 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 4.8 t -155.02 69.13 5.59 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.633 0.73 . . . . 0.0 110.848 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -175.81 1.27 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.652 2.235 . . . . 0.0 112.357 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . -106.29 150.67 25.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.113 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -60.91 150.36 33.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.894 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 37.2 mm-40 -95.79 37.69 1.2 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.943 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 2.9 tpp85 -105.23 -78.67 0.57 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.852 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 108' ' ' ALA . . . . . 0.686 ' HB3' HG21 ' B' ' 112' ' ' THR . . . -141.07 173.18 11.73 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.128 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 109' ' ' SER . . . . . 0.675 ' O ' HG22 ' B' ' 112' ' ' THR . 0.3 OUTLIER -49.51 164.34 0.33 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.654 0.74 . . . . 0.0 110.849 -179.756 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -11.61 31.18 Favored 'Trans proline' 0 C--O 1.232 0.216 0 C-N-CA 122.685 2.256 . . . . 0.0 112.329 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 111' ' ' LEU . . . . . 0.451 HD13 ' C ' ' B' ' 111' ' ' LEU . 3.0 tm? -81.84 -36.61 28.09 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.929 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 112' ' ' THR . . . . . 0.686 HG21 ' HB3' ' B' ' 108' ' ' ALA . 6.0 t -48.62 -31.86 7.31 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.134 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -65.12 -47.71 76.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.83 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 114' ' ' ILE . . . . . 0.661 ' O ' HG23 ' B' ' 118' ' ' VAL . 52.6 mt -61.68 -45.66 98.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.099 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.538 ' O ' HG23 ' B' ' 119' ' ' VAL . 10.9 mt -53.53 -54.04 21.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.147 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 43.5 t -57.52 -37.5 73.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.852 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -62.81 -57.88 9.37 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.101 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.661 HG23 ' O ' ' B' ' 114' ' ' ILE . 9.3 t -51.54 -51.51 25.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.17 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.68 HG12 HD11 ' B' ' 123' ' ' LEU . 98.9 t -48.51 -59.04 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.129 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 120' ' ' GLY . . . . . 0.477 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -50.29 -54.8 18.39 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.493 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 55.5 mt -58.46 -54.88 27.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.865 0.364 . . . . 0.0 111.119 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 122' ' ' LEU . . . . . 0.877 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.1 -59.85 3.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.897 179.903 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 123' ' ' LEU . . . . . 1.012 HD23 HG22 ' A' ' 26' ' ' VAL . 9.7 mt -43.26 -55.77 3.84 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 124' ' ' VAL . . . . . 0.477 HG23 ' O ' ' B' ' 120' ' ' GLY . 89.3 t -52.43 -51.21 34.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.173 179.82 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 69.2 t -61.48 -40.56 86.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.161 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 126' ' ' VAL . . . . . 1.001 HG22 HD23 ' A' ' 23' ' ' LEU . 42.3 t -51.5 -59.18 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.092 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 127' ' ' LEU . . . . . 0.74 HD23 HD23 ' A' ' 27' ' ' LEU . 45.2 mt -68.14 -46.26 71.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.916 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.56 -47.65 51.29 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.507 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 56.0 t -76.37 -54.25 13.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.845 0.355 . . . . 0.0 111.077 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 130' ' ' VAL . . . . . 0.705 HG21 HD11 ' A' ' 27' ' ' LEU . 20.2 t -49.8 -42.72 18.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.114 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 131' ' ' PHE . . . . . 0.404 ' HB3' HD12 ' B' ' 135' ' ' ILE . 4.8 m-85 -77.77 -41.96 35.7 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.859 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -52.93 -47.16 60.08 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.491 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 22.6 mt -76.16 -51.55 19.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.884 0.373 . . . . 0.0 111.141 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 134' ' ' LEU . . . . . 0.409 HD23 ' HA ' ' B' ' 134' ' ' LEU . 23.2 mt -50.8 -55.79 15.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.861 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.404 HD12 ' HB3' ' B' ' 131' ' ' PHE . 17.4 mt -61.87 -48.85 86.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.17 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 3.8 tmtt? -51.2 -44.51 61.59 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.91 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 45.4 mtp85 -64.89 -38.37 90.74 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.907 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 65.0 mtp85 -67.57 -48.03 68.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.863 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 14.1 mm100 -62.02 176.03 0.62 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.938 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -75.32 177.38 6.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.864 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 3.6 mmmm -111.07 47.79 0.97 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.917 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 142' ' ' ILE . . . . . . . . . . . . . 30.5 mm -111.11 123.17 66.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.088 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -107.48 70.46 0.78 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.877 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.871 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.476 -0.249 . . . . 0.0 112.476 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 1.8 m -87.25 160.53 48.45 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.576 0.703 . . . . 0.0 110.896 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 78.59 1.01 Allowed 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.691 2.261 . . . . 0.0 112.324 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.53 93.89 3.12 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.142 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -57.97 118.63 5.59 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.881 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -98.19 -167.1 1.46 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.872 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -61.67 -166.0 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.831 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.573 ' HB3' HG21 ' A' ' 12' ' ' THR . . . -127.85 164.86 21.3 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.13 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.675 ' O ' HG22 ' A' ' 12' ' ' THR . 0.3 OUTLIER -50.52 164.21 0.42 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.689 0.757 . . . . 0.0 110.832 -179.758 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -11.93 31.81 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.681 2.254 . . . . 0.0 112.366 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.447 HD13 ' C ' ' A' ' 11' ' ' LEU . 3.0 tm? -81.08 -33.63 33.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.934 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.675 HG22 ' O ' ' A' ' 9' ' ' SER . 6.6 t -49.06 -31.65 8.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.093 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 1.3 t -62.64 -53.26 57.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.844 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.634 ' O ' HG23 ' A' ' 18' ' ' VAL . 3.7 mp -59.05 -43.16 88.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.123 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.554 ' O ' HG23 ' A' ' 19' ' ' VAL . 4.0 mt -53.77 -53.1 28.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.125 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.405 ' N ' HG22 ' A' ' 15' ' ' ILE . 3.5 t -58.74 -37.43 76.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.872 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -61.8 -57.84 10.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.115 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.634 HG23 ' O ' ' A' ' 14' ' ' ILE . 8.7 t -51.78 -51.07 29.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.16 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.697 HG12 HD11 ' A' ' 23' ' ' LEU . 91.3 t -48.65 -59.48 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.121 179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.47 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -50.05 -54.55 18.41 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.508 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 90.4 mt -58.47 -54.71 29.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.832 0.349 . . . . 0.0 111.111 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.876 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.46 -59.7 3.51 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.937 179.908 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 1.025 HD23 HG22 ' B' ' 126' ' ' VAL . 9.0 mt -43.26 -55.37 4.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.937 179.877 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.47 HG23 ' O ' ' A' ' 20' ' ' GLY . 86.9 t -52.52 -51.61 32.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.17 179.809 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 73.6 t -61.47 -40.28 85.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.169 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 1.026 HG22 HD23 ' B' ' 123' ' ' LEU . 44.4 t -51.5 -59.0 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.124 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.73 HD11 HG21 ' B' ' 130' ' ' VAL . 48.8 mt -67.7 -46.76 71.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.941 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.54 -47.22 52.28 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.52 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 56.3 t -76.6 -54.3 13.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.913 0.387 . . . . 0.0 111.122 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.727 HG21 HD11 ' B' ' 127' ' ' LEU . 19.9 t -49.78 -42.45 18.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.116 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.41 ' HB3' HD12 ' A' ' 35' ' ' ILE . 4.8 m-85 -77.57 -43.19 32.58 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.845 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -52.59 -47.68 57.17 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.476 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 30.3 mt -74.84 -51.86 20.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.842 0.353 . . . . 0.0 111.137 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 22.9 mt -50.97 -57.92 7.34 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.931 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.41 HD12 ' HB3' ' A' ' 31' ' ' PHE . 14.4 mt -59.3 -48.3 87.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.118 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 9.4 ttmm -50.81 -38.01 46.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.922 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 66.4 mtp180 -75.33 -34.5 61.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.908 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 70.8 mtp85 -64.66 -33.22 75.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.848 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 50.5 mt-30 -51.63 148.96 4.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.922 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 32.6 mt-30 -97.96 88.47 4.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.895 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 5.9 ttmm -115.11 42.0 2.3 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.868 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.4 tt -125.62 135.44 63.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.099 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 63.0 mtp180 -80.82 67.11 6.59 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.879 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 6.7 tptt . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.922 179.956 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.536 -0.226 . . . . 0.0 112.536 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 1.8 m -87.75 160.31 47.39 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.582 0.706 . . . . 0.0 110.898 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 81.86 0.79 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.656 2.238 . . . . 0.0 112.353 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . -133.16 95.22 3.49 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.087 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -56.95 119.58 6.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.872 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 1.4 mt-30 -99.84 -86.25 0.39 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.908 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 14.6 ttt180 -52.22 -76.81 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.884 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 108' ' ' ALA . . . . . 0.654 ' HB3' HG21 ' B' ' 112' ' ' THR . . . -119.09 166.0 13.46 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.07 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 109' ' ' SER . . . . . 0.672 ' O ' HG22 ' B' ' 112' ' ' THR . 0.3 OUTLIER -49.56 164.36 0.34 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.692 0.758 . . . . 0.0 110.808 -179.758 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 -11.89 31.72 Favored 'Trans proline' 0 C--O 1.232 0.201 0 C-N-CA 122.678 2.252 . . . . 0.0 112.345 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 111' ' ' LEU . . . . . 0.456 HD13 ' C ' ' B' ' 111' ' ' LEU . 3.0 tm? -81.06 -34.94 32.37 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.902 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 112' ' ' THR . . . . . 0.672 HG22 ' O ' ' B' ' 109' ' ' SER . 6.3 t -49.05 -31.38 7.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.113 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 1.3 t -63.73 -53.03 57.48 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.883 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 114' ' ' ILE . . . . . 0.606 ' O ' HG23 ' B' ' 118' ' ' VAL . 3.7 mp -58.55 -43.3 86.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.13 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.569 ' O ' HG23 ' B' ' 119' ' ' VAL . 4.4 mt -54.0 -52.85 32.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.094 179.889 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 3.5 t -58.74 -36.9 75.09 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.865 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -62.18 -58.22 8.58 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.083 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.606 HG23 ' O ' ' B' ' 114' ' ' ILE . 9.4 t -51.55 -51.03 27.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.115 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.708 HG12 HD11 ' B' ' 123' ' ' LEU . 90.2 t -48.7 -59.5 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.11 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 120' ' ' GLY . . . . . 0.473 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -50.04 -54.55 18.39 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.46 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 90.1 mt -58.47 -54.75 28.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.83 0.347 . . . . 0.0 111.095 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 122' ' ' LEU . . . . . 0.875 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.43 -59.83 3.38 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.9 179.886 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 123' ' ' LEU . . . . . 1.026 HD23 HG22 ' A' ' 26' ' ' VAL . 9.1 mt -43.13 -55.4 3.91 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.857 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 124' ' ' VAL . . . . . 0.473 HG23 ' O ' ' B' ' 120' ' ' GLY . 87.0 t -52.63 -51.66 33.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.116 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 73.1 t -61.41 -40.19 85.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.096 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 126' ' ' VAL . . . . . 1.025 HG22 HD23 ' A' ' 23' ' ' LEU . 44.1 t -51.52 -59.13 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.101 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 127' ' ' LEU . . . . . 0.727 HD11 HG21 ' A' ' 30' ' ' VAL . 48.5 mt -67.64 -46.83 71.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.929 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.57 -47.18 52.47 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.486 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 56.1 t -76.65 -54.25 13.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.83 0.348 . . . . 0.0 111.121 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 130' ' ' VAL . . . . . 0.73 HG21 HD11 ' A' ' 27' ' ' LEU . 20.0 t -49.8 -42.47 18.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.119 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 131' ' ' PHE . . . . . 0.42 ' HB3' HD12 ' B' ' 135' ' ' ILE . 4.7 m-85 -77.46 -43.23 33.06 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.871 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -52.23 -47.9 54.61 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.501 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 30.5 mt -74.88 -51.68 21.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.841 0.353 . . . . 0.0 111.113 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 134' ' ' LEU . . . . . 0.402 HD23 ' HA ' ' B' ' 134' ' ' LEU . 21.9 mt -50.91 -57.98 7.15 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.904 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.42 HD12 ' HB3' ' B' ' 131' ' ' PHE . 14.2 mt -59.28 -48.99 85.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.107 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 9.7 ttmm -51.44 -36.85 45.8 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.909 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 67.7 mtp180 -75.36 -34.72 61.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.888 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 70.2 mtp85 -62.5 -47.96 81.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.881 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 50.0 mt-30 -63.88 153.55 36.48 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.912 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 31.8 mt-30 -91.73 62.55 4.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.925 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 3.6 ttmm -134.61 71.84 1.45 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.89 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 142' ' ' ILE . . . . . . . . . . . . . 20.2 tt -101.2 140.29 20.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.132 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 69.9 mtp180 -75.23 86.55 2.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.855 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 3.4 tptt . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.907 179.95 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 38.6 t -159.03 70.12 3.47 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.652 0.739 . . . . 0.0 110.913 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 159.61 52.79 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.688 2.259 . . . . 0.0 112.339 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -106.65 105.22 15.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.093 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -121.16 154.37 36.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.882 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 86.0 mt-30 -91.69 106.91 18.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.881 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.67 -165.83 0.07 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.872 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.524 ' HB1' HG21 ' A' ' 12' ' ' THR . . . -113.78 175.99 5.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.129 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -50.84 163.83 0.46 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.683 0.754 . . . . 0.0 110.844 -179.807 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.407 ' O ' HD12 ' A' ' 14' ' ' ILE . 54.2 Cg_endo -69.75 -16.41 37.57 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.696 2.264 . . . . 0.0 112.348 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.451 HD13 ' C ' ' A' ' 11' ' ' LEU . 2.5 tm? -86.93 -37.82 17.27 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.93 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.524 HG21 ' HB1' ' A' ' 8' ' ' ALA . 25.9 p -50.55 -43.58 56.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.135 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -51.62 -51.34 56.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.861 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.465 ' O ' HG23 ' A' ' 18' ' ' VAL . 3.1 mp -58.7 -45.54 90.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.112 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.647 ' O ' HG23 ' A' ' 19' ' ' VAL . 25.6 mt -54.08 -51.11 49.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.132 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -58.82 -36.11 73.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.83 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -61.77 -60.12 4.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.1 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 14' ' ' ILE . 5.9 t -51.05 -48.92 29.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.088 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.647 HG23 ' O ' ' A' ' 15' ' ' ILE . 98.3 t -49.6 -63.35 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.129 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -48.57 -55.69 10.65 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.497 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.402 ' O ' HG23 ' A' ' 25' ' ' VAL . 20.4 mt -55.52 -41.02 61.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.863 0.363 . . . . 0.0 111.111 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.77 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.8 OUTLIER -57.15 -50.68 72.05 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.877 179.926 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.808 HD22 HG22 ' B' ' 126' ' ' VAL . 1.1 mt -54.47 -51.67 64.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.901 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 98.1 t -55.44 -45.97 78.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.118 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.402 HG23 ' O ' ' A' ' 21' ' ' ILE . 70.6 t -64.83 -43.18 96.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.101 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.806 HG22 HD22 ' B' ' 123' ' ' LEU . 73.3 t -51.27 -54.31 11.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.113 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.814 HD23 HD23 ' B' ' 127' ' ' LEU . 56.4 mt -70.13 -47.28 62.39 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.885 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.82 -45.88 55.14 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.538 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 57.4 t -76.81 -54.67 12.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.84 0.352 . . . . 0.0 111.136 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.732 HG21 HD11 ' B' ' 127' ' ' LEU . 17.6 t -49.9 -43.05 19.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.158 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.404 ' HB3' HD12 ' A' ' 35' ' ' ILE . 5.1 m-85 -77.22 -44.95 28.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.825 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -52.29 -48.0 54.72 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.47 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 45.4 mt -73.22 -52.55 21.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.848 0.356 . . . . 0.0 111.126 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 23.7 mt -51.03 -60.75 2.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.89 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.404 HD12 ' HB3' ' A' ' 31' ' ' PHE . 11.8 mt -55.7 -48.68 77.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.117 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 63.6 tttt -52.45 -51.58 58.51 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.877 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 68.0 mtp180 -52.23 -43.69 64.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.845 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 51.0 mtp85 -66.19 -48.25 71.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.875 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 6.0 mm100 -67.01 179.56 1.11 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.957 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 17.2 mm100 -72.71 174.43 7.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.887 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 12.5 ttmt -136.4 156.16 49.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.913 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 14.1 pt -133.49 -179.96 3.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.106 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 26.8 ptt85 -123.6 177.09 5.84 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.868 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 16.1 mmtt . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.933 179.94 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.372 0 N-CA-C 112.467 -0.253 . . . . 0.0 112.467 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 38.7 t -159.01 72.94 3.55 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.599 0.714 . . . . 0.0 110.849 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 160.72 48.65 Favored 'Trans proline' 0 N--CA 1.465 -0.169 0 C-N-CA 122.694 2.262 . . . . 0.0 112.353 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . -105.83 96.78 6.73 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.128 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -128.63 152.34 48.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.936 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 87.3 mt-30 -92.87 79.93 4.66 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.88 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.49 -76.49 0.51 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.913 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 108' ' ' ALA . . . . . 0.472 ' HB1' HG21 ' B' ' 112' ' ' THR . . . -107.57 -179.64 3.97 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.094 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 109' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -50.28 164.34 0.39 Allowed Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.657 0.741 . . . . 0.0 110.87 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 110' ' ' PRO . . . . . 0.419 ' O ' HD12 ' B' ' 114' ' ' ILE . 53.5 Cg_endo -69.78 -16.24 37.4 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.673 2.249 . . . . 0.0 112.336 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 111' ' ' LEU . . . . . 0.461 ' O ' HD22 ' B' ' 111' ' ' LEU . 2.5 tm? -87.93 -37.96 15.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.901 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 112' ' ' THR . . . . . 0.472 HG21 ' HB1' ' B' ' 108' ' ' ALA . 26.6 p -51.23 -43.62 61.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.122 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -51.4 -51.93 50.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.842 -179.852 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 114' ' ' ILE . . . . . 0.472 ' O ' HG23 ' B' ' 118' ' ' VAL . 2.9 mp -58.39 -45.39 89.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.147 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.652 ' O ' HG23 ' B' ' 119' ' ' VAL . 23.5 mt -54.0 -51.42 46.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.143 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -58.75 -35.97 73.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.854 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -61.63 -59.97 4.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.111 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.472 HG23 ' O ' ' B' ' 114' ' ' ILE . 6.1 t -51.27 -48.78 32.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.103 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.652 HG23 ' O ' ' B' ' 115' ' ' ILE . 98.4 t -49.66 -63.28 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.123 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.73 -55.48 11.2 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.499 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 20.0 mt -55.64 -40.8 61.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.884 0.373 . . . . 0.0 111.163 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 122' ' ' LEU . . . . . 0.773 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.8 OUTLIER -57.44 -50.25 73.61 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.945 179.868 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 123' ' ' LEU . . . . . 0.806 HD22 HG22 ' A' ' 26' ' ' VAL . 1.1 mt -54.73 -51.35 65.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.956 179.875 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 99.6 t -55.93 -46.0 80.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.113 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 71.0 t -64.64 -43.12 96.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.136 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 126' ' ' VAL . . . . . 0.808 HG22 HD22 ' A' ' 23' ' ' LEU . 71.7 t -51.42 -54.36 12.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.105 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 127' ' ' LEU . . . . . 0.814 HD23 HD23 ' A' ' 27' ' ' LEU . 57.1 mt -70.15 -47.39 61.89 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.927 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.81 -45.81 55.12 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.458 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 58.1 t -76.77 -54.82 12.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.931 0.396 . . . . 0.0 111.191 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 130' ' ' VAL . . . . . 0.726 HG21 HD11 ' A' ' 27' ' ' LEU . 17.6 t -49.89 -43.06 19.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.137 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 131' ' ' PHE . . . . . 0.415 ' HB3' HD12 ' B' ' 135' ' ' ILE . 5.1 m-85 -77.16 -44.83 28.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.898 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -52.3 -48.11 54.57 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.479 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 46.1 mt -73.21 -52.43 21.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.874 0.369 . . . . 0.0 111.149 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 134' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' B' ' 134' ' ' LEU . 23.9 mt -51.14 -60.77 2.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.914 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.415 HD12 ' HB3' ' B' ' 131' ' ' PHE . 12.0 mt -55.73 -48.62 77.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.094 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 63.5 tttt -52.44 -51.66 58.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.892 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 68.5 mtp180 -52.38 -43.59 64.8 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.876 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 51.4 mtp85 -63.61 -47.96 79.28 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.88 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 6.2 mm100 -63.87 179.35 0.52 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.895 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 17.1 mm100 -73.6 174.54 8.17 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.918 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 12.4 ttmt -136.57 156.95 47.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.92 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 142' ' ' ILE . . . . . . . . . . . . . 14.2 pt -132.94 179.65 4.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.119 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 27.2 ptt85 -123.7 177.69 5.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.854 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 16.2 mmtt . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.898 179.965 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.275 0 N-CA-C 112.473 -0.251 . . . . 0.0 112.473 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 1.7 m -101.06 160.48 26.55 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-O 121.599 0.714 . . . . 0.0 110.918 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -7.62 21.51 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.658 2.239 . . . . 0.0 112.361 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.17 -18.07 23.21 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.104 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -67.84 117.33 9.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.914 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 9.0 tt0 -91.65 100.91 13.55 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.898 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.76 151.17 39.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.911 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.69 ' HB3' HG21 ' A' ' 12' ' ' THR . . . -129.96 177.65 7.12 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.12 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.684 ' O ' HG22 ' A' ' 12' ' ' THR . 0.3 OUTLIER -49.48 164.57 0.32 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.671 0.748 . . . . 0.0 110.892 -179.809 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -11.87 31.72 Favored 'Trans proline' 0 C--O 1.232 0.221 0 C-N-CA 122.675 2.25 . . . . 0.0 112.332 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.468 HD22 ' O ' ' A' ' 11' ' ' LEU . 2.5 tm? -82.4 -36.48 26.68 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.881 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.69 HG21 ' HB3' ' A' ' 8' ' ' ALA . 5.5 t -49.56 -31.38 10.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.156 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -68.25 -44.61 75.24 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.89 -179.857 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.515 ' O ' HG23 ' A' ' 18' ' ' VAL . 51.0 mt -62.09 -45.81 97.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.143 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.652 ' O ' HG23 ' A' ' 19' ' ' VAL . 25.0 mt -57.11 -51.46 68.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.128 179.859 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 10.8 t -59.3 -32.9 70.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.851 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -64.5 -60.29 3.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.041 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.515 HG23 ' O ' ' A' ' 14' ' ' ILE . 5.9 t -51.58 -48.72 35.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.134 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.652 HG23 ' O ' ' A' ' 15' ' ' ILE . 92.1 t -50.04 -63.44 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.132 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -48.41 -55.48 10.69 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.527 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 22.1 mt -55.84 -40.86 64.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.816 0.341 . . . . 0.0 111.085 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.777 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.9 OUTLIER -57.46 -49.62 75.69 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.927 179.897 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.811 HD22 HG22 ' B' ' 126' ' ' VAL . 2.0 mt -55.18 -51.44 66.52 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.942 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 98.9 t -55.92 -46.17 80.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.122 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 76.0 t -63.75 -43.59 98.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.147 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.83 HG22 HD22 ' B' ' 123' ' ' LEU . 76.2 t -51.67 -53.72 15.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.107 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.793 HD23 HD23 ' B' ' 127' ' ' LEU . 54.0 mt -71.72 -45.73 60.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.923 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.77 -46.39 59.94 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.469 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -76.08 -54.21 14.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.851 0.358 . . . . 0.0 111.134 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.667 HG21 HD11 ' B' ' 127' ' ' LEU . 18.4 t -50.64 -44.6 25.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.14 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.442 ' HB3' HD12 ' A' ' 35' ' ' ILE . 5.3 m-85 -76.79 -39.07 52.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.9 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -54.71 -49.37 61.79 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 23.3 mt -74.78 -50.25 26.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.888 0.375 . . . . 0.0 111.165 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 25.4 mt -51.86 -56.28 14.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.934 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.442 HD12 ' HB3' ' A' ' 31' ' ' PHE . 21.6 mt -61.32 -44.09 97.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.179 179.799 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 16.8 mttt -50.52 -42.89 55.63 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.877 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 33.8 mtp180 -74.24 -32.98 63.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.917 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 79.6 mtp180 -69.97 -31.7 69.54 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.861 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -174.23 177.85 2.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.939 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 2.2 tp60 -122.77 168.32 12.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.906 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 7.5 mmtp -123.31 179.38 4.74 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.866 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.89 173.38 14.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.152 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 4.8 ptp180 -144.64 178.06 8.25 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.927 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.333 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.881 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.466 -0.253 . . . . 0.0 112.466 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 1.7 m -100.86 160.38 26.92 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.61 0.719 . . . . 0.0 110.885 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 -7.56 21.37 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.727 2.284 . . . . 0.0 112.365 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . 48.12 30.21 2.06 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.092 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -67.07 112.84 4.61 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.892 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 8.8 tt0 -95.43 104.45 16.35 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.919 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.41 147.31 41.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.841 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 108' ' ' ALA . . . . . 0.676 ' HB3' HG21 ' B' ' 112' ' ' THR . . . -132.67 176.79 8.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.115 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 109' ' ' SER . . . . . 0.683 ' O ' HG22 ' B' ' 112' ' ' THR . 0.3 OUTLIER -49.53 164.85 0.31 Allowed Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.639 0.733 . . . . 0.0 110.897 -179.797 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -11.81 31.63 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.687 2.258 . . . . 0.0 112.382 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 111' ' ' LEU . . . . . 0.457 ' O ' HD22 ' B' ' 111' ' ' LEU . 2.5 tm? -81.96 -36.55 27.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.877 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 112' ' ' THR . . . . . 0.683 HG22 ' O ' ' B' ' 109' ' ' SER . 5.7 t -49.38 -31.51 9.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.145 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -67.85 -45.0 75.86 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.846 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 114' ' ' ILE . . . . . 0.506 ' O ' HG23 ' B' ' 118' ' ' VAL . 51.4 mt -61.89 -45.53 98.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.15 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.668 ' O ' HG23 ' B' ' 119' ' ' VAL . 25.7 mt -57.04 -51.0 74.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.099 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 10.6 t -59.59 -33.19 71.14 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.844 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -64.25 -60.2 3.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.033 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.506 HG23 ' O ' ' B' ' 114' ' ' ILE . 5.7 t -51.54 -48.77 35.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.128 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 119' ' ' VAL . . . . . 0.668 HG23 ' O ' ' B' ' 115' ' ' ILE . 92.9 t -49.97 -63.41 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.101 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.46 -55.46 10.79 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.459 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 22.2 mt -55.89 -40.73 63.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.877 0.37 . . . . 0.0 111.118 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 122' ' ' LEU . . . . . 0.778 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.9 OUTLIER -57.57 -49.49 76.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.946 179.867 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 123' ' ' LEU . . . . . 0.83 HD22 HG22 ' A' ' 26' ' ' VAL . 2.0 mt -55.38 -51.48 66.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.902 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 98.0 t -55.81 -46.0 79.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.156 179.831 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 78.0 t -63.99 -43.45 97.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.148 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 126' ' ' VAL . . . . . 0.811 HG22 HD22 ' A' ' 23' ' ' LEU . 76.0 t -51.68 -53.68 15.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.143 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 127' ' ' LEU . . . . . 0.793 HD23 HD23 ' A' ' 27' ' ' LEU . 52.7 mt -71.78 -45.84 60.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.921 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -52.63 -46.12 59.4 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.506 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.4 t -76.41 -54.2 13.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.876 0.369 . . . . 0.0 111.097 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 130' ' ' VAL . . . . . 0.691 HG21 HD11 ' A' ' 27' ' ' LEU . 18.6 t -50.7 -44.31 25.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.179 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 131' ' ' PHE . . . . . 0.436 ' HB3' HD12 ' B' ' 135' ' ' ILE . 5.2 m-85 -77.0 -39.29 50.94 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.863 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -54.56 -49.09 62.33 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.478 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 22.2 mt -75.04 -50.6 24.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.809 0.338 . . . . 0.0 111.129 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 25.0 mt -51.54 -55.74 17.38 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.898 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.436 HD12 ' HB3' ' B' ' 131' ' ' PHE . 21.9 mt -61.9 -44.34 98.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.146 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 19.8 mttt -50.52 -42.44 55.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.898 179.838 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 33.6 mtp180 -74.56 -33.24 62.65 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.839 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 79.8 mtp180 -68.98 -35.38 76.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.847 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -174.84 -179.48 1.44 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.929 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 3.7 tp60 -121.96 171.28 9.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.959 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 7.3 mmtp -119.51 174.96 6.08 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.888 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 142' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -140.55 176.23 5.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.124 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 4.5 ptp180 -142.8 176.75 8.82 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.872 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.918 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.861 0.362 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.424 HG23 ' H ' ' A' ' 18' ' ' VAL . 9.7 t -51.0 -51.14 22.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.138 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.699 HG12 HD11 ' A' ' 23' ' ' LEU . 88.7 t -48.7 -59.61 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.146 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.481 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -49.88 -54.49 17.95 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.51 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 62.5 mt -58.48 -54.84 27.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.854 0.359 . . . . 0.0 111.114 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.871 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.42 -59.44 3.72 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.903 179.955 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.977 HD23 HG22 ' B' ' 126' ' ' VAL . 9.0 mt -43.44 -55.52 4.12 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.918 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 20' ' ' GLY . 87.2 t -52.4 -51.26 34.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.144 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.8 t -61.75 -40.5 87.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.141 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.987 HG22 HD23 ' B' ' 123' ' ' LEU . 44.2 t -51.22 -59.28 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.149 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.726 HD23 HD23 ' B' ' 127' ' ' LEU . 47.6 mt -67.45 -46.41 73.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.894 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.62 -48.13 50.4 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.491 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.4 t -75.97 -54.19 14.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.883 0.373 . . . . 0.0 111.142 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.728 HG21 HD11 ' B' ' 127' ' ' LEU . 20.3 t -49.72 -42.78 18.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.11 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -77.52 -34.84 53.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.892 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -57.39 -48.69 78.77 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.494 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 16.0 mt -76.91 -47.56 27.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.869 0.366 . . . . 0.0 111.141 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 28.2 mt -55.41 -53.13 60.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.937 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 79.3 mt -63.46 -49.49 82.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.123 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 27.8 ttpt . . . . . 0 C--N 1.328 -0.358 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.891 179.841 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.812 0.339 . . . . 0.0 111.098 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 10.1 t -50.85 -51.45 20.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.111 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.717 HG12 HD11 ' B' ' 123' ' ' LEU . 87.8 t -48.49 -59.68 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.127 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . 0.48 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -49.79 -54.74 16.61 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.481 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 63.7 mt -58.32 -54.93 26.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.843 0.354 . . . . 0.0 111.119 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 122' ' ' LEU . . . . . 0.859 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.35 -59.8 3.39 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.911 179.913 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 123' ' ' LEU . . . . . 0.987 HD23 HG22 ' A' ' 26' ' ' VAL . 9.1 mt -43.18 -55.56 3.88 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.9 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 124' ' ' VAL . . . . . 0.48 HG23 ' O ' ' B' ' 120' ' ' GLY . 87.0 t -52.38 -51.61 31.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.11 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 72.5 t -61.4 -40.49 86.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.114 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 126' ' ' VAL . . . . . 0.977 HG22 HD23 ' A' ' 23' ' ' LEU . 43.8 t -51.27 -59.27 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.129 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 127' ' ' LEU . . . . . 0.728 HD11 HG21 ' A' ' 30' ' ' VAL . 47.3 mt -67.52 -46.37 73.03 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.904 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.61 -47.81 51.17 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.537 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.6 t -76.25 -54.17 13.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.911 0.386 . . . . 0.0 111.141 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 130' ' ' VAL . . . . . 0.705 HG21 HD11 ' A' ' 27' ' ' LEU . 19.9 t -49.81 -42.54 18.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.112 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -77.66 -35.19 52.67 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.879 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -57.32 -48.38 80.85 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.496 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 17.2 mt -77.05 -47.81 26.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.855 0.36 . . . . 0.0 111.121 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 28.2 mt -55.29 -53.05 60.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.904 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 77.9 mt -63.39 -49.84 81.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.17 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 27.9 ttpt . . . . . 0 C--N 1.328 -0.342 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.888 179.853 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.071 0 CA-C-O 120.801 0.334 . . . . 0.0 111.076 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.403 HG23 ' H ' ' A' ' 18' ' ' VAL . 9.6 t -51.38 -51.07 25.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.123 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.685 HG12 HD11 ' A' ' 23' ' ' LEU . 95.0 t -48.55 -59.49 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.081 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.484 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -50.07 -54.46 18.88 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.527 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 66.9 mt -58.5 -54.77 28.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.919 0.39 . . . . 0.0 111.131 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.869 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.4 -59.7 3.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.922 179.922 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.987 HD23 HG22 ' B' ' 126' ' ' VAL . 9.1 mt -43.24 -55.53 3.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.905 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 20' ' ' GLY . 87.2 t -52.4 -51.47 32.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.152 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.7 t -61.52 -40.59 87.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.118 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.976 HG22 HD23 ' B' ' 123' ' ' LEU . 43.3 t -51.29 -59.12 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.108 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.722 HD23 HD23 ' B' ' 127' ' ' LEU . 46.4 mt -67.79 -46.36 72.19 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.899 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.6 -47.8 51.13 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.472 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -76.26 -54.32 13.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.862 0.363 . . . . 0.0 111.11 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.722 HG21 HD11 ' B' ' 127' ' ' LEU . 20.1 t -49.7 -42.5 17.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.137 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.422 ' HB3' HD12 ' A' ' 35' ' ' ILE . 4.7 m-85 -77.85 -37.34 48.56 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.85 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -56.29 -47.78 79.76 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.499 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 19.5 mt -76.69 -49.4 24.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.833 0.349 . . . . 0.0 111.149 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 28.6 mt -53.81 -52.86 58.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.955 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.422 HD12 ' HB3' ' A' ' 31' ' ' PHE . 49.2 mt -63.59 -47.48 91.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.135 179.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 32.3 ttpt . . . . . 0 C--N 1.328 -0.352 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.844 179.904 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.811 0.339 . . . . 0.0 111.089 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.8 t -51.35 -51.0 25.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.155 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.706 HG12 HD11 ' B' ' 123' ' ' LEU . 93.6 t -48.63 -59.43 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.147 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . 0.48 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -50.13 -54.49 18.96 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.472 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 67.0 mt -58.48 -54.85 27.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.917 0.389 . . . . 0.0 111.16 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 122' ' ' LEU . . . . . 0.867 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.31 -59.94 3.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.897 179.894 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 123' ' ' LEU . . . . . 0.976 HD23 HG22 ' A' ' 26' ' ' VAL . 9.2 mt -43.12 -55.41 3.9 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.933 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 124' ' ' VAL . . . . . 0.48 HG23 ' O ' ' B' ' 120' ' ' GLY . 87.4 t -52.55 -51.62 32.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.104 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 72.5 t -61.38 -40.61 86.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.1 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 126' ' ' VAL . . . . . 0.987 HG22 HD23 ' A' ' 23' ' ' LEU . 43.1 t -51.19 -59.19 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.121 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 127' ' ' LEU . . . . . 0.722 HD11 HG21 ' A' ' 30' ' ' VAL . 45.4 mt -67.8 -46.15 72.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.972 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.69 -47.9 51.4 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.461 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.0 t -76.24 -54.19 13.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.895 0.379 . . . . 0.0 111.093 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 130' ' ' VAL . . . . . 0.721 HG21 HD11 ' A' ' 27' ' ' LEU . 20.2 t -49.7 -42.59 17.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.141 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . 0.439 ' HB3' HD12 ' B' ' 135' ' ' ILE . 4.6 m-85 -77.72 -37.03 50.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.879 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -56.04 -47.86 77.52 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.517 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 18.2 mt -77.07 -49.25 23.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.826 0.346 . . . . 0.0 111.127 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 27.8 mt -53.57 -52.02 61.07 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.919 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.439 HD12 ' HB3' ' B' ' 131' ' ' PHE . 49.3 mt -64.85 -46.67 91.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.096 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 32.1 ttpt . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.899 179.904 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.798 0.332 . . . . 0.0 111.069 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.408 HG23 ' H ' ' A' ' 18' ' ' VAL . 12.0 t -52.24 -51.09 34.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.148 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.68 HG12 HD11 ' A' ' 23' ' ' LEU . 94.9 t -48.79 -59.15 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.137 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.483 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -50.26 -54.72 18.59 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.492 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 92.5 mt -58.37 -54.83 27.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.861 0.362 . . . . 0.0 111.089 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.885 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.28 -59.81 3.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.933 179.922 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 1.038 HD23 HG22 ' B' ' 126' ' ' VAL . 9.4 mt -43.21 -55.36 4.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.873 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.483 HG23 ' O ' ' A' ' 20' ' ' GLY . 90.5 t -52.61 -51.6 33.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.112 179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 70.9 t -61.37 -40.56 86.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.108 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 1.027 HG22 HD23 ' B' ' 123' ' ' LEU . 43.0 t -51.25 -59.3 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.133 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.707 HD11 HG21 ' B' ' 130' ' ' VAL . 44.5 mt -68.01 -46.26 71.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.906 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.51 -47.52 51.33 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.49 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.5 t -76.74 -54.21 13.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.855 0.359 . . . . 0.0 111.12 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.686 HG21 HD11 ' B' ' 127' ' ' LEU . 20.1 t -49.73 -42.02 17.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.118 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 5.3 m-85 -78.28 -34.29 48.99 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.885 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -57.51 -46.89 91.5 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.509 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 17.6 mt -79.38 -45.48 23.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.848 0.356 . . . . 0.0 111.116 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 27.4 mt -57.84 -43.79 86.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.868 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 72.4 mt -71.28 -58.95 4.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.161 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 8.3 pttp . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.937 179.781 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.795 0.331 . . . . 0.0 111.082 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 12.0 t -52.35 -51.09 35.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.127 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.689 HG12 HD11 ' B' ' 123' ' ' LEU . 95.5 t -48.89 -59.17 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.141 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . 0.48 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -50.2 -54.63 18.7 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.525 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 92.9 mt -58.4 -54.84 27.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.867 0.365 . . . . 0.0 111.158 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 122' ' ' LEU . . . . . 0.871 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.26 -59.87 3.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.945 179.877 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 123' ' ' LEU . . . . . 1.027 HD23 HG22 ' A' ' 26' ' ' VAL . 9.3 mt -43.08 -55.49 3.83 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.916 179.841 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 124' ' ' VAL . . . . . 0.48 HG23 ' O ' ' B' ' 120' ' ' GLY . 90.0 t -52.61 -51.51 34.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.13 179.87 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 69.9 t -61.48 -40.31 85.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.111 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 126' ' ' VAL . . . . . 1.038 HG22 HD23 ' A' ' 23' ' ' LEU . 43.1 t -51.4 -59.14 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.146 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 127' ' ' LEU . . . . . 0.701 HD23 HD23 ' A' ' 27' ' ' LEU . 45.6 mt -68.02 -46.41 71.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.875 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.6 -47.29 52.42 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.467 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.6 t -76.83 -54.18 13.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.853 0.358 . . . . 0.0 111.159 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 130' ' ' VAL . . . . . 0.707 HG21 HD11 ' A' ' 27' ' ' LEU . 19.7 t -49.8 -41.92 17.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.118 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -78.4 -36.37 45.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.859 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -56.06 -46.38 85.03 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.506 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 18.4 mt -79.18 -49.9 19.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 120.889 0.376 . . . . 0.0 111.151 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 27.8 mt -53.1 -48.1 68.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.933 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 69.9 mt -68.92 -49.93 58.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.125 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 11.5 tttp . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.899 179.802 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.085 0 CA-C-O 120.818 0.342 . . . . 0.0 111.092 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.427 HG23 ' H ' ' A' ' 18' ' ' VAL . 11.3 t -51.59 -51.21 27.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.122 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.723 HG12 HD11 ' A' ' 23' ' ' LEU . 84.0 t -48.62 -59.96 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.161 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.477 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -49.54 -54.71 15.74 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.475 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 96.2 mt -58.35 -54.81 27.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.884 0.373 . . . . 0.0 111.183 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.87 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.45 -59.56 3.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.871 179.907 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.992 HD23 HG22 ' B' ' 126' ' ' VAL . 8.8 mt -43.19 -55.55 3.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.925 179.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.477 HG23 ' O ' ' A' ' 20' ' ' GLY . 89.7 t -52.48 -51.74 31.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.144 179.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 73.4 t -61.44 -39.87 84.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.158 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 1.001 HG22 HD23 ' B' ' 123' ' ' LEU . 46.0 t -51.64 -58.69 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.131 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.726 HD23 HD23 ' B' ' 127' ' ' LEU . 56.6 mt -67.25 -47.6 70.25 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.962 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.3 -47.46 50.31 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.476 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.9 t -75.99 -54.4 13.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.904 0.383 . . . . 0.0 111.166 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.795 HG21 HD11 ' B' ' 127' ' ' LEU . 19.4 t -49.46 -43.29 17.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.13 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.404 ' HB3' HD12 ' A' ' 35' ' ' ILE . 7.5 m-85 -77.2 -41.53 41.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.879 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -53.35 -48.16 60.48 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.477 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 38.4 mt -74.89 -50.91 23.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.859 0.361 . . . . 0.0 111.115 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 23.2 mt -51.25 -57.64 8.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.937 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.404 HD12 ' HB3' ' A' ' 31' ' ' PHE . 14.4 mt -59.81 -48.48 87.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.126 179.838 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 14.8 tttm . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.914 179.824 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.847 0.356 . . . . 0.0 111.066 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . 0.418 ' H ' HG23 ' B' ' 118' ' ' VAL . 11.6 t -51.7 -51.34 27.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.181 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.712 HG12 HD11 ' B' ' 123' ' ' LEU . 89.1 t -48.6 -59.47 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.13 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . 0.473 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -50.05 -54.88 17.09 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.484 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 96.3 mt -58.28 -54.87 26.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.908 0.385 . . . . 0.0 111.128 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 122' ' ' LEU . . . . . 0.87 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.3 -59.69 3.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.907 179.93 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 123' ' ' LEU . . . . . 1.001 HD23 HG22 ' A' ' 26' ' ' VAL . 9.3 mt -43.22 -55.71 3.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.914 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 124' ' ' VAL . . . . . 0.473 HG23 ' O ' ' B' ' 120' ' ' GLY . 90.4 t -52.33 -51.83 29.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.087 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 74.0 t -61.19 -40.74 86.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.104 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 126' ' ' VAL . . . . . 0.992 HG22 HD23 ' A' ' 23' ' ' LEU . 45.4 t -50.89 -59.49 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.132 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 127' ' ' LEU . . . . . 0.795 HD11 HG21 ' A' ' 30' ' ' VAL . 49.0 mt -67.43 -46.67 72.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.924 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -50.89 -47.4 47.85 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.486 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 58.4 t -77.77 -54.66 12.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.895 0.379 . . . . 0.0 111.156 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 130' ' ' VAL . . . . . 0.659 HG21 HD11 ' A' ' 27' ' ' LEU . 20.4 t -49.31 -39.15 12.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.125 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . 0.5 ' HB3' HD12 ' B' ' 135' ' ' ILE . 3.5 m-30 -76.32 -42.76 43.97 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.874 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -51.74 -50.21 44.26 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.509 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 40.6 mt -73.23 -52.06 23.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.907 0.384 . . . . 0.0 111.131 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 24.5 mt -50.52 -61.35 2.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.932 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.5 HD12 ' HB3' ' B' ' 131' ' ' PHE . 13.6 mt -56.59 -46.46 82.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.152 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 14.6 tttm . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.907 179.838 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.809 0.338 . . . . 0.0 111.077 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.412 HG23 ' H ' ' A' ' 18' ' ' VAL . 11.3 t -51.86 -50.69 32.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.101 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.75 HG12 HD11 ' A' ' 23' ' ' LEU . 86.6 t -48.85 -60.23 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.161 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.489 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -49.49 -54.28 17.19 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.465 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 39.0 mt -58.52 -54.72 29.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.862 0.363 . . . . 0.0 111.156 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.872 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.71 -59.49 3.76 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.892 179.898 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.985 HD23 HG22 ' B' ' 126' ' ' VAL . 8.5 mt -43.23 -55.35 4.03 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.919 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.489 HG23 ' O ' ' A' ' 20' ' ' GLY . 91.8 t -52.46 -51.74 31.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.127 179.852 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 74.8 t -61.62 -39.84 84.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.171 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.989 HG22 HD23 ' B' ' 123' ' ' LEU . 46.5 t -51.62 -59.51 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.13 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.72 HD11 HG21 ' B' ' 130' ' ' VAL . 57.0 mt -66.39 -47.81 72.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.876 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.18 -47.58 49.31 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.452 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.4 t -76.32 -54.59 13.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.825 0.345 . . . . 0.0 111.141 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.731 HG21 HD11 ' B' ' 127' ' ' LEU . 19.8 t -49.34 -42.33 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.141 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.402 ' HB3' HD12 ' A' ' 35' ' ' ILE . 4.9 m-85 -77.05 -44.39 30.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -52.35 -48.61 53.81 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.458 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 42.2 mt -73.03 -52.06 23.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.88 0.371 . . . . 0.0 111.118 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 22.8 mt -51.21 -60.78 2.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.876 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.402 HD12 ' HB3' ' A' ' 31' ' ' PHE . 11.9 mt -55.56 -49.07 76.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.16 179.828 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 8.0 tmtt? . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 179.833 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.861 0.363 . . . . 0.0 111.09 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . 0.414 ' H ' HG23 ' B' ' 118' ' ' VAL . 11.3 t -51.86 -50.7 32.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.155 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.74 HG12 HD11 ' B' ' 123' ' ' LEU . 87.7 t -48.82 -60.26 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.134 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . 0.49 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -49.44 -54.25 17.13 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.488 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 38.8 mt -58.56 -54.85 27.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.857 0.361 . . . . 0.0 111.135 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 122' ' ' LEU . . . . . 0.874 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.57 -59.43 3.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.945 179.884 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 123' ' ' LEU . . . . . 0.989 HD23 HG22 ' A' ' 26' ' ' VAL . 8.5 mt -43.28 -55.35 4.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.942 179.883 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 124' ' ' VAL . . . . . 0.49 HG23 ' O ' ' B' ' 120' ' ' GLY . 92.1 t -52.39 -51.81 30.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.135 179.823 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 74.8 t -61.61 -39.83 84.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.12 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 126' ' ' VAL . . . . . 0.985 HG22 HD23 ' A' ' 23' ' ' LEU . 46.2 t -51.67 -59.58 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.141 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 127' ' ' LEU . . . . . 0.731 HD11 HG21 ' A' ' 30' ' ' VAL . 55.9 mt -66.31 -47.81 72.34 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.937 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.21 -47.52 49.61 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.47 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 55.9 t -76.34 -54.63 13.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.848 0.356 . . . . 0.0 111.142 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 130' ' ' VAL . . . . . 0.72 HG21 HD11 ' A' ' 27' ' ' LEU . 20.2 t -49.28 -42.37 15.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.132 179.883 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . 0.414 ' HB3' HD12 ' B' ' 135' ' ' ILE . 4.8 m-85 -76.95 -44.57 30.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.933 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -52.28 -48.55 53.51 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.489 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 42.2 mt -73.02 -52.1 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.846 0.355 . . . . 0.0 111.18 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 23.0 mt -51.17 -60.87 2.64 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.919 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.414 HD12 ' HB3' ' B' ' 131' ' ' PHE . 11.8 mt -55.42 -49.52 72.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.129 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 8.0 tmtt? . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.89 179.866 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.814 0.34 . . . . 0.0 111.096 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.4 t -50.81 -50.87 22.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.133 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.69 HG12 HD11 ' A' ' 23' ' ' LEU . 96.0 t -48.4 -59.46 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.087 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.48 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -50.44 -54.52 20.13 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.538 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 99.0 mt -58.41 -54.82 27.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.826 0.346 . . . . 0.0 111.124 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.891 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.54 -59.44 3.76 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.902 179.921 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 1.017 HD23 HG22 ' B' ' 126' ' ' VAL . 9.8 mt -43.31 -55.33 4.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.884 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 20' ' ' GLY . 89.5 t -52.6 -52.03 30.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.114 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.9 t -61.05 -40.21 84.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.126 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 1.012 HG22 HD23 ' B' ' 123' ' ' LEU . 44.5 t -51.64 -59.29 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.101 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.745 HD11 HG21 ' B' ' 130' ' ' VAL . 48.6 mt -67.58 -46.66 71.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.893 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.6 -47.57 51.73 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.451 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -76.41 -54.16 13.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.896 0.379 . . . . 0.0 111.148 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.739 HG21 HD11 ' B' ' 127' ' ' LEU . 19.8 t -49.79 -42.65 18.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.145 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.411 ' HB3' HD12 ' A' ' 35' ' ' ILE . 4.7 m-85 -77.44 -40.58 42.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.902 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -53.48 -48.4 60.5 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.49 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 28.8 mt -75.56 -50.47 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.849 0.357 . . . . 0.0 111.11 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 22.4 mt -51.28 -56.71 11.55 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.947 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.411 HD12 ' HB3' ' A' ' 31' ' ' PHE . 18.2 mt -60.96 -49.34 85.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.116 179.822 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 30.7 ttpt . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.854 179.922 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.807 0.336 . . . . 0.0 111.08 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . 0.416 HG23 ' H ' ' B' ' 118' ' ' VAL . 11.0 t -51.64 -51.05 28.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.112 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.685 HG12 HD11 ' B' ' 123' ' ' LEU . 91.1 t -48.37 -59.35 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.141 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . 0.468 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -50.51 -54.68 19.77 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.522 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 98.9 mt -58.23 -54.88 26.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.844 0.355 . . . . 0.0 111.103 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 122' ' ' LEU . . . . . 0.89 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.37 -59.55 3.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.937 179.877 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 123' ' ' LEU . . . . . 1.012 HD23 HG22 ' A' ' 26' ' ' VAL . 9.6 mt -43.28 -55.32 4.09 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.925 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 124' ' ' VAL . . . . . 0.468 HG23 ' O ' ' B' ' 120' ' ' GLY . 90.4 t -52.74 -51.96 31.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.119 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 72.7 t -60.94 -40.25 84.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.129 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 126' ' ' VAL . . . . . 1.017 HG22 HD23 ' A' ' 23' ' ' LEU . 44.9 t -51.47 -59.3 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.141 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 127' ' ' LEU . . . . . 0.742 HD23 HD23 ' A' ' 27' ' ' LEU . 49.7 mt -67.59 -46.88 71.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.907 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.52 -47.53 51.33 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.453 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.0 t -76.24 -54.37 13.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.892 0.377 . . . . 0.0 111.153 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 130' ' ' VAL . . . . . 0.745 HG21 HD11 ' A' ' 27' ' ' LEU . 19.7 t -49.69 -42.71 17.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.114 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . 0.423 ' HB3' HD12 ' B' ' 135' ' ' ILE . 4.8 m-85 -77.41 -41.04 41.41 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.864 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -53.27 -48.43 59.45 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.486 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 30.1 mt -75.25 -50.37 24.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.827 0.346 . . . . 0.0 111.117 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 21.9 mt -51.53 -57.42 9.11 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.894 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.423 HD12 ' HB3' ' B' ' 131' ' ' PHE . 17.2 mt -59.94 -50.01 81.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.115 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 31.0 ttpt . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.897 179.865 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.828 0.347 . . . . 0.0 111.076 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 9.5 t -51.36 -51.62 23.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.159 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.673 HG12 HD11 ' A' ' 23' ' ' LEU . 99.4 t -48.48 -59.04 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.105 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.475 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -50.23 -54.81 18.12 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.486 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 55.1 mt -58.43 -54.89 26.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.856 0.36 . . . . 0.0 111.124 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.863 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.1 -59.83 3.31 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.948 179.884 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 1.001 HD23 HG22 ' B' ' 126' ' ' VAL . 9.6 mt -43.29 -55.65 3.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.935 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.475 HG23 ' O ' ' A' ' 20' ' ' GLY . 88.4 t -52.47 -51.14 35.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.142 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 69.8 t -61.6 -40.65 87.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.082 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 1.012 HG22 HD23 ' B' ' 123' ' ' LEU . 41.8 t -51.37 -58.89 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.136 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.74 HD23 HD23 ' B' ' 127' ' ' LEU . 45.9 mt -68.47 -46.16 70.51 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.912 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.79 -47.62 52.65 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.477 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.7 t -76.11 -54.32 13.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.918 0.389 . . . . 0.0 111.169 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.704 HG21 HD11 ' B' ' 127' ' ' LEU . 20.0 t -49.8 -43.01 18.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.114 179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.423 ' HB3' HD12 ' A' ' 35' ' ' ILE . 4.8 m-85 -77.61 -41.5 38.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.902 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -53.28 -47.36 61.95 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.489 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 22.3 mt -76.04 -51.37 20.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.833 0.349 . . . . 0.0 111.141 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 23.7 mt -51.0 -55.92 15.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.903 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.423 HD12 ' HB3' ' A' ' 31' ' ' PHE . 18.3 mt -61.71 -48.48 88.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.116 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 3.9 tmtt? . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.886 179.882 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.82 0.343 . . . . 0.0 111.101 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.3 t -51.54 -51.51 25.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.17 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.68 HG12 HD11 ' B' ' 123' ' ' LEU . 98.9 t -48.51 -59.04 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.129 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . 0.477 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -50.29 -54.8 18.39 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.493 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 55.5 mt -58.46 -54.88 27.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.865 0.364 . . . . 0.0 111.119 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 122' ' ' LEU . . . . . 0.877 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.1 -59.85 3.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.897 179.903 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 123' ' ' LEU . . . . . 1.012 HD23 HG22 ' A' ' 26' ' ' VAL . 9.7 mt -43.26 -55.77 3.84 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 124' ' ' VAL . . . . . 0.477 HG23 ' O ' ' B' ' 120' ' ' GLY . 89.3 t -52.43 -51.21 34.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.173 179.82 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 69.2 t -61.48 -40.56 86.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.161 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 126' ' ' VAL . . . . . 1.001 HG22 HD23 ' A' ' 23' ' ' LEU . 42.3 t -51.5 -59.18 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.092 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 127' ' ' LEU . . . . . 0.74 HD23 HD23 ' A' ' 27' ' ' LEU . 45.2 mt -68.14 -46.26 71.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.916 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.56 -47.65 51.29 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.507 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 56.0 t -76.37 -54.25 13.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.845 0.355 . . . . 0.0 111.077 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 130' ' ' VAL . . . . . 0.705 HG21 HD11 ' A' ' 27' ' ' LEU . 20.2 t -49.8 -42.72 18.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.114 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . 0.404 ' HB3' HD12 ' B' ' 135' ' ' ILE . 4.8 m-85 -77.77 -41.96 35.7 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.859 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -52.93 -47.16 60.08 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.491 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 22.6 mt -76.16 -51.55 19.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.884 0.373 . . . . 0.0 111.141 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 134' ' ' LEU . . . . . 0.409 HD23 ' HA ' ' B' ' 134' ' ' LEU . 23.2 mt -50.8 -55.79 15.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.861 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.404 HD12 ' HB3' ' B' ' 131' ' ' PHE . 17.4 mt -61.87 -48.85 86.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.17 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 3.8 tmtt? . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.91 179.806 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.799 0.333 . . . . 0.0 111.115 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.7 t -51.78 -51.07 29.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.16 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.697 HG12 HD11 ' A' ' 23' ' ' LEU . 91.3 t -48.65 -59.48 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.121 179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.47 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -50.05 -54.55 18.41 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.508 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 90.4 mt -58.47 -54.71 29.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.832 0.349 . . . . 0.0 111.111 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.876 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.46 -59.7 3.51 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.937 179.908 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 1.025 HD23 HG22 ' B' ' 126' ' ' VAL . 9.0 mt -43.26 -55.37 4.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.937 179.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.47 HG23 ' O ' ' A' ' 20' ' ' GLY . 86.9 t -52.52 -51.61 32.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.17 179.809 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 73.6 t -61.47 -40.28 85.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.169 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 1.026 HG22 HD23 ' B' ' 123' ' ' LEU . 44.4 t -51.5 -59.0 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.124 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.73 HD11 HG21 ' B' ' 130' ' ' VAL . 48.8 mt -67.7 -46.76 71.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.941 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.54 -47.22 52.28 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.52 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 56.3 t -76.6 -54.3 13.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.913 0.387 . . . . 0.0 111.122 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.727 HG21 HD11 ' B' ' 127' ' ' LEU . 19.9 t -49.78 -42.45 18.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.116 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.41 ' HB3' HD12 ' A' ' 35' ' ' ILE . 4.8 m-85 -77.57 -43.19 32.58 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.845 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -52.59 -47.68 57.17 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.476 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 30.3 mt -74.84 -51.86 20.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.842 0.353 . . . . 0.0 111.137 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 22.9 mt -50.97 -57.92 7.34 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.931 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.41 HD12 ' HB3' ' A' ' 31' ' ' PHE . 14.4 mt -59.3 -48.3 87.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.118 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 9.4 ttmm . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.922 179.826 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.83 0.348 . . . . 0.0 111.083 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 9.4 t -51.55 -51.03 27.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.115 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.708 HG12 HD11 ' B' ' 123' ' ' LEU . 90.2 t -48.7 -59.5 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.11 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . 0.473 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -50.04 -54.55 18.39 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.46 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 90.1 mt -58.47 -54.75 28.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.83 0.347 . . . . 0.0 111.095 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 122' ' ' LEU . . . . . 0.875 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.43 -59.83 3.38 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.9 179.886 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 123' ' ' LEU . . . . . 1.026 HD23 HG22 ' A' ' 26' ' ' VAL . 9.1 mt -43.13 -55.4 3.91 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.857 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 124' ' ' VAL . . . . . 0.473 HG23 ' O ' ' B' ' 120' ' ' GLY . 87.0 t -52.63 -51.66 33.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.116 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 73.1 t -61.41 -40.19 85.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.096 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 126' ' ' VAL . . . . . 1.025 HG22 HD23 ' A' ' 23' ' ' LEU . 44.1 t -51.52 -59.13 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.101 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 127' ' ' LEU . . . . . 0.727 HD11 HG21 ' A' ' 30' ' ' VAL . 48.5 mt -67.64 -46.83 71.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.929 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.57 -47.18 52.47 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.486 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 56.1 t -76.65 -54.25 13.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.83 0.348 . . . . 0.0 111.121 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 130' ' ' VAL . . . . . 0.73 HG21 HD11 ' A' ' 27' ' ' LEU . 20.0 t -49.8 -42.47 18.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.119 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . 0.42 ' HB3' HD12 ' B' ' 135' ' ' ILE . 4.7 m-85 -77.46 -43.23 33.06 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.871 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -52.23 -47.9 54.61 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.501 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 30.5 mt -74.88 -51.68 21.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.841 0.353 . . . . 0.0 111.113 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 134' ' ' LEU . . . . . 0.402 HD23 ' HA ' ' B' ' 134' ' ' LEU . 21.9 mt -50.91 -57.98 7.15 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.904 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.42 HD12 ' HB3' ' B' ' 131' ' ' PHE . 14.2 mt -59.28 -48.99 85.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.107 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 9.7 ttmm . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.909 179.871 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.825 0.345 . . . . 0.0 111.1 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 5.9 t -51.05 -48.92 29.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.088 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.494 ' O ' ' HG ' ' A' ' 23' ' ' LEU . 98.3 t -49.6 -63.35 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.129 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -48.57 -55.69 10.65 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.497 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.402 ' O ' HG23 ' A' ' 25' ' ' VAL . 20.4 mt -55.52 -41.02 61.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.863 0.363 . . . . 0.0 111.111 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.77 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.8 OUTLIER -57.15 -50.68 72.05 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.877 179.926 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.808 HD22 HG22 ' B' ' 126' ' ' VAL . 1.1 mt -54.47 -51.67 64.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.901 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 98.1 t -55.44 -45.97 78.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.118 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.402 HG23 ' O ' ' A' ' 21' ' ' ILE . 70.6 t -64.83 -43.18 96.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.101 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.806 HG22 HD22 ' B' ' 123' ' ' LEU . 73.3 t -51.27 -54.31 11.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.113 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.814 HD23 HD23 ' B' ' 127' ' ' LEU . 56.4 mt -70.13 -47.28 62.39 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.885 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.82 -45.88 55.14 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.538 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 57.4 t -76.81 -54.67 12.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.84 0.352 . . . . 0.0 111.136 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.732 HG21 HD11 ' B' ' 127' ' ' LEU . 17.6 t -49.9 -43.05 19.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.158 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.404 ' HB3' HD12 ' A' ' 35' ' ' ILE . 5.1 m-85 -77.22 -44.95 28.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.825 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -52.29 -48.0 54.72 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.47 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 45.4 mt -73.22 -52.55 21.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.848 0.356 . . . . 0.0 111.126 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 23.7 mt -51.03 -60.75 2.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.89 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.404 HD12 ' HB3' ' A' ' 31' ' ' PHE . 11.8 mt -55.7 -48.68 77.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.117 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 63.6 tttt . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.877 179.897 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.827 0.346 . . . . 0.0 111.111 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 6.1 t -51.27 -48.78 32.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.103 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.491 ' O ' ' HG ' ' B' ' 123' ' ' LEU . 98.4 t -49.66 -63.28 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.123 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.73 -55.48 11.2 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.499 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 20.0 mt -55.64 -40.8 61.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.884 0.373 . . . . 0.0 111.163 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 122' ' ' LEU . . . . . 0.773 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.8 OUTLIER -57.44 -50.25 73.61 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.945 179.868 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 123' ' ' LEU . . . . . 0.806 HD22 HG22 ' A' ' 26' ' ' VAL . 1.1 mt -54.73 -51.35 65.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.956 179.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 99.6 t -55.93 -46.0 80.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.113 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 71.0 t -64.64 -43.12 96.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.136 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 126' ' ' VAL . . . . . 0.808 HG22 HD22 ' A' ' 23' ' ' LEU . 71.7 t -51.42 -54.36 12.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.105 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 127' ' ' LEU . . . . . 0.814 HD23 HD23 ' A' ' 27' ' ' LEU . 57.1 mt -70.15 -47.39 61.89 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.927 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.81 -45.81 55.12 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.458 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 58.1 t -76.77 -54.82 12.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.931 0.396 . . . . 0.0 111.191 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 130' ' ' VAL . . . . . 0.726 HG21 HD11 ' A' ' 27' ' ' LEU . 17.6 t -49.89 -43.06 19.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.137 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . 0.415 ' HB3' HD12 ' B' ' 135' ' ' ILE . 5.1 m-85 -77.16 -44.83 28.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.898 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -52.3 -48.11 54.57 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.479 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 46.1 mt -73.21 -52.43 21.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.874 0.369 . . . . 0.0 111.149 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 134' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' B' ' 134' ' ' LEU . 23.9 mt -51.14 -60.77 2.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.914 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.415 HD12 ' HB3' ' B' ' 131' ' ' PHE . 12.0 mt -55.73 -48.62 77.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.094 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 63.5 tttt . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.892 179.885 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.828 0.347 . . . . 0.0 111.041 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.408 HG23 ' H ' ' A' ' 18' ' ' VAL . 5.9 t -51.58 -48.72 35.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.134 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.493 ' O ' ' HG ' ' A' ' 23' ' ' LEU . 92.1 t -50.04 -63.44 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.132 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -48.41 -55.48 10.69 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.527 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 22.1 mt -55.84 -40.86 64.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.816 0.341 . . . . 0.0 111.085 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.777 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.9 OUTLIER -57.46 -49.62 75.69 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.927 179.897 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.811 HD22 HG22 ' B' ' 126' ' ' VAL . 2.0 mt -55.18 -51.44 66.52 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.942 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 98.9 t -55.92 -46.17 80.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.122 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 76.0 t -63.75 -43.59 98.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.147 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.83 HG22 HD22 ' B' ' 123' ' ' LEU . 76.2 t -51.67 -53.72 15.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.107 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.793 HD23 HD23 ' B' ' 127' ' ' LEU . 54.0 mt -71.72 -45.73 60.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.923 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.77 -46.39 59.94 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.469 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -76.08 -54.21 14.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.851 0.358 . . . . 0.0 111.134 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.667 HG21 HD11 ' B' ' 127' ' ' LEU . 18.4 t -50.64 -44.6 25.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.14 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.442 ' HB3' HD12 ' A' ' 35' ' ' ILE . 5.3 m-85 -76.79 -39.07 52.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.9 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -54.71 -49.37 61.79 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 23.3 mt -74.78 -50.25 26.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.888 0.375 . . . . 0.0 111.165 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 25.4 mt -51.86 -56.28 14.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.934 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.442 HD12 ' HB3' ' A' ' 31' ' ' PHE . 21.6 mt -61.32 -44.09 97.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.179 179.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 16.8 mttt . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.877 179.852 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.836 0.351 . . . . 0.0 111.033 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . . . . . . . . . 5.7 t -51.54 -48.77 35.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.128 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 119' ' ' VAL . . . . . 0.491 ' O ' ' HG ' ' B' ' 123' ' ' LEU . 92.9 t -49.97 -63.41 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.101 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.46 -55.46 10.79 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.459 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 22.2 mt -55.89 -40.73 63.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.877 0.37 . . . . 0.0 111.118 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 122' ' ' LEU . . . . . 0.778 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.9 OUTLIER -57.57 -49.49 76.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.946 179.867 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 123' ' ' LEU . . . . . 0.83 HD22 HG22 ' A' ' 26' ' ' VAL . 2.0 mt -55.38 -51.48 66.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.902 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 98.0 t -55.81 -46.0 79.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.156 179.831 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 78.0 t -63.99 -43.45 97.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.148 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 126' ' ' VAL . . . . . 0.811 HG22 HD22 ' A' ' 23' ' ' LEU . 76.0 t -51.68 -53.68 15.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.143 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 127' ' ' LEU . . . . . 0.793 HD23 HD23 ' A' ' 27' ' ' LEU . 52.7 mt -71.78 -45.84 60.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.921 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -52.63 -46.12 59.4 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.506 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.4 t -76.41 -54.2 13.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.876 0.369 . . . . 0.0 111.097 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 130' ' ' VAL . . . . . 0.691 HG21 HD11 ' A' ' 27' ' ' LEU . 18.6 t -50.7 -44.31 25.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.179 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . 0.436 ' HB3' HD12 ' B' ' 135' ' ' ILE . 5.2 m-85 -77.0 -39.29 50.94 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.863 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -54.56 -49.09 62.33 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.478 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 22.2 mt -75.04 -50.6 24.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.809 0.338 . . . . 0.0 111.129 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 25.0 mt -51.54 -55.74 17.38 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.898 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.436 HD12 ' HB3' ' B' ' 131' ' ' PHE . 21.9 mt -61.9 -44.34 98.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.146 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 19.8 mttt . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.898 179.838 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 N-CA-C 112.543 -0.223 . . . . 0.0 112.543 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 6.6 p -134.14 70.33 73.84 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.656 0.741 . . . . 0.0 110.883 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 173.46 10.94 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.686 2.258 . . . . 0.0 112.363 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . 55.73 45.92 23.53 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.127 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -99.74 43.01 1.08 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.927 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 23.9 mt-30 -105.51 136.0 45.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.908 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 4.0 ppt_? -115.67 34.62 4.83 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.863 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.612 ' HB3' HG21 ' A' ' 12' ' ' THR . . . -67.11 166.94 12.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.116 179.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.705 ' O ' HG22 ' A' ' 12' ' ' THR . 0.3 OUTLIER -49.34 164.9 0.29 Allowed Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.647 0.737 . . . . 0.0 110.878 -179.825 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 -11.87 31.68 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.655 2.237 . . . . 0.0 112.345 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.459 HD13 ' C ' ' A' ' 11' ' ' LEU . 3.0 tm? -79.12 -36.58 40.36 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.9 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.705 HG22 ' O ' ' A' ' 9' ' ' SER . 7.4 t -48.88 -32.87 9.61 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.132 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -65.33 -48.37 73.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.816 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.54 ' O ' HG23 ' A' ' 18' ' ' VAL . 52.3 mt -59.7 -45.24 94.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.137 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.556 ' O ' HG23 ' A' ' 19' ' ' VAL . 11.9 mt -55.14 -51.69 52.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.127 179.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -58.11 -36.29 72.68 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.83 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -62.79 -58.86 5.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.118 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.54 HG23 ' O ' ' A' ' 14' ' ' ILE . 9.7 t -51.0 -51.14 22.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.138 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.699 HG12 HD11 ' A' ' 23' ' ' LEU . 88.7 t -48.7 -59.61 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.146 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.481 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -49.88 -54.49 17.95 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.51 179.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 62.5 mt -58.48 -54.84 27.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.854 0.359 . . . . 0.0 111.114 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.871 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.42 -59.44 3.72 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.903 179.955 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.977 HD23 HG22 ' B' ' 126' ' ' VAL . 9.0 mt -43.44 -55.52 4.12 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.918 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 20' ' ' GLY . 87.2 t -52.4 -51.26 34.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.144 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.8 t -61.75 -40.5 87.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.141 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.987 HG22 HD23 ' B' ' 123' ' ' LEU . 44.2 t -51.22 -59.28 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.149 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.726 HD23 HD23 ' B' ' 127' ' ' LEU . 47.6 mt -67.45 -46.41 73.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.894 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.62 -48.13 50.4 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.491 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.4 t -75.97 -54.19 14.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.883 0.373 . . . . 0.0 111.142 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.728 HG21 HD11 ' B' ' 127' ' ' LEU . 20.3 t -49.72 -42.78 18.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.11 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -77.52 -34.84 53.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.892 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -57.39 -48.69 78.77 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.494 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 16.0 mt -76.91 -47.56 27.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.869 0.366 . . . . 0.0 111.141 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 28.2 mt -55.41 -53.13 60.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.937 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 79.3 mt -63.46 -49.49 82.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.123 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 27.8 ttpt -62.3 -16.87 56.68 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.891 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 46.0 mtp85 -84.02 -37.91 21.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.861 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -85.07 -49.16 8.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.891 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.7 mt-30 49.59 52.29 14.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.875 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 11.7 mm100 -115.68 48.49 1.2 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.886 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 3.8 tppt? -152.93 136.33 15.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.906 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 1.9 mt 45.91 83.57 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.143 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 15.6 ttm180 -85.82 130.7 34.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.883 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 22.5 ttmm . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 179.95 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 7.0 p -135.15 68.84 69.86 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.62 0.724 . . . . 0.0 110.9 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 171.32 14.67 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.731 2.287 . . . . 0.0 112.37 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . 54.54 49.45 18.22 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.065 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -99.52 31.31 3.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.89 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 20.8 mt-30 -117.83 136.43 53.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.887 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 3.3 ppt_? -115.17 9.79 15.91 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.869 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 108' ' ' ALA . . . . . 0.657 ' HB3' HG21 ' B' ' 112' ' ' THR . . . -100.6 166.75 10.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.091 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 109' ' ' SER . . . . . 0.673 ' O ' HG22 ' B' ' 112' ' ' THR . 0.3 OUTLIER -50.97 164.1 0.46 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.693 0.758 . . . . 0.0 110.879 -179.76 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 -11.77 31.55 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.678 2.252 . . . . 0.0 112.359 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 111' ' ' LEU . . . . . 0.462 HD13 ' C ' ' B' ' 111' ' ' LEU . 3.0 tm? -81.96 -34.67 29.63 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.911 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 112' ' ' THR . . . . . 0.673 HG22 ' O ' ' B' ' 109' ' ' SER . 6.1 t -48.79 -31.76 7.56 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.188 179.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -65.4 -50.16 66.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.844 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 114' ' ' ILE . . . . . 0.537 ' O ' HG23 ' B' ' 118' ' ' VAL . 50.1 mt -59.14 -45.91 92.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.105 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.546 ' O ' HG23 ' B' ' 119' ' ' VAL . 6.8 mt -53.91 -52.23 37.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.14 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -57.85 -36.62 72.58 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.863 -179.896 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -62.7 -58.75 6.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.098 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.537 HG23 ' O ' ' B' ' 114' ' ' ILE . 10.1 t -50.85 -51.45 20.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.111 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.717 HG12 HD11 ' B' ' 123' ' ' LEU . 87.8 t -48.49 -59.68 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.127 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . 0.48 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -49.79 -54.74 16.61 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.481 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 63.7 mt -58.32 -54.93 26.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.843 0.354 . . . . 0.0 111.119 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 122' ' ' LEU . . . . . 0.859 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.35 -59.8 3.39 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.911 179.913 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 123' ' ' LEU . . . . . 0.987 HD23 HG22 ' A' ' 26' ' ' VAL . 9.1 mt -43.18 -55.56 3.88 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.9 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 124' ' ' VAL . . . . . 0.48 HG23 ' O ' ' B' ' 120' ' ' GLY . 87.0 t -52.38 -51.61 31.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.11 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 72.5 t -61.4 -40.49 86.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.114 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 126' ' ' VAL . . . . . 0.977 HG22 HD23 ' A' ' 23' ' ' LEU . 43.8 t -51.27 -59.27 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.129 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 127' ' ' LEU . . . . . 0.728 HD11 HG21 ' A' ' 30' ' ' VAL . 47.3 mt -67.52 -46.37 73.03 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.904 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.61 -47.81 51.17 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.537 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.6 t -76.25 -54.17 13.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.911 0.386 . . . . 0.0 111.141 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 130' ' ' VAL . . . . . 0.705 HG21 HD11 ' A' ' 27' ' ' LEU . 19.9 t -49.81 -42.54 18.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.112 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -77.66 -35.19 52.67 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.879 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -57.32 -48.38 80.85 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.496 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 17.2 mt -77.05 -47.81 26.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.855 0.36 . . . . 0.0 111.121 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 28.2 mt -55.29 -53.05 60.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.904 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 77.9 mt -63.39 -49.84 81.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.17 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 27.9 ttpt -61.96 -17.06 55.67 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.888 179.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 46.1 mtp85 -83.74 -38.15 21.74 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.835 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.75 -49.16 8.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.865 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 2.6 mt-30 49.08 51.74 15.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.886 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 13.1 mm100 -114.68 46.36 1.41 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.965 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 4.9 tppt? -156.94 141.48 16.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.929 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 142' ' ' ILE . . . . . . . . . . . . . 5.4 pt -44.09 105.79 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.105 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 16.3 ttm180 -70.93 130.66 42.18 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.861 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 22.1 ttmm . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.867 179.979 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.504 -0.238 . . . . 0.0 112.504 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 4.6 p -140.91 156.57 68.54 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.558 0.694 . . . . 0.0 110.896 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -172.89 0.62 Allowed 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.685 2.257 . . . . 0.0 112.312 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.88 161.4 4.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.11 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 17.2 tp10 -56.65 111.84 1.12 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.889 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 1.6 tp60 -115.9 141.1 48.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.856 -179.882 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.37 176.94 9.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.863 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.65 ' HB3' HG21 ' A' ' 12' ' ' THR . . . -142.38 168.78 18.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.101 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.678 ' O ' HG22 ' A' ' 12' ' ' THR . 0.3 OUTLIER -49.62 164.51 0.33 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.663 0.744 . . . . 0.0 110.877 -179.799 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.7 -11.62 31.3 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.674 2.249 . . . . 0.0 112.355 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.462 HD22 ' O ' ' A' ' 11' ' ' LEU . 2.5 tm? -80.77 -35.91 32.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.902 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.678 HG22 ' O ' ' A' ' 9' ' ' SER . 6.4 t -48.88 -32.03 8.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.119 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.39 -50.87 65.95 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.913 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.596 ' O ' HG23 ' A' ' 18' ' ' VAL . 3.3 mp -59.1 -43.16 88.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.088 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.52 ' O ' HG23 ' A' ' 19' ' ' VAL . 13.1 mt -55.26 -53.17 37.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.097 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.3 t -57.87 -36.3 72.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.873 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -62.46 -58.64 6.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.076 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.596 HG23 ' O ' ' A' ' 14' ' ' ILE . 9.6 t -51.38 -51.07 25.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.123 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.685 HG12 HD11 ' A' ' 23' ' ' LEU . 95.0 t -48.55 -59.49 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.081 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.484 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -50.07 -54.46 18.88 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.527 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 66.9 mt -58.5 -54.77 28.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.919 0.39 . . . . 0.0 111.131 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.869 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.4 -59.7 3.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.922 179.922 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.987 HD23 HG22 ' B' ' 126' ' ' VAL . 9.1 mt -43.24 -55.53 3.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.905 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 20' ' ' GLY . 87.2 t -52.4 -51.47 32.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.152 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.7 t -61.52 -40.59 87.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.118 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.976 HG22 HD23 ' B' ' 123' ' ' LEU . 43.3 t -51.29 -59.12 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.108 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.722 HD23 HD23 ' B' ' 127' ' ' LEU . 46.4 mt -67.79 -46.36 72.19 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.899 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.6 -47.8 51.13 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.472 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -76.26 -54.32 13.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.862 0.363 . . . . 0.0 111.11 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.722 HG21 HD11 ' B' ' 127' ' ' LEU . 20.1 t -49.7 -42.5 17.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.137 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.422 ' HB3' HD12 ' A' ' 35' ' ' ILE . 4.7 m-85 -77.85 -37.34 48.56 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.85 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -56.29 -47.78 79.76 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.499 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.614 HG22 ' HD2' ' A' ' 37' ' ' ARG . 19.5 mt -76.69 -49.4 24.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.833 0.349 . . . . 0.0 111.149 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 28.6 mt -53.81 -52.86 58.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.955 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.422 HD12 ' HB3' ' A' ' 31' ' ' PHE . 49.2 mt -63.59 -47.48 91.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.135 179.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 32.3 ttpt -62.84 -17.97 62.16 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.844 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.614 ' HD2' HG22 ' A' ' 33' ' ' ILE . 0.2 OUTLIER -82.53 -39.38 22.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.863 179.973 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 11.0 mtp180 -83.71 -48.99 9.57 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.866 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 3.7 mt-30 49.55 41.81 21.89 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.864 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 9.1 mm100 -125.13 116.29 21.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.915 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 25.4 pttt -171.6 167.44 6.57 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.928 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 4.6 pt -63.57 143.11 15.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.11 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 1.8 mpt_? -103.3 62.55 0.79 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.884 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.911 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.46 -0.256 . . . . 0.0 112.46 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 4.5 p -141.64 156.6 66.28 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.656 0.741 . . . . 0.0 110.875 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -171.99 0.53 Allowed 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.699 2.266 . . . . 0.0 112.361 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . -58.47 161.45 4.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.112 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 16.8 tp10 -56.91 110.82 0.88 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.872 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -117.65 141.09 48.78 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.89 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.41 177.44 8.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.875 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 108' ' ' ALA . . . . . 0.653 ' HB3' HG21 ' B' ' 112' ' ' THR . . . -138.74 169.09 18.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.076 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 109' ' ' SER . . . . . 0.678 ' O ' HG22 ' B' ' 112' ' ' THR . 0.3 OUTLIER -49.9 164.53 0.35 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.678 0.751 . . . . 0.0 110.834 -179.798 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -11.57 31.17 Favored 'Trans proline' 0 C--O 1.232 0.223 0 C-N-CA 122.693 2.262 . . . . 0.0 112.368 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 111' ' ' LEU . . . . . 0.467 ' O ' HD22 ' B' ' 111' ' ' LEU . 2.6 tm? -80.75 -36.05 32.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.937 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 112' ' ' THR . . . . . 0.678 HG22 ' O ' ' B' ' 109' ' ' SER . 6.4 t -49.13 -31.8 8.86 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.15 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.83 -50.88 64.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.803 -179.847 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 114' ' ' ILE . . . . . 0.582 ' O ' HG23 ' B' ' 118' ' ' VAL . 3.3 mp -58.9 -43.51 88.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.095 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.516 ' O ' HG23 ' B' ' 119' ' ' VAL . 13.1 mt -55.11 -53.77 31.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.117 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 11.7 t -57.47 -35.59 70.36 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.902 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -63.1 -58.65 6.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.089 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.582 HG23 ' O ' ' B' ' 114' ' ' ILE . 9.8 t -51.35 -51.0 25.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.155 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.706 HG12 HD11 ' B' ' 123' ' ' LEU . 93.6 t -48.63 -59.43 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.147 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . 0.48 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -50.13 -54.49 18.96 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.472 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 67.0 mt -58.48 -54.85 27.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.917 0.389 . . . . 0.0 111.16 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 122' ' ' LEU . . . . . 0.867 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.31 -59.94 3.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.897 179.894 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 123' ' ' LEU . . . . . 0.976 HD23 HG22 ' A' ' 26' ' ' VAL . 9.2 mt -43.12 -55.41 3.9 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.933 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 124' ' ' VAL . . . . . 0.48 HG23 ' O ' ' B' ' 120' ' ' GLY . 87.4 t -52.55 -51.62 32.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.104 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 72.5 t -61.38 -40.61 86.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.1 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 126' ' ' VAL . . . . . 0.987 HG22 HD23 ' A' ' 23' ' ' LEU . 43.1 t -51.19 -59.19 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.121 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 127' ' ' LEU . . . . . 0.722 HD11 HG21 ' A' ' 30' ' ' VAL . 45.4 mt -67.8 -46.15 72.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.972 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.69 -47.9 51.4 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.461 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.0 t -76.24 -54.19 13.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.895 0.379 . . . . 0.0 111.093 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 130' ' ' VAL . . . . . 0.721 HG21 HD11 ' A' ' 27' ' ' LEU . 20.2 t -49.7 -42.59 17.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.141 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . 0.439 ' HB3' HD12 ' B' ' 135' ' ' ILE . 4.6 m-85 -77.72 -37.03 50.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.879 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -56.04 -47.86 77.52 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.517 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 133' ' ' ILE . . . . . 0.627 HG22 ' HD2' ' B' ' 137' ' ' ARG . 18.2 mt -77.07 -49.25 23.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.826 0.346 . . . . 0.0 111.127 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 27.8 mt -53.57 -52.02 61.07 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.919 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.439 HD12 ' HB3' ' B' ' 131' ' ' PHE . 49.3 mt -64.85 -46.67 91.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.096 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 32.1 ttpt -63.36 -17.28 62.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.899 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 137' ' ' ARG . . . . . 0.627 ' HD2' HG22 ' B' ' 133' ' ' ILE . 0.2 OUTLIER -83.8 -38.83 20.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.908 179.961 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 11.1 mtp180 -84.38 -48.82 9.29 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.874 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 50.66 41.27 25.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.905 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 9.0 mm100 -126.68 115.7 19.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.935 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 25.1 pttt -169.32 176.8 5.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.865 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 142' ' ' ILE . . . . . 0.536 HD12 ' HB2' ' B' ' 144' ' ' LYS . 4.7 pt -55.57 148.87 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.142 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 2.2 mtt180 -97.1 77.13 2.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.827 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 144' ' ' LYS . . . . . 0.536 ' HB2' HD12 ' B' ' 142' ' ' ILE . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.934 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.454 -0.258 . . . . 0.0 112.454 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 26.5 t -173.8 72.46 0.36 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.604 0.716 . . . . 0.0 110.899 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 84.04 0.68 Allowed 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.666 2.244 . . . . 0.0 112.353 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -171.18 179.4 3.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.094 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -63.08 -177.18 0.16 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.857 -179.908 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -70.56 83.96 0.61 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.874 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 21.5 ttm-85 -105.68 130.36 53.71 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.924 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -137.0 157.95 45.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.09 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.607 ' O ' HG22 ' A' ' 12' ' ' THR . 0.3 OUTLIER -51.13 163.48 0.52 Allowed Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.705 0.764 . . . . 0.0 110.852 -179.763 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -11.96 31.91 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.648 2.232 . . . . 0.0 112.368 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.688 HD13 HG13 ' A' ' 15' ' ' ILE . 2.3 tm? -79.02 -26.26 43.24 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.916 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.607 HG22 ' O ' ' A' ' 9' ' ' SER . 13.6 t -50.71 -36.08 34.42 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.166 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -56.86 -52.52 64.79 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.866 -179.838 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.729 ' O ' HG23 ' A' ' 18' ' ' VAL . 4.1 mp -60.16 -40.4 83.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.097 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.688 HG13 HD13 ' A' ' 11' ' ' LEU . 44.7 mt -54.37 -55.84 12.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.184 179.88 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.8 t -58.64 -36.71 74.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.884 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -62.34 -57.16 12.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.069 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.729 HG23 ' O ' ' A' ' 14' ' ' ILE . 12.0 t -52.24 -51.09 34.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.148 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.68 HG12 HD11 ' A' ' 23' ' ' LEU . 94.9 t -48.79 -59.15 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.137 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.483 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -50.26 -54.72 18.59 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.492 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 92.5 mt -58.37 -54.83 27.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.861 0.362 . . . . 0.0 111.089 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.885 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.28 -59.81 3.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.933 179.922 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 1.038 HD23 HG22 ' B' ' 126' ' ' VAL . 9.4 mt -43.21 -55.36 4.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.873 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.483 HG23 ' O ' ' A' ' 20' ' ' GLY . 90.5 t -52.61 -51.6 33.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.112 179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 70.9 t -61.37 -40.56 86.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.108 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 1.027 HG22 HD23 ' B' ' 123' ' ' LEU . 43.0 t -51.25 -59.3 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.133 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.707 HD11 HG21 ' B' ' 130' ' ' VAL . 44.5 mt -68.01 -46.26 71.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.906 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.51 -47.52 51.33 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.49 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.5 t -76.74 -54.21 13.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.855 0.359 . . . . 0.0 111.12 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.686 HG21 HD11 ' B' ' 127' ' ' LEU . 20.1 t -49.73 -42.02 17.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.118 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 5.3 m-85 -78.28 -34.29 48.99 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.885 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -57.51 -46.89 91.5 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.509 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.497 HG22 ' CD ' ' A' ' 37' ' ' ARG . 17.6 mt -79.38 -45.48 23.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.848 0.356 . . . . 0.0 111.116 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 27.4 mt -57.84 -43.79 86.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.868 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 72.4 mt -71.28 -58.95 4.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.161 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 8.3 pttp -51.56 -28.06 12.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.937 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.497 ' CD ' HG22 ' A' ' 33' ' ' ILE . 49.5 mtp85 -77.75 -37.14 49.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.9 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 29.3 mtt180 -63.26 -28.35 69.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.878 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -174.36 138.23 0.54 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.947 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 18.3 pt20 -171.54 164.3 6.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.919 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 14.4 pttp -98.37 31.91 2.66 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.846 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.5 pp -148.59 178.24 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.118 179.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 6.3 ptm180 -121.93 141.28 51.46 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.921 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 6.5 tmtt? . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.908 179.904 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.286 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 24.1 t -174.11 72.87 0.34 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.605 0.716 . . . . 0.0 110.912 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.76 83.14 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.623 2.215 . . . . 0.0 112.341 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . -171.2 178.24 3.37 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.135 179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -64.17 -176.62 0.22 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.873 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -71.15 83.19 0.72 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.908 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 21.6 ttm-85 -105.69 128.81 53.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.846 -179.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 108' ' ' ALA . . . . . . . . . . . . . . . -139.78 158.37 44.21 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.131 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 109' ' ' SER . . . . . 0.594 ' O ' HG22 ' B' ' 112' ' ' THR . 0.3 OUTLIER -51.06 163.36 0.52 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.632 0.729 . . . . 0.0 110.872 -179.74 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -11.98 31.93 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.718 2.279 . . . . 0.0 112.314 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 111' ' ' LEU . . . . . 0.717 HD13 HG13 ' B' ' 115' ' ' ILE . 2.3 tm? -79.33 -26.35 42.18 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.95 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 112' ' ' THR . . . . . 0.594 HG22 ' O ' ' B' ' 109' ' ' SER . 13.1 t -50.77 -35.96 34.45 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.152 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -56.91 -52.52 64.86 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.867 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 114' ' ' ILE . . . . . 0.732 ' O ' HG23 ' B' ' 118' ' ' VAL . 4.1 mp -60.18 -40.41 83.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.118 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.717 HG13 HD13 ' B' ' 111' ' ' LEU . 42.7 mt -54.28 -55.96 12.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.122 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 7.7 t -58.78 -36.49 74.51 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.85 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -62.64 -57.0 12.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.082 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.732 HG23 ' O ' ' B' ' 114' ' ' ILE . 12.0 t -52.35 -51.09 35.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.127 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.689 HG12 HD11 ' B' ' 123' ' ' LEU . 95.5 t -48.89 -59.17 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.141 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . 0.48 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -50.2 -54.63 18.7 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.525 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 92.9 mt -58.4 -54.84 27.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.867 0.365 . . . . 0.0 111.158 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 122' ' ' LEU . . . . . 0.871 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.26 -59.87 3.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.945 179.877 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 123' ' ' LEU . . . . . 1.027 HD23 HG22 ' A' ' 26' ' ' VAL . 9.3 mt -43.08 -55.49 3.83 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.916 179.841 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 124' ' ' VAL . . . . . 0.48 HG23 ' O ' ' B' ' 120' ' ' GLY . 90.0 t -52.61 -51.51 34.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.13 179.87 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 69.9 t -61.48 -40.31 85.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.111 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 126' ' ' VAL . . . . . 1.038 HG22 HD23 ' A' ' 23' ' ' LEU . 43.1 t -51.4 -59.14 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.146 179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 127' ' ' LEU . . . . . 0.701 HD23 HD23 ' A' ' 27' ' ' LEU . 45.6 mt -68.02 -46.41 71.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.875 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.6 -47.29 52.42 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.467 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.6 t -76.83 -54.18 13.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.853 0.358 . . . . 0.0 111.159 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 130' ' ' VAL . . . . . 0.707 HG21 HD11 ' A' ' 27' ' ' LEU . 19.7 t -49.8 -41.92 17.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.118 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -78.4 -36.37 45.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.859 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -56.06 -46.38 85.03 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.506 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 18.4 mt -79.18 -49.9 19.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 120.889 0.376 . . . . 0.0 111.151 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 27.8 mt -53.1 -48.1 68.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.933 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 69.9 mt -68.92 -49.93 58.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.125 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 11.5 tttp -52.68 -30.53 32.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.899 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 54.2 mtp85 -80.2 -35.07 36.82 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.86 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 29.5 mtt180 -61.49 -25.58 67.34 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 12.4 pt20 -172.82 138.07 0.79 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.893 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 140' ' ' GLN . . . . . 0.417 ' OE1' HD11 ' B' ' 142' ' ' ILE . 18.0 pt20 -172.29 165.32 5.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.862 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 14.4 pttp -96.52 32.92 1.91 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.915 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 142' ' ' ILE . . . . . 0.417 HD11 ' OE1' ' B' ' 140' ' ' GLN . 2.5 pp -147.85 177.77 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.119 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 19.6 ttm-85 -122.77 141.38 51.88 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.82 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 6.5 tmtt? . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.966 179.923 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.381 0 N-CA-C 112.531 -0.228 . . . . 0.0 112.531 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 79.3 m -142.5 71.14 21.17 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-O 121.645 0.736 . . . . 0.0 110.89 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.77 154.87 67.18 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.692 2.261 . . . . 0.0 112.333 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -167.5 163.8 14.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.092 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -70.2 120.2 15.53 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.881 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 41.6 tt0 -154.91 150.03 26.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.916 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -78.07 132.22 37.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.915 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -137.75 169.89 17.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.031 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.662 ' O ' HG22 ' A' ' 12' ' ' THR . 0.3 OUTLIER -50.71 163.92 0.45 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.668 0.747 . . . . 0.0 110.866 -179.801 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 -11.94 31.9 Favored 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.63 2.22 . . . . 0.0 112.346 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.611 HD13 HG12 ' A' ' 15' ' ' ILE . 2.6 tm? -79.9 -30.38 40.1 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.931 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.662 HG22 ' O ' ' A' ' 9' ' ' SER . 8.3 t -51.14 -34.78 32.6 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.156 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -59.46 -49.99 75.65 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.906 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.703 ' O ' HG23 ' A' ' 18' ' ' VAL . 60.3 mt -61.14 -41.21 88.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.108 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.611 HG12 HD13 ' A' ' 11' ' ' LEU . 26.6 mm -55.14 -54.9 19.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.094 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -58.15 -37.36 74.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.888 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -61.74 -57.82 10.41 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.092 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.703 HG23 ' O ' ' A' ' 14' ' ' ILE . 11.3 t -51.59 -51.21 27.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.122 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.723 HG12 HD11 ' A' ' 23' ' ' LEU . 84.0 t -48.62 -59.96 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.161 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.477 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -49.54 -54.71 15.74 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.475 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 96.2 mt -58.35 -54.81 27.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.884 0.373 . . . . 0.0 111.183 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.87 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.45 -59.56 3.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.871 179.907 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.992 HD23 HG22 ' B' ' 126' ' ' VAL . 8.8 mt -43.19 -55.55 3.89 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.925 179.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.477 HG23 ' O ' ' A' ' 20' ' ' GLY . 89.7 t -52.48 -51.74 31.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.144 179.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 73.4 t -61.44 -39.87 84.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.158 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 1.001 HG22 HD23 ' B' ' 123' ' ' LEU . 46.0 t -51.64 -58.69 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.131 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.726 HD23 HD23 ' B' ' 127' ' ' LEU . 56.6 mt -67.25 -47.6 70.25 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.962 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.3 -47.46 50.31 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.476 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.9 t -75.99 -54.4 13.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.904 0.383 . . . . 0.0 111.166 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.795 HG21 HD11 ' B' ' 127' ' ' LEU . 19.4 t -49.46 -43.29 17.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.13 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.404 ' HB3' HD12 ' A' ' 35' ' ' ILE . 7.5 m-85 -77.2 -41.53 41.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.879 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -53.35 -48.16 60.48 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.477 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 38.4 mt -74.89 -50.91 23.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.859 0.361 . . . . 0.0 111.115 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 23.2 mt -51.25 -57.64 8.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.937 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.404 HD12 ' HB3' ' A' ' 31' ' ' PHE . 14.4 mt -59.81 -48.48 87.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.126 179.838 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 14.8 tttm -50.48 -52.88 34.2 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.914 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 46.3 mtp85 -59.12 -38.68 80.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.91 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 48.8 mtp180 -65.16 -47.71 76.07 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.866 -179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 67.4 mt-30 -55.31 174.74 0.08 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.892 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -90.7 107.95 19.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.949 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 31.4 mttt -140.03 168.51 19.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.875 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 70.4 mt -136.39 126.31 39.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.115 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 13.1 mmt-85 -70.11 168.83 14.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.918 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 1.6 mtpp . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.894 179.97 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.372 0 N-CA-C 112.514 -0.234 . . . . 0.0 112.514 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 79.1 m -142.48 71.31 21.19 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.623 0.725 . . . . 0.0 110.864 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 154.6 67.39 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.69 2.26 . . . . 0.0 112.309 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . -167.58 164.53 14.69 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.076 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -69.38 121.46 16.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.908 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 41.5 tt0 -152.29 149.43 28.67 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.914 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -79.51 132.65 36.39 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.839 -179.858 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 108' ' ' ALA . . . . . 0.49 ' HB3' HG21 ' B' ' 112' ' ' THR . . . -136.46 169.25 17.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.089 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 109' ' ' SER . . . . . 0.673 ' O ' HG22 ' B' ' 112' ' ' THR . 0.3 OUTLIER -50.67 163.66 0.46 Allowed Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.701 0.762 . . . . 0.0 110.841 -179.8 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -11.66 31.29 Favored 'Trans proline' 0 C--O 1.233 0.231 0 C-N-CA 122.645 2.23 . . . . 0.0 112.35 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 111' ' ' LEU . . . . . 0.619 HD13 HG12 ' B' ' 115' ' ' ILE . 2.6 tm? -81.58 -30.71 32.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.882 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 112' ' ' THR . . . . . 0.673 HG22 ' O ' ' B' ' 109' ' ' SER . 6.8 t -51.29 -34.55 33.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.185 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -59.43 -49.61 77.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.892 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 114' ' ' ILE . . . . . 0.716 ' O ' HG23 ' B' ' 118' ' ' VAL . 60.2 mt -61.74 -41.63 91.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.164 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.619 HG12 HD13 ' B' ' 111' ' ' LEU . 26.5 mm -54.48 -55.58 14.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.134 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -58.38 -36.93 74.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.854 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -62.15 -57.66 10.7 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.066 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.716 HG23 ' O ' ' B' ' 114' ' ' ILE . 11.6 t -51.7 -51.34 27.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.181 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.712 HG12 HD11 ' B' ' 123' ' ' LEU . 89.1 t -48.6 -59.47 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.13 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . 0.473 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -50.05 -54.88 17.09 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.484 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 96.3 mt -58.28 -54.87 26.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.908 0.385 . . . . 0.0 111.128 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 122' ' ' LEU . . . . . 0.87 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.3 -59.69 3.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.907 179.93 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 123' ' ' LEU . . . . . 1.001 HD23 HG22 ' A' ' 26' ' ' VAL . 9.3 mt -43.22 -55.71 3.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.914 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 124' ' ' VAL . . . . . 0.473 HG23 ' O ' ' B' ' 120' ' ' GLY . 90.4 t -52.33 -51.83 29.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.087 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 74.0 t -61.19 -40.74 86.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.104 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 126' ' ' VAL . . . . . 0.992 HG22 HD23 ' A' ' 23' ' ' LEU . 45.4 t -50.89 -59.49 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.132 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 127' ' ' LEU . . . . . 0.795 HD11 HG21 ' A' ' 30' ' ' VAL . 49.0 mt -67.43 -46.67 72.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.924 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -50.89 -47.4 47.85 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.486 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 58.4 t -77.77 -54.66 12.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.895 0.379 . . . . 0.0 111.156 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 130' ' ' VAL . . . . . 0.659 HG21 HD11 ' A' ' 27' ' ' LEU . 20.4 t -49.31 -39.15 12.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.125 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . 0.5 ' HB3' HD12 ' B' ' 135' ' ' ILE . 3.5 m-30 -76.32 -42.76 43.97 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.874 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -51.74 -50.21 44.26 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.509 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 40.6 mt -73.23 -52.06 23.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.907 0.384 . . . . 0.0 111.131 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 24.5 mt -50.52 -61.35 2.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.932 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.5 HD12 ' HB3' ' B' ' 131' ' ' PHE . 13.6 mt -56.59 -46.46 82.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.152 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 14.6 tttm -51.08 -55.97 14.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.907 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 46.6 mtp85 -53.63 -39.8 65.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.846 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 47.8 mtp180 -64.21 -45.95 86.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.873 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 67.6 mt-30 -55.85 176.42 0.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.9 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -89.42 106.95 18.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.883 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 31.0 mttt -139.73 166.96 23.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.892 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 142' ' ' ILE . . . . . . . . . . . . . 70.0 mt -138.43 125.02 26.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.075 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 13.5 mmt-85 -71.65 170.23 13.9 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.925 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 1.4 mppp? . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.901 179.985 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 112.522 -0.231 . . . . 0.0 112.522 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 1.2 m -53.53 160.75 1.77 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.598 0.713 . . . . 0.0 110.864 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 165.45 30.99 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.664 2.242 . . . . 0.0 112.309 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -46.15 105.51 0.06 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.128 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -91.89 160.26 15.37 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.852 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 14.6 tt0 -56.96 157.81 5.42 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.912 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.79 -29.25 29.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.899 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -156.89 165.17 36.96 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.062 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.534 ' O ' HG22 ' A' ' 12' ' ' THR . 0.3 OUTLIER -51.77 162.54 0.74 Allowed Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.69 0.757 . . . . 0.0 110.862 -179.807 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 -14.81 36.37 Favored 'Trans proline' 0 C--O 1.232 0.203 0 C-N-CA 122.676 2.251 . . . . 0.0 112.349 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.69 HD13 HG13 ' A' ' 15' ' ' ILE . 2.3 tm? -74.19 -18.15 60.8 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.937 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.534 HG22 ' O ' ' A' ' 9' ' ' SER . 8.9 t -48.6 -39.95 25.67 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.121 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -51.62 -53.9 33.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.861 -179.849 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.72 ' O ' HG23 ' A' ' 18' ' ' VAL . 58.9 mt -60.31 -41.25 86.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.139 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.69 HG13 HD13 ' A' ' 11' ' ' LEU . 26.2 mt -52.72 -57.75 3.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.121 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 33.5 t -57.46 -37.55 73.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.885 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -61.01 -57.79 11.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.077 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.72 HG23 ' O ' ' A' ' 14' ' ' ILE . 11.3 t -51.86 -50.69 32.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.101 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.75 HG12 HD11 ' A' ' 23' ' ' LEU . 86.6 t -48.85 -60.23 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.161 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.489 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -49.49 -54.28 17.19 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.465 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 39.0 mt -58.52 -54.72 29.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.862 0.363 . . . . 0.0 111.156 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.872 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.71 -59.49 3.76 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.892 179.898 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.985 HD23 HG22 ' B' ' 126' ' ' VAL . 8.5 mt -43.23 -55.35 4.03 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.919 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.489 HG23 ' O ' ' A' ' 20' ' ' GLY . 91.8 t -52.46 -51.74 31.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.127 179.852 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 74.8 t -61.62 -39.84 84.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.171 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.989 HG22 HD23 ' B' ' 123' ' ' LEU . 46.5 t -51.62 -59.51 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.13 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.72 HD11 HG21 ' B' ' 130' ' ' VAL . 57.0 mt -66.39 -47.81 72.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.876 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.18 -47.58 49.31 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.452 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.4 t -76.32 -54.59 13.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.825 0.345 . . . . 0.0 111.141 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.731 HG21 HD11 ' B' ' 127' ' ' LEU . 19.8 t -49.34 -42.33 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.141 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.402 ' HB3' HD12 ' A' ' 35' ' ' ILE . 4.9 m-85 -77.05 -44.39 30.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -52.35 -48.61 53.81 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.458 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 42.2 mt -73.03 -52.06 23.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.88 0.371 . . . . 0.0 111.118 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 22.8 mt -51.21 -60.78 2.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.876 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.402 HD12 ' HB3' ' A' ' 31' ' ' PHE . 11.9 mt -55.56 -49.07 76.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.16 179.828 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 8.0 tmtt? -58.13 -25.99 62.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 32.4 mtp180 -81.65 -31.57 32.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.04 -47.97 82.35 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.879 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -59.79 123.48 17.12 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.914 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -175.37 172.37 2.7 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.861 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 21.2 mttm -85.81 139.88 30.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.852 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.441 HD13 ' N ' ' A' ' 43' ' ' ARG . 0.0 OUTLIER -154.25 144.83 13.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.111 179.82 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.441 ' N ' HD13 ' A' ' 42' ' ' ILE . 44.4 mtp180 -107.19 112.54 25.47 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.854 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 4.4 tppp? . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.862 179.942 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.455 -0.258 . . . . 0.0 112.455 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 1.2 m -54.58 160.71 2.53 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.582 0.706 . . . . 0.0 110.877 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 160.43 49.72 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.687 2.258 . . . . 0.0 112.322 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . 45.98 84.87 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.117 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -100.12 159.13 15.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.903 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 14.1 tt0 -57.64 161.17 3.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.88 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.87 -26.61 40.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.873 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 108' ' ' ALA . . . . . . . . . . . . . . . -155.32 167.64 29.69 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.078 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 109' ' ' SER . . . . . 0.525 ' O ' HG22 ' B' ' 112' ' ' THR . 0.3 OUTLIER -51.52 162.58 0.68 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.685 0.755 . . . . 0.0 110.836 -179.811 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 -15.09 37.1 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.701 2.267 . . . . 0.0 112.348 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 111' ' ' LEU . . . . . 0.701 ' CD2' HD12 ' B' ' 114' ' ' ILE . 2.3 tm? -74.46 -18.45 60.63 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.947 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 112' ' ' THR . . . . . 0.525 HG22 ' O ' ' B' ' 109' ' ' SER . 10.1 t -48.58 -39.81 25.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.169 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -51.75 -53.59 37.91 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.869 -179.841 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 114' ' ' ILE . . . . . 0.706 ' O ' HG23 ' B' ' 118' ' ' VAL . 59.2 mt -60.49 -41.29 87.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.085 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.674 HG13 HD13 ' B' ' 111' ' ' LEU . 25.4 mt -53.12 -57.73 4.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.12 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 33.6 t -57.26 -37.41 72.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.846 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -60.99 -58.02 10.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.09 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.706 HG23 ' O ' ' B' ' 114' ' ' ILE . 11.3 t -51.86 -50.7 32.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.155 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.74 HG12 HD11 ' B' ' 123' ' ' LEU . 87.7 t -48.82 -60.26 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.134 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . 0.49 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -49.44 -54.25 17.13 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.488 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 38.8 mt -58.56 -54.85 27.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.857 0.361 . . . . 0.0 111.135 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 122' ' ' LEU . . . . . 0.874 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.57 -59.43 3.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.945 179.884 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 123' ' ' LEU . . . . . 0.989 HD23 HG22 ' A' ' 26' ' ' VAL . 8.5 mt -43.28 -55.35 4.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.942 179.883 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 124' ' ' VAL . . . . . 0.49 HG23 ' O ' ' B' ' 120' ' ' GLY . 92.1 t -52.39 -51.81 30.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.135 179.823 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 74.8 t -61.61 -39.83 84.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.12 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 126' ' ' VAL . . . . . 0.985 HG22 HD23 ' A' ' 23' ' ' LEU . 46.2 t -51.67 -59.58 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.141 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 127' ' ' LEU . . . . . 0.731 HD11 HG21 ' A' ' 30' ' ' VAL . 55.9 mt -66.31 -47.81 72.34 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.937 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.21 -47.52 49.61 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.47 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 55.9 t -76.34 -54.63 13.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.848 0.356 . . . . 0.0 111.142 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 130' ' ' VAL . . . . . 0.72 HG21 HD11 ' A' ' 27' ' ' LEU . 20.2 t -49.28 -42.37 15.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.132 179.883 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . 0.414 ' HB3' HD12 ' B' ' 135' ' ' ILE . 4.8 m-85 -76.95 -44.57 30.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.933 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -52.28 -48.55 53.51 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.489 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 42.2 mt -73.02 -52.1 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.846 0.355 . . . . 0.0 111.18 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 23.0 mt -51.17 -60.87 2.64 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.919 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.414 HD12 ' HB3' ' B' ' 131' ' ' PHE . 11.8 mt -55.42 -49.52 72.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.129 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 8.0 tmtt? -57.7 -26.18 61.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.89 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 32.1 mtp180 -81.41 -31.69 33.08 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.892 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.6 -47.9 83.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.889 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -60.49 123.65 17.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.88 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -175.4 174.18 2.38 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.934 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 21.2 mttm -84.14 141.15 31.29 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.875 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 142' ' ' ILE . . . . . 0.461 HD13 ' N ' ' B' ' 143' ' ' ARG . 0.0 OUTLIER -153.5 145.39 14.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.121 179.876 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . 0.461 ' N ' HD13 ' B' ' 142' ' ' ILE . 23.5 mtm180 -106.92 113.45 26.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.882 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 4.4 tppp? . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.91 179.956 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 N-CA-C 112.511 -0.236 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 36.5 m -132.43 72.66 77.98 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.624 0.726 . . . . 0.0 110.886 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.71 -177.5 1.89 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.663 2.242 . . . . 0.0 112.403 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -78.56 -167.13 0.99 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.089 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -81.91 109.1 15.96 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.88 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 6.9 tp60 -71.23 142.74 50.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.896 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 20.8 ptt180 -69.21 146.94 51.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.41 ' HB3' HG21 ' A' ' 12' ' ' THR . . . -126.29 166.82 16.43 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.141 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.622 ' O ' HG22 ' A' ' 12' ' ' THR . 0.3 OUTLIER -49.39 165.13 0.29 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.646 0.736 . . . . 0.0 110.895 -179.795 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.72 -11.54 31.09 Favored 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.702 2.268 . . . . 0.0 112.355 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.424 HD13 ' C ' ' A' ' 11' ' ' LEU . 2.8 tm? -77.24 -36.45 54.54 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.878 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.622 HG22 ' O ' ' A' ' 9' ' ' SER . 6.7 t -48.7 -33.2 9.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.125 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 1.5 t -64.98 -49.4 70.42 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.933 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.49 ' O ' HG23 ' A' ' 18' ' ' VAL . 56.2 mt -58.77 -46.0 90.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.088 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.588 ' O ' HG23 ' A' ' 19' ' ' VAL . 17.0 mt -54.55 -51.44 50.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.098 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 1.9 t -57.14 -37.86 72.66 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.887 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -62.02 -59.57 4.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.096 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 14' ' ' ILE . 11.4 t -50.81 -50.87 22.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.133 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.69 HG12 HD11 ' A' ' 23' ' ' LEU . 96.0 t -48.4 -59.46 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.087 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.48 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -50.44 -54.52 20.13 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.538 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 99.0 mt -58.41 -54.82 27.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.826 0.346 . . . . 0.0 111.124 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.891 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.54 -59.44 3.76 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.902 179.921 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 1.017 HD23 HG22 ' B' ' 126' ' ' VAL . 9.8 mt -43.31 -55.33 4.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.884 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 20' ' ' GLY . 89.5 t -52.6 -52.03 30.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.114 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 71.9 t -61.05 -40.21 84.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.126 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 1.012 HG22 HD23 ' B' ' 123' ' ' LEU . 44.5 t -51.64 -59.29 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.101 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.745 HD11 HG21 ' B' ' 130' ' ' VAL . 48.6 mt -67.58 -46.66 71.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.893 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.6 -47.57 51.73 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.451 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -76.41 -54.16 13.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.896 0.379 . . . . 0.0 111.148 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.739 HG21 HD11 ' B' ' 127' ' ' LEU . 19.8 t -49.79 -42.65 18.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.145 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.411 ' HB3' HD12 ' A' ' 35' ' ' ILE . 4.7 m-85 -77.44 -40.58 42.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.902 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -53.48 -48.4 60.5 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.49 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 28.8 mt -75.56 -50.47 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.849 0.357 . . . . 0.0 111.11 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 22.4 mt -51.28 -56.71 11.55 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.947 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.411 HD12 ' HB3' ' A' ' 31' ' ' PHE . 18.2 mt -60.96 -49.34 85.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.116 179.822 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 30.7 ttpt -54.98 -29.44 57.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.854 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 56.8 mtp180 -78.04 -37.0 47.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.879 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -67.96 -42.07 81.47 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.841 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -76.26 75.68 3.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.932 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 7.4 mm-40 -118.41 176.31 5.3 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.932 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 16.2 mmtp -108.19 140.1 41.91 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.929 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.2 tt -129.02 148.75 33.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.141 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 65.5 mtt180 -95.25 176.44 6.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.887 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 10.6 ptpp? . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.914 179.971 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 36.2 m -131.56 72.87 80.1 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.641 0.734 . . . . 0.0 110.88 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 -174.41 0.91 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.695 2.263 . . . . 0.0 112.342 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . -75.09 -82.38 0.07 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.09 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -78.32 112.13 15.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.865 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 6.9 tp60 -67.8 144.92 55.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.918 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 20.9 ptt180 -66.65 149.5 50.41 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 108' ' ' ALA . . . . . 0.649 ' HB1' ' CG2' ' B' ' 112' ' ' THR . . . -123.18 159.69 28.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.05 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 109' ' ' SER . . . . . 0.412 ' CB ' ' HD2' ' B' ' 110' ' ' PRO . 0.3 OUTLIER -48.51 165.71 0.24 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.668 0.747 . . . . 0.0 110.836 -179.791 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 110' ' ' PRO . . . . . 0.412 ' HD2' ' CB ' ' B' ' 109' ' ' SER . 53.9 Cg_endo -69.75 -17.23 37.75 Favored 'Trans proline' 0 C--O 1.232 0.201 0 C-N-CA 122.69 2.26 . . . . 0.0 112.326 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 111' ' ' LEU . . . . . 0.468 HD13 ' C ' ' B' ' 111' ' ' LEU . 2.9 tm? -88.52 -45.34 9.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.903 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 112' ' ' THR . . . . . 0.649 ' CG2' ' HB1' ' B' ' 108' ' ' ALA . 1.4 t -69.54 -30.58 68.42 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.167 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 1.8 t -65.97 -50.16 65.3 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.886 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 114' ' ' ILE . . . . . 0.467 ' O ' HG23 ' B' ' 118' ' ' VAL . 71.5 mt -62.34 -49.0 85.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.13 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.604 ' O ' HG23 ' B' ' 119' ' ' VAL . 39.6 mt -51.79 -50.39 32.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.143 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 1.9 t -59.93 -37.5 79.68 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.872 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -61.25 -58.29 8.88 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.08 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.467 HG23 ' O ' ' B' ' 114' ' ' ILE . 11.0 t -51.64 -51.05 28.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.112 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.685 HG12 HD11 ' B' ' 123' ' ' LEU . 91.1 t -48.37 -59.35 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.141 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . 0.468 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -50.51 -54.68 19.77 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.522 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 98.9 mt -58.23 -54.88 26.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.844 0.355 . . . . 0.0 111.103 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 122' ' ' LEU . . . . . 0.89 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.37 -59.55 3.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.937 179.877 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 123' ' ' LEU . . . . . 1.012 HD23 HG22 ' A' ' 26' ' ' VAL . 9.6 mt -43.28 -55.32 4.09 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.925 179.896 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 124' ' ' VAL . . . . . 0.468 HG23 ' O ' ' B' ' 120' ' ' GLY . 90.4 t -52.74 -51.96 31.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.119 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 72.7 t -60.94 -40.25 84.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.129 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 126' ' ' VAL . . . . . 1.017 HG22 HD23 ' A' ' 23' ' ' LEU . 44.9 t -51.47 -59.3 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.141 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 127' ' ' LEU . . . . . 0.742 HD23 HD23 ' A' ' 27' ' ' LEU . 49.7 mt -67.59 -46.88 71.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.907 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.52 -47.53 51.33 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.453 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.0 t -76.24 -54.37 13.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.892 0.377 . . . . 0.0 111.153 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 130' ' ' VAL . . . . . 0.745 HG21 HD11 ' A' ' 27' ' ' LEU . 19.7 t -49.69 -42.71 17.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.114 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . 0.423 ' HB3' HD12 ' B' ' 135' ' ' ILE . 4.8 m-85 -77.41 -41.04 41.41 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.864 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -53.27 -48.43 59.45 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.486 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 133' ' ' ILE . . . . . 0.433 HG22 ' CD ' ' B' ' 137' ' ' ARG . 30.1 mt -75.25 -50.37 24.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.827 0.346 . . . . 0.0 111.117 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 21.9 mt -51.53 -57.42 9.11 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.894 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.423 HD12 ' HB3' ' B' ' 131' ' ' PHE . 17.2 mt -59.94 -50.01 81.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.115 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 31.0 ttpt -55.82 -28.02 54.2 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.897 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 137' ' ' ARG . . . . . 0.433 ' CD ' HG22 ' B' ' 133' ' ' ILE . 55.3 mtp180 -79.68 -33.55 41.06 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.883 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 1.2 mtt-85 -57.56 -46.13 84.3 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.879 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -91.83 43.46 1.14 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.944 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 9.9 mm-40 -152.32 -179.63 7.72 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.887 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 15.2 mmtp -107.09 129.86 54.76 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.9 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 142' ' ' ILE . . . . . . . . . . . . . 21.5 tt -135.96 149.34 27.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.133 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 66.5 mtt180 -96.5 179.34 5.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.897 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 10.6 ptpp? . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.909 179.957 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 N-CA-C 112.453 -0.259 . . . . 0.0 112.453 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 4.8 t -154.99 68.27 5.43 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.629 0.728 . . . . 0.0 110.901 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 -174.06 0.83 Allowed 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.688 2.258 . . . . 0.0 112.31 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -104.15 150.69 24.12 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.097 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 13.0 tt0 -59.41 146.46 39.96 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.867 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 34.6 mm-40 -100.53 39.24 1.39 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.912 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 3.6 tpp85 -102.94 149.92 24.05 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.886 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.613 ' HB3' HG21 ' A' ' 12' ' ' THR . . . -150.71 170.97 17.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.104 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.667 ' O ' HG22 ' A' ' 12' ' ' THR . 0.3 OUTLIER -50.32 164.57 0.38 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.691 0.758 . . . . 0.0 110.873 -179.803 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -11.74 31.51 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 122.707 2.272 . . . . 0.0 112.347 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.435 HD13 ' C ' ' A' ' 11' ' ' LEU . 2.9 tm? -80.7 -36.46 32.23 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.916 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.667 HG22 ' O ' ' A' ' 9' ' ' SER . 6.3 t -48.45 -32.22 7.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.169 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -64.69 -48.09 75.96 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.884 -179.877 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.645 ' O ' HG23 ' A' ' 18' ' ' VAL . 53.6 mt -61.35 -45.6 98.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.144 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.538 ' O ' HG23 ' A' ' 19' ' ' VAL . 10.9 mt -53.45 -53.86 21.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.144 179.857 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 43.6 t -57.62 -37.44 73.28 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.853 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -62.79 -57.96 9.1 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.076 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.645 HG23 ' O ' ' A' ' 14' ' ' ILE . 9.5 t -51.36 -51.62 23.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.159 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.673 HG12 HD11 ' A' ' 23' ' ' LEU . 99.4 t -48.48 -59.04 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.105 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.475 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -50.23 -54.81 18.12 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.486 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 55.1 mt -58.43 -54.89 26.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.856 0.36 . . . . 0.0 111.124 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.863 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.1 -59.83 3.31 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.948 179.884 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 1.001 HD23 HG22 ' B' ' 126' ' ' VAL . 9.6 mt -43.29 -55.65 3.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.935 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.475 HG23 ' O ' ' A' ' 20' ' ' GLY . 88.4 t -52.47 -51.14 35.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.142 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 69.8 t -61.6 -40.65 87.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.082 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 1.012 HG22 HD23 ' B' ' 123' ' ' LEU . 41.8 t -51.37 -58.89 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.136 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.74 HD23 HD23 ' B' ' 127' ' ' LEU . 45.9 mt -68.47 -46.16 70.51 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.912 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.79 -47.62 52.65 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.477 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.7 t -76.11 -54.32 13.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.918 0.389 . . . . 0.0 111.169 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.704 HG21 HD11 ' B' ' 127' ' ' LEU . 20.0 t -49.8 -43.01 18.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.114 179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.423 ' HB3' HD12 ' A' ' 35' ' ' ILE . 4.8 m-85 -77.61 -41.5 38.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.902 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -53.28 -47.36 61.95 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.489 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 22.3 mt -76.04 -51.37 20.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.833 0.349 . . . . 0.0 111.141 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 23.7 mt -51.0 -55.92 15.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.903 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.423 HD12 ' HB3' ' A' ' 31' ' ' PHE . 18.3 mt -61.71 -48.48 88.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.116 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 3.9 tmtt? -51.13 -45.3 61.58 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.886 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 43.1 mtp85 -63.9 -38.75 92.24 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.903 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 65.0 mtp85 -68.54 -43.77 75.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.856 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 13.8 mm100 -57.52 -179.51 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.9 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -70.3 176.31 4.04 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.896 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 4.6 mmmm -115.84 65.45 0.7 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.93 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 32.3 mm -91.88 122.49 43.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.175 179.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 71.0 mtm180 -108.01 69.04 0.72 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.886 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.975 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.484 -0.246 . . . . 0.0 112.484 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 4.8 t -155.02 69.13 5.59 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.633 0.73 . . . . 0.0 110.848 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -175.81 1.27 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.652 2.235 . . . . 0.0 112.357 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . -106.29 150.67 25.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.113 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -60.91 150.36 33.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.894 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 37.2 mm-40 -95.79 37.69 1.2 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.943 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 2.9 tpp85 -105.23 -78.67 0.57 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.852 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 108' ' ' ALA . . . . . 0.686 ' HB3' HG21 ' B' ' 112' ' ' THR . . . -141.07 173.18 11.73 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.128 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 109' ' ' SER . . . . . 0.675 ' O ' HG22 ' B' ' 112' ' ' THR . 0.3 OUTLIER -49.51 164.34 0.33 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.654 0.74 . . . . 0.0 110.849 -179.756 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -11.61 31.18 Favored 'Trans proline' 0 C--O 1.232 0.216 0 C-N-CA 122.685 2.256 . . . . 0.0 112.329 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 111' ' ' LEU . . . . . 0.451 HD13 ' C ' ' B' ' 111' ' ' LEU . 3.0 tm? -81.84 -36.61 28.09 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.929 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 112' ' ' THR . . . . . 0.686 HG21 ' HB3' ' B' ' 108' ' ' ALA . 6.0 t -48.62 -31.86 7.31 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.134 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -65.12 -47.71 76.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.83 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 114' ' ' ILE . . . . . 0.661 ' O ' HG23 ' B' ' 118' ' ' VAL . 52.6 mt -61.68 -45.66 98.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.099 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.538 ' O ' HG23 ' B' ' 119' ' ' VAL . 10.9 mt -53.53 -54.04 21.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.147 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 43.5 t -57.52 -37.5 73.13 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.852 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -62.81 -57.88 9.37 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.101 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.661 HG23 ' O ' ' B' ' 114' ' ' ILE . 9.3 t -51.54 -51.51 25.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.17 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.68 HG12 HD11 ' B' ' 123' ' ' LEU . 98.9 t -48.51 -59.04 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.129 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . 0.477 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -50.29 -54.8 18.39 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.493 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 55.5 mt -58.46 -54.88 27.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.865 0.364 . . . . 0.0 111.119 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 122' ' ' LEU . . . . . 0.877 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.1 -59.85 3.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.897 179.903 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 123' ' ' LEU . . . . . 1.012 HD23 HG22 ' A' ' 26' ' ' VAL . 9.7 mt -43.26 -55.77 3.84 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 124' ' ' VAL . . . . . 0.477 HG23 ' O ' ' B' ' 120' ' ' GLY . 89.3 t -52.43 -51.21 34.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.173 179.82 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 69.2 t -61.48 -40.56 86.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.161 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 126' ' ' VAL . . . . . 1.001 HG22 HD23 ' A' ' 23' ' ' LEU . 42.3 t -51.5 -59.18 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.092 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 127' ' ' LEU . . . . . 0.74 HD23 HD23 ' A' ' 27' ' ' LEU . 45.2 mt -68.14 -46.26 71.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.916 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.56 -47.65 51.29 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.507 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 56.0 t -76.37 -54.25 13.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.845 0.355 . . . . 0.0 111.077 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 130' ' ' VAL . . . . . 0.705 HG21 HD11 ' A' ' 27' ' ' LEU . 20.2 t -49.8 -42.72 18.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.114 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . 0.404 ' HB3' HD12 ' B' ' 135' ' ' ILE . 4.8 m-85 -77.77 -41.96 35.7 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.859 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -52.93 -47.16 60.08 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.491 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 22.6 mt -76.16 -51.55 19.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.884 0.373 . . . . 0.0 111.141 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 134' ' ' LEU . . . . . 0.409 HD23 ' HA ' ' B' ' 134' ' ' LEU . 23.2 mt -50.8 -55.79 15.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.861 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.404 HD12 ' HB3' ' B' ' 131' ' ' PHE . 17.4 mt -61.87 -48.85 86.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.17 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 3.8 tmtt? -51.2 -44.51 61.59 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.91 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 45.4 mtp85 -64.89 -38.37 90.74 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.907 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 65.0 mtp85 -67.57 -48.03 68.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.863 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 14.1 mm100 -62.02 176.03 0.62 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.938 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -75.32 177.38 6.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.864 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 3.6 mmmm -111.07 47.79 0.97 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.917 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 142' ' ' ILE . . . . . . . . . . . . . 30.5 mm -111.11 123.17 66.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.088 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -107.48 70.46 0.78 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.877 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.871 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.476 -0.249 . . . . 0.0 112.476 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 1.8 m -87.25 160.53 48.45 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.576 0.703 . . . . 0.0 110.896 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 78.59 1.01 Allowed 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.691 2.261 . . . . 0.0 112.324 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -134.53 93.89 3.12 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.142 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -57.97 118.63 5.59 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.881 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -98.19 -167.1 1.46 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.872 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -61.67 -166.0 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.831 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.573 ' HB3' HG21 ' A' ' 12' ' ' THR . . . -127.85 164.86 21.3 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.13 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.675 ' O ' HG22 ' A' ' 12' ' ' THR . 0.3 OUTLIER -50.52 164.21 0.42 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.689 0.757 . . . . 0.0 110.832 -179.758 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -11.93 31.81 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.681 2.254 . . . . 0.0 112.366 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.447 HD13 ' C ' ' A' ' 11' ' ' LEU . 3.0 tm? -81.08 -33.63 33.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.934 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.675 HG22 ' O ' ' A' ' 9' ' ' SER . 6.6 t -49.06 -31.65 8.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.093 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 1.3 t -62.64 -53.26 57.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.844 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.634 ' O ' HG23 ' A' ' 18' ' ' VAL . 3.7 mp -59.05 -43.16 88.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.123 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.554 ' O ' HG23 ' A' ' 19' ' ' VAL . 4.0 mt -53.77 -53.1 28.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.125 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.405 ' N ' HG22 ' A' ' 15' ' ' ILE . 3.5 t -58.74 -37.43 76.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.872 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -61.8 -57.84 10.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.115 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.634 HG23 ' O ' ' A' ' 14' ' ' ILE . 8.7 t -51.78 -51.07 29.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.16 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.697 HG12 HD11 ' A' ' 23' ' ' LEU . 91.3 t -48.65 -59.48 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.121 179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.47 ' O ' HG23 ' A' ' 24' ' ' VAL . . . -50.05 -54.55 18.41 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.508 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 90.4 mt -58.47 -54.71 29.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.832 0.349 . . . . 0.0 111.111 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.876 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.5 OUTLIER -49.46 -59.7 3.51 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.937 179.908 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 1.025 HD23 HG22 ' B' ' 126' ' ' VAL . 9.0 mt -43.26 -55.37 4.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.937 179.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.47 HG23 ' O ' ' A' ' 20' ' ' GLY . 86.9 t -52.52 -51.61 32.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.17 179.809 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 73.6 t -61.47 -40.28 85.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.169 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 1.026 HG22 HD23 ' B' ' 123' ' ' LEU . 44.4 t -51.5 -59.0 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.124 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.73 HD11 HG21 ' B' ' 130' ' ' VAL . 48.8 mt -67.7 -46.76 71.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.941 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.54 -47.22 52.28 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.52 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 56.3 t -76.6 -54.3 13.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.913 0.387 . . . . 0.0 111.122 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.727 HG21 HD11 ' B' ' 127' ' ' LEU . 19.9 t -49.78 -42.45 18.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.116 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.41 ' HB3' HD12 ' A' ' 35' ' ' ILE . 4.8 m-85 -77.57 -43.19 32.58 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.845 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -52.59 -47.68 57.17 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.476 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 30.3 mt -74.84 -51.86 20.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.842 0.353 . . . . 0.0 111.137 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 22.9 mt -50.97 -57.92 7.34 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.931 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.41 HD12 ' HB3' ' A' ' 31' ' ' PHE . 14.4 mt -59.3 -48.3 87.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.118 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 9.4 ttmm -50.81 -38.01 46.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.922 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 66.4 mtp180 -75.33 -34.5 61.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.908 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 70.8 mtp85 -64.66 -33.22 75.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.848 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 50.5 mt-30 -51.63 148.96 4.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.922 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 32.6 mt-30 -97.96 88.47 4.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.895 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 5.9 ttmm -115.11 42.0 2.3 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.868 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.4 tt -125.62 135.44 63.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.099 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 63.0 mtp180 -80.82 67.11 6.59 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.879 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 6.7 tptt . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.922 179.956 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.536 -0.226 . . . . 0.0 112.536 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 1.8 m -87.75 160.31 47.39 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.582 0.706 . . . . 0.0 110.898 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 81.86 0.79 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.656 2.238 . . . . 0.0 112.353 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . -133.16 95.22 3.49 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.087 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -56.95 119.58 6.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.872 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 1.4 mt-30 -99.84 -86.25 0.39 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.908 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 14.6 ttt180 -52.22 -76.81 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.884 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 108' ' ' ALA . . . . . 0.654 ' HB3' HG21 ' B' ' 112' ' ' THR . . . -119.09 166.0 13.46 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.07 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 109' ' ' SER . . . . . 0.672 ' O ' HG22 ' B' ' 112' ' ' THR . 0.3 OUTLIER -49.56 164.36 0.34 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.692 0.758 . . . . 0.0 110.808 -179.758 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 -11.89 31.72 Favored 'Trans proline' 0 C--O 1.232 0.201 0 C-N-CA 122.678 2.252 . . . . 0.0 112.345 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 111' ' ' LEU . . . . . 0.456 HD13 ' C ' ' B' ' 111' ' ' LEU . 3.0 tm? -81.06 -34.94 32.37 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.902 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 112' ' ' THR . . . . . 0.672 HG22 ' O ' ' B' ' 109' ' ' SER . 6.3 t -49.05 -31.38 7.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.113 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 1.3 t -63.73 -53.03 57.48 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.883 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 114' ' ' ILE . . . . . 0.606 ' O ' HG23 ' B' ' 118' ' ' VAL . 3.7 mp -58.55 -43.3 86.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.13 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.569 ' O ' HG23 ' B' ' 119' ' ' VAL . 4.4 mt -54.0 -52.85 32.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.094 179.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 3.5 t -58.74 -36.9 75.09 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.865 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -62.18 -58.22 8.58 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.083 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.606 HG23 ' O ' ' B' ' 114' ' ' ILE . 9.4 t -51.55 -51.03 27.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.115 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.708 HG12 HD11 ' B' ' 123' ' ' LEU . 90.2 t -48.7 -59.5 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.11 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . 0.473 ' O ' HG23 ' B' ' 124' ' ' VAL . . . -50.04 -54.55 18.39 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.46 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 90.1 mt -58.47 -54.75 28.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.83 0.347 . . . . 0.0 111.095 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 122' ' ' LEU . . . . . 0.875 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.5 OUTLIER -49.43 -59.83 3.38 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.9 179.886 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 123' ' ' LEU . . . . . 1.026 HD23 HG22 ' A' ' 26' ' ' VAL . 9.1 mt -43.13 -55.4 3.91 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.857 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 124' ' ' VAL . . . . . 0.473 HG23 ' O ' ' B' ' 120' ' ' GLY . 87.0 t -52.63 -51.66 33.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.116 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 73.1 t -61.41 -40.19 85.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.096 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 126' ' ' VAL . . . . . 1.025 HG22 HD23 ' A' ' 23' ' ' LEU . 44.1 t -51.52 -59.13 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.101 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 127' ' ' LEU . . . . . 0.727 HD11 HG21 ' A' ' 30' ' ' VAL . 48.5 mt -67.64 -46.83 71.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.929 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.57 -47.18 52.47 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.486 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 56.1 t -76.65 -54.25 13.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.83 0.348 . . . . 0.0 111.121 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 130' ' ' VAL . . . . . 0.73 HG21 HD11 ' A' ' 27' ' ' LEU . 20.0 t -49.8 -42.47 18.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.119 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . 0.42 ' HB3' HD12 ' B' ' 135' ' ' ILE . 4.7 m-85 -77.46 -43.23 33.06 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.871 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -52.23 -47.9 54.61 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.501 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 30.5 mt -74.88 -51.68 21.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.841 0.353 . . . . 0.0 111.113 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 134' ' ' LEU . . . . . 0.402 HD23 ' HA ' ' B' ' 134' ' ' LEU . 21.9 mt -50.91 -57.98 7.15 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.904 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.42 HD12 ' HB3' ' B' ' 131' ' ' PHE . 14.2 mt -59.28 -48.99 85.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.107 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 9.7 ttmm -51.44 -36.85 45.8 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.909 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 67.7 mtp180 -75.36 -34.72 61.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.888 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 70.2 mtp85 -62.5 -47.96 81.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.881 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 50.0 mt-30 -63.88 153.55 36.48 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.912 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 31.8 mt-30 -91.73 62.55 4.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.925 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 3.6 ttmm -134.61 71.84 1.45 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.89 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 142' ' ' ILE . . . . . . . . . . . . . 20.2 tt -101.2 140.29 20.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.132 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 69.9 mtp180 -75.23 86.55 2.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.855 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 3.4 tptt . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.907 179.95 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 38.6 t -159.03 70.12 3.47 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.652 0.739 . . . . 0.0 110.913 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 159.61 52.79 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.688 2.259 . . . . 0.0 112.339 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -106.65 105.22 15.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.093 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -121.16 154.37 36.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.882 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 86.0 mt-30 -91.69 106.91 18.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.881 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.67 -165.83 0.07 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.872 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.524 ' HB1' HG21 ' A' ' 12' ' ' THR . . . -113.78 175.99 5.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.129 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -50.84 163.83 0.46 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.683 0.754 . . . . 0.0 110.844 -179.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.407 ' O ' HD12 ' A' ' 14' ' ' ILE . 54.2 Cg_endo -69.75 -16.41 37.57 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.696 2.264 . . . . 0.0 112.348 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.451 HD13 ' C ' ' A' ' 11' ' ' LEU . 2.5 tm? -86.93 -37.82 17.27 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.93 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.524 HG21 ' HB1' ' A' ' 8' ' ' ALA . 25.9 p -50.55 -43.58 56.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.135 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -51.62 -51.34 56.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.861 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.465 ' O ' HG23 ' A' ' 18' ' ' VAL . 3.1 mp -58.7 -45.54 90.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.112 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.647 ' O ' HG23 ' A' ' 19' ' ' VAL . 25.6 mt -54.08 -51.11 49.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.132 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -58.82 -36.11 73.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.83 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -61.77 -60.12 4.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.1 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 14' ' ' ILE . 5.9 t -51.05 -48.92 29.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.088 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.647 HG23 ' O ' ' A' ' 15' ' ' ILE . 98.3 t -49.6 -63.35 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.129 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -48.57 -55.69 10.65 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.497 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.402 ' O ' HG23 ' A' ' 25' ' ' VAL . 20.4 mt -55.52 -41.02 61.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.863 0.363 . . . . 0.0 111.111 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.77 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.8 OUTLIER -57.15 -50.68 72.05 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.877 179.926 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.808 HD22 HG22 ' B' ' 126' ' ' VAL . 1.1 mt -54.47 -51.67 64.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.901 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 98.1 t -55.44 -45.97 78.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.118 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.402 HG23 ' O ' ' A' ' 21' ' ' ILE . 70.6 t -64.83 -43.18 96.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.101 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.806 HG22 HD22 ' B' ' 123' ' ' LEU . 73.3 t -51.27 -54.31 11.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.113 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.814 HD23 HD23 ' B' ' 127' ' ' LEU . 56.4 mt -70.13 -47.28 62.39 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.885 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -51.82 -45.88 55.14 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.538 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 57.4 t -76.81 -54.67 12.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.84 0.352 . . . . 0.0 111.136 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.732 HG21 HD11 ' B' ' 127' ' ' LEU . 17.6 t -49.9 -43.05 19.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.158 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.404 ' HB3' HD12 ' A' ' 35' ' ' ILE . 5.1 m-85 -77.22 -44.95 28.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.825 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -52.29 -48.0 54.72 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.47 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 45.4 mt -73.22 -52.55 21.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.848 0.356 . . . . 0.0 111.126 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 23.7 mt -51.03 -60.75 2.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.89 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.404 HD12 ' HB3' ' A' ' 31' ' ' PHE . 11.8 mt -55.7 -48.68 77.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.117 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 63.6 tttt -52.45 -51.58 58.51 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.877 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 68.0 mtp180 -52.23 -43.69 64.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.845 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 51.0 mtp85 -66.19 -48.25 71.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.875 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 6.0 mm100 -67.01 179.56 1.11 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.957 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 17.2 mm100 -72.71 174.43 7.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.887 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 12.5 ttmt -136.4 156.16 49.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.913 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 14.1 pt -133.49 -179.96 3.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.106 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 26.8 ptt85 -123.6 177.09 5.84 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.868 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 16.1 mmtt . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.933 179.94 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.372 0 N-CA-C 112.467 -0.253 . . . . 0.0 112.467 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 38.7 t -159.01 72.94 3.55 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.599 0.714 . . . . 0.0 110.849 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 160.72 48.65 Favored 'Trans proline' 0 N--CA 1.465 -0.169 0 C-N-CA 122.694 2.262 . . . . 0.0 112.353 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . -105.83 96.78 6.73 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.128 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 11.7 tt0 -128.63 152.34 48.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.936 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 87.3 mt-30 -92.87 79.93 4.66 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.88 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.49 -76.49 0.51 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.913 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 108' ' ' ALA . . . . . 0.472 ' HB1' HG21 ' B' ' 112' ' ' THR . . . -107.57 -179.64 3.97 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.094 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 109' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -50.28 164.34 0.39 Allowed Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.657 0.741 . . . . 0.0 110.87 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 110' ' ' PRO . . . . . 0.419 ' O ' HD12 ' B' ' 114' ' ' ILE . 53.5 Cg_endo -69.78 -16.24 37.4 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.673 2.249 . . . . 0.0 112.336 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 111' ' ' LEU . . . . . 0.461 ' O ' HD22 ' B' ' 111' ' ' LEU . 2.5 tm? -87.93 -37.96 15.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.901 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 112' ' ' THR . . . . . 0.472 HG21 ' HB1' ' B' ' 108' ' ' ALA . 26.6 p -51.23 -43.62 61.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.122 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -51.4 -51.93 50.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.842 -179.852 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 114' ' ' ILE . . . . . 0.472 ' O ' HG23 ' B' ' 118' ' ' VAL . 2.9 mp -58.39 -45.39 89.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.147 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.652 ' O ' HG23 ' B' ' 119' ' ' VAL . 23.5 mt -54.0 -51.42 46.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.143 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -58.75 -35.97 73.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.854 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -61.63 -59.97 4.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.111 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.472 HG23 ' O ' ' B' ' 114' ' ' ILE . 6.1 t -51.27 -48.78 32.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.103 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.652 HG23 ' O ' ' B' ' 115' ' ' ILE . 98.4 t -49.66 -63.28 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.123 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.73 -55.48 11.2 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.499 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 20.0 mt -55.64 -40.8 61.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.884 0.373 . . . . 0.0 111.163 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 122' ' ' LEU . . . . . 0.773 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.8 OUTLIER -57.44 -50.25 73.61 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.945 179.868 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 123' ' ' LEU . . . . . 0.806 HD22 HG22 ' A' ' 26' ' ' VAL . 1.1 mt -54.73 -51.35 65.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.956 179.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 99.6 t -55.93 -46.0 80.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.113 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 71.0 t -64.64 -43.12 96.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.136 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 126' ' ' VAL . . . . . 0.808 HG22 HD22 ' A' ' 23' ' ' LEU . 71.7 t -51.42 -54.36 12.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.105 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 127' ' ' LEU . . . . . 0.814 HD23 HD23 ' A' ' 27' ' ' LEU . 57.1 mt -70.15 -47.39 61.89 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.927 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -51.81 -45.81 55.12 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.458 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 58.1 t -76.77 -54.82 12.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.931 0.396 . . . . 0.0 111.191 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 130' ' ' VAL . . . . . 0.726 HG21 HD11 ' A' ' 27' ' ' LEU . 17.6 t -49.89 -43.06 19.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.137 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . 0.415 ' HB3' HD12 ' B' ' 135' ' ' ILE . 5.1 m-85 -77.16 -44.83 28.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.898 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -52.3 -48.11 54.57 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.479 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 46.1 mt -73.21 -52.43 21.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.874 0.369 . . . . 0.0 111.149 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 134' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' B' ' 134' ' ' LEU . 23.9 mt -51.14 -60.77 2.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.914 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.415 HD12 ' HB3' ' B' ' 131' ' ' PHE . 12.0 mt -55.73 -48.62 77.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.094 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 63.5 tttt -52.44 -51.66 58.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.892 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 68.5 mtp180 -52.38 -43.59 64.8 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.876 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 51.4 mtp85 -63.61 -47.96 79.28 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.88 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 6.2 mm100 -63.87 179.35 0.52 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.895 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 17.1 mm100 -73.6 174.54 8.17 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.918 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 12.4 ttmt -136.57 156.95 47.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.92 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 142' ' ' ILE . . . . . . . . . . . . . 14.2 pt -132.94 179.65 4.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.119 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 27.2 ptt85 -123.7 177.69 5.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.854 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 16.2 mmtt . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.898 179.965 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.275 0 N-CA-C 112.473 -0.251 . . . . 0.0 112.473 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 1.7 m -101.06 160.48 26.55 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-O 121.599 0.714 . . . . 0.0 110.918 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -7.62 21.51 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.658 2.239 . . . . 0.0 112.361 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.17 -18.07 23.21 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.104 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -67.84 117.33 9.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.914 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 9.0 tt0 -91.65 100.91 13.55 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.898 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.76 151.17 39.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.911 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.69 ' HB3' HG21 ' A' ' 12' ' ' THR . . . -129.96 177.65 7.12 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.12 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.684 ' O ' HG22 ' A' ' 12' ' ' THR . 0.3 OUTLIER -49.48 164.57 0.32 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.671 0.748 . . . . 0.0 110.892 -179.809 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -11.87 31.72 Favored 'Trans proline' 0 C--O 1.232 0.221 0 C-N-CA 122.675 2.25 . . . . 0.0 112.332 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.468 HD22 ' O ' ' A' ' 11' ' ' LEU . 2.5 tm? -82.4 -36.48 26.68 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.881 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.69 HG21 ' HB3' ' A' ' 8' ' ' ALA . 5.5 t -49.56 -31.38 10.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.156 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -68.25 -44.61 75.24 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.89 -179.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.515 ' O ' HG23 ' A' ' 18' ' ' VAL . 51.0 mt -62.09 -45.81 97.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.143 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.652 ' O ' HG23 ' A' ' 19' ' ' VAL . 25.0 mt -57.11 -51.46 68.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.128 179.859 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 10.8 t -59.3 -32.9 70.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.851 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -64.5 -60.29 3.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.041 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.515 HG23 ' O ' ' A' ' 14' ' ' ILE . 5.9 t -51.58 -48.72 35.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.134 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.652 HG23 ' O ' ' A' ' 15' ' ' ILE . 92.1 t -50.04 -63.44 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.132 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -48.41 -55.48 10.69 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.527 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 22.1 mt -55.84 -40.86 64.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.816 0.341 . . . . 0.0 111.085 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.777 ' O ' HG23 ' A' ' 26' ' ' VAL . 0.9 OUTLIER -57.46 -49.62 75.69 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.927 179.897 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.811 HD22 HG22 ' B' ' 126' ' ' VAL . 2.0 mt -55.18 -51.44 66.52 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.942 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 98.9 t -55.92 -46.17 80.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.122 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 76.0 t -63.75 -43.59 98.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.147 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.83 HG22 HD22 ' B' ' 123' ' ' LEU . 76.2 t -51.67 -53.72 15.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.107 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.793 HD23 HD23 ' B' ' 127' ' ' LEU . 54.0 mt -71.72 -45.73 60.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.923 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -52.77 -46.39 59.94 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.469 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 53.1 t -76.08 -54.21 14.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.851 0.358 . . . . 0.0 111.134 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.667 HG21 HD11 ' B' ' 127' ' ' LEU . 18.4 t -50.64 -44.6 25.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.14 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.442 ' HB3' HD12 ' A' ' 35' ' ' ILE . 5.3 m-85 -76.79 -39.07 52.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.9 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -54.71 -49.37 61.79 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 23.3 mt -74.78 -50.25 26.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.888 0.375 . . . . 0.0 111.165 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 25.4 mt -51.86 -56.28 14.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.934 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.442 HD12 ' HB3' ' A' ' 31' ' ' PHE . 21.6 mt -61.32 -44.09 97.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.179 179.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 16.8 mttt -50.52 -42.89 55.63 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.877 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 33.8 mtp180 -74.24 -32.98 63.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.917 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 79.6 mtp180 -69.97 -31.7 69.54 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.861 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -174.23 177.85 2.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.939 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLN . . . . . . . . . . . . . 2.2 tp60 -122.77 168.32 12.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.906 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 7.5 mmtp -123.31 179.38 4.74 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.866 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.89 173.38 14.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.152 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 4.8 ptp180 -144.64 178.06 8.25 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.927 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.333 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.881 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.466 -0.253 . . . . 0.0 112.466 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 102' ' ' CYS . . . . . . . . . . . . . 1.7 m -100.86 160.38 26.92 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.61 0.719 . . . . 0.0 110.885 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 103' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 -7.56 21.37 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.727 2.284 . . . . 0.0 112.365 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 104' ' ' ALA . . . . . . . . . . . . . . . 48.12 30.21 2.06 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.092 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 105' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -67.07 112.84 4.61 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.892 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 106' ' ' GLN . . . . . . . . . . . . . 8.8 tt0 -95.43 104.45 16.35 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.919 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 107' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.41 147.31 41.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.841 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 108' ' ' ALA . . . . . 0.676 ' HB3' HG21 ' B' ' 112' ' ' THR . . . -132.67 176.79 8.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.115 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 109' ' ' SER . . . . . 0.683 ' O ' HG22 ' B' ' 112' ' ' THR . 0.3 OUTLIER -49.53 164.85 0.31 Allowed Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.639 0.733 . . . . 0.0 110.897 -179.797 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 110' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -11.81 31.63 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.687 2.258 . . . . 0.0 112.382 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 111' ' ' LEU . . . . . 0.457 ' O ' HD22 ' B' ' 111' ' ' LEU . 2.5 tm? -81.96 -36.55 27.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.877 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 112' ' ' THR . . . . . 0.683 HG22 ' O ' ' B' ' 109' ' ' SER . 5.7 t -49.38 -31.51 9.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.145 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 113' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -67.85 -45.0 75.86 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.846 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 114' ' ' ILE . . . . . 0.506 ' O ' HG23 ' B' ' 118' ' ' VAL . 51.4 mt -61.89 -45.53 98.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.15 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.668 ' O ' HG23 ' B' ' 119' ' ' VAL . 25.7 mt -57.04 -51.0 74.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.099 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 116' ' ' SER . . . . . . . . . . . . . 10.6 t -59.59 -33.19 71.14 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.844 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 117' ' ' ALA . . . . . . . . . . . . . . . -64.25 -60.2 3.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.033 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.506 HG23 ' O ' ' B' ' 114' ' ' ILE . 5.7 t -51.54 -48.77 35.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.128 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 119' ' ' VAL . . . . . 0.668 HG23 ' O ' ' B' ' 115' ' ' ILE . 92.9 t -49.97 -63.41 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.101 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -48.46 -55.46 10.79 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.459 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 121' ' ' ILE . . . . . . . . . . . . . 22.2 mt -55.89 -40.73 63.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.877 0.37 . . . . 0.0 111.118 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 122' ' ' LEU . . . . . 0.778 ' O ' HG23 ' B' ' 126' ' ' VAL . 0.9 OUTLIER -57.57 -49.49 76.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.946 179.867 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 123' ' ' LEU . . . . . 0.83 HD22 HG22 ' A' ' 26' ' ' VAL . 2.0 mt -55.38 -51.48 66.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.902 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 124' ' ' VAL . . . . . . . . . . . . . 98.0 t -55.81 -46.0 79.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.156 179.831 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 125' ' ' VAL . . . . . . . . . . . . . 78.0 t -63.99 -43.45 97.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.148 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 126' ' ' VAL . . . . . 0.811 HG22 HD22 ' A' ' 23' ' ' LEU . 76.0 t -51.68 -53.68 15.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.143 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 127' ' ' LEU . . . . . 0.793 HD23 HD23 ' A' ' 27' ' ' LEU . 52.7 mt -71.78 -45.84 60.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.921 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 128' ' ' GLY . . . . . . . . . . . . . . . -52.63 -46.12 59.4 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.506 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 129' ' ' VAL . . . . . . . . . . . . . 53.4 t -76.41 -54.2 13.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.876 0.369 . . . . 0.0 111.097 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 130' ' ' VAL . . . . . 0.691 HG21 HD11 ' A' ' 27' ' ' LEU . 18.6 t -50.7 -44.31 25.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.179 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . 0.436 ' HB3' HD12 ' B' ' 135' ' ' ILE . 5.2 m-85 -77.0 -39.29 50.94 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.863 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 132' ' ' GLY . . . . . . . . . . . . . . . -54.56 -49.09 62.33 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.478 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 133' ' ' ILE . . . . . . . . . . . . . 22.2 mt -75.04 -50.6 24.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.809 0.338 . . . . 0.0 111.129 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 134' ' ' LEU . . . . . . . . . . . . . 25.0 mt -51.54 -55.74 17.38 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.898 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.436 HD12 ' HB3' ' B' ' 131' ' ' PHE . 21.9 mt -61.9 -44.34 98.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.146 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 19.8 mttt -50.52 -42.44 55.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.898 179.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 137' ' ' ARG . . . . . . . . . . . . . 33.6 mtp180 -74.56 -33.24 62.65 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.839 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 138' ' ' ARG . . . . . . . . . . . . . 79.8 mtp180 -68.98 -35.38 76.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.847 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 139' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -174.84 -179.48 1.44 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.929 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 140' ' ' GLN . . . . . . . . . . . . . 3.7 tp60 -121.96 171.28 9.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.959 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 141' ' ' LYS . . . . . . . . . . . . . 7.3 mmtp -119.51 174.96 6.08 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.888 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 142' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -140.55 176.23 5.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.124 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 143' ' ' ARG . . . . . . . . . . . . . 4.5 ptp180 -142.8 176.75 8.82 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.872 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.918 179.982 . . . . . . . . 1 1 . 1 stop_ save_